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Abstract
Minimizing Tracer Interference to Assess in vivo Hepatic Metabolism with Glutaminegenerated Mass Isotopomers
Stephan Siebel
2021
Stable isotope tracers are widely used to study the in vivo kinetics of central carbon
metabolism in diseases such as obesity, type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). However, despite their common use,

13C-labeled

acetate, lactate, and propionate have led to large incongruities and inconsistencies in
their in vivo measurement of hepatic metabolism. To resolve major discrepancies and
recent controversies of hepatic metabolism we developed and validated [1,2-13C2]-Lglutamine as a novel tracer strategy for measuring hepatic central carbon metabolism. In
our rodent studies [1,2-13C2]-L-glutamine generated a straightforward labeling pattern of
key metabolites suitable for the interpretation of LC-MS/MS spectra using Mass
Isotopomer Multi Ordinate Spectral Analysis (MIMOSA) principles and thereby enabled
an unencumbered independent assessment of Krebs cycle fluxes. In a head-to-head
comparison, we found that [1,2-13C2]-L-glutamine had many favorable qualities and few
liabilities compared to the other tracer strategies. Additionally, given that in vivo NMR
studies of mitochondrial metabolism often depend on the signal for glutamate and other
abundant metabolites that act as label-trapping pools for Krebs Cycle intermediates, we
were able to directly measure α-Ketoglutarate-Glutamate exchange rate (Vx) and show
evidence for the assumption that the intramitochondrial metabolite pool is in rapid
exchange with NMR observable cytosolic metabolites. Here we report the development

i

and in vivo kinetic and steady state validation of [1,2-13C2]-L-glutamine as an independent
tracer of hepatic metabolism.
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“Measure what is measurable, and make measurable what is not so”
Galileo Galilei
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CHAPTER I: INTRODUCTION

Hepatic Krebs cycle in health and disease
The liver is an essential metabolic organ which plays a central role not only in liver
specific metabolism, but it also governs the entire body’s energy metabolism by
providing important substrates, such as glucose and lipids, among others, to all vital
tissues. Central to the liver’s role in carbon metabolism are mitochondria. Housed within
the cytoplasm of each hepatocyte these organelles maintain glucose, and lipid
homeostasis through the Tricarboxylic acid cycle (TCA for short) also commonly
referred to as the Krebs cycle. By coordinating the delicate balance between
degradation and biosynthesis of these macronutrients the hepatic Krebs cycle ensures
normoglycemia, and normolipidemia. Considering its central role in macronutrient
homeostasis Sir Hans Krebs predicted during his Nobel banquet address in 1953, ‘‘I am
convinced that an understanding of the process of energy production will eventually
help us in solving some of the practical problems of medicine’’. Since Krebs’ pioneering
work in the discovery and investigation of the Krebs cycle, a plethora of research has
shown that aberrant central carbon metabolism plays a crucial role in the pathogenesis
and pathophysiology of many disorders [26]. The most prominent metabolic disorders
include non-alcoholic fatty liver (NAFLD), obesity, insulin resistance (IR) and type 2
diabetes mellitus (T2DM) [27-39], all of which promote morbidity and mortality in our
society [27, 40-43]. To date Diabetes affects close to 10% of the US population and
more than ~300 million people worldwide, with over 5000 children and adolescents
being diagnosed with T2DM annually in the US alone[44]. Short- and long-term
3

complications of T2DM are grave, affect almost every organ system, and predispose
patients to serious cardiovascular, renal and liver disease which can ultimately lead to
premature deaths [45]. The majority of patients with T2DM also suffer from obesity and
NAFLD, which affects 10% of children and 68% of adults in the U.S. NAFLD is now the
most common liver disease in the obese and diabetic adult and pediatric population
where it is not only a comorbidity but also a critical predisposing factor to T2DM [46, 47].
Additionally, mitochondrial oxidative, reductive and biosynthetic dysregulation have
been discovered to be part of the development and progression of a variety of cancers,
such as renal cell carcinoma, hereditary pheochromocytoma and paraganglioma
syndrome, and gastrointestinal stromal tumors, and hepatocellular carcinoma among
others [29, 37, 43, 47-50]. All of these disorders which together or by themselves affect
millions of people in the US and many more worldwide, often times lead to devastating
morbidity and ultimately to higher mortality. Therefore, in our pursuit of effective
diagnostic, therapeutic, and curative targets for these disorders it is of utmost
importance to develop a solid understanding of the fundamentals of hepatic metabolism.

Krebs cycle and hepatic metabolism
Metabolism refers to all chemical reactions that constitute networks of biochemical
pathways within cells or organisms that are necessary to maintain life. Metabolic
pathways consist of a series of coupled chemical reactions that are catalyzed by
enzymes. Each of the consecutive enzymatic steps facilitates the chemical processing of
a precursor into an intermediate molecule which is eventually converted into its final
4

product. Metabolism exists in one of two phases: 1. anabolism or catabolism. During
catabolism larger organic nutrient molecule, such as carbohydrates, lipids, or proteins,
are broken down into smaller, simpler products, such as pyruvate, lactate, CO2, NH3, and
others. Catabolic reactions are crucial for energy production in form of reducing
equivalents, such as FADH2, NADH, NADPH, or high energy molecules, such as ATP
and GTP. In anabolic pathways, on the other hand, smaller precursors, such as PEP and
acetyl CoA, are used as building blocks for larger, more complex products, such as
polysaccharides, lipids, proteins and nucleic acids. In contrast to catabolic reaction,
anabolism consumes energy in the form of ATP, GTP, NADH, NADPH, and FADH2.
Amphibolic systems can perform both anabolism and catabolism. However, to avoid
wasting energy by running both simultaneously, anabolism and catabolism are usually
reciprocally regulated and tightly controlled [1] (Figure 1). The major regulatory
connecting hub for glucose, lipid and protein ana- and catabolism is the Citric Acid (CAC)
or Tricarboxylic Acid (TCA) cycle [9]. Although, it is commonly referred to as the Krebs
cycle, named after Sir Hans Krebs, whose pioneering work laid the foundation for our
modern understanding of central carbon metabolism [2]. After oxidation of their respective
carbon backbones in either glycolysis, lipolysis, or proteolysis, glucose, lipid and protein
metabolism converges in the Krebs cycle through their common end product acetate,
which is then activated by acetyl CoA Synthetase (ACS) to acetyl CoA. The cyclic
sequence of Krebs cycle reactions begins when acetyl-CoA undergoes an aldol
condensation with oxaloacetate (OAA) to form citrate. This first committed step of the
Krebs cycle is catalyzed by Citrate Synthase (CS). After its formation from acetyl CoA
and OAA citrate is converted to isocitrate via aconitase which is then oxidized by isocitrate
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dehydrogenase (IDH) to α-ketoglutarate (αKG). Subsequently, succinate CoA is formed
from the decarboxylation reaction of aKG catalyzed by aKG Dehydrogenase (OGDH).
succinate CoA synthetase then gives rise to succinate. Succinate is a symmetric
intramitochondrial metabolite which is exclusively formed within the Krebs Cycle and
metabolized to fumarate via succinate dehydrogenase (SDH). Fumarase catalyzes the
conversion of fumarate to malate (M) which is then oxidized to oxaloacetate (OAA) by
malate dehydrogenase (MDH) thus completing one full turn of the Krebs cycle. Through
this series of cyclic enzymatic reactions, acetyl CoA is completely oxidized to CO2 during
one full turn of the cycle. During some of the chemical processes of the Krebs Cycle
reducing equivalents, such as NADH and FADH2, are formed. These are crucial
components of the mitochondrial electron transfer chain and oxidative phosphorylation
allowing the mitochondrion to produce and conserve large amounts of energy in the form
of ATP, necessary for all vital cellular processes. The four major oxidative reactions of
the Krebs Cycle are catalyzed by isocitrate dehydrogenase (forward reaction), αKG
dehydrogenase, succinate dehydrogenase and malate dehydrogenase.

6

Figure 1. Krebs cycle metabolism.
Top Panel: The Krebs is an amphibolic connecting hub which mediates the two phases of
metabolism, anabolism and catabolism. Depending on the metabolic state of the cell
reducing equivalences and high energy molecules are either synthesized or utilized. Bottom
Panel: A depiction of all major metabolic reactions associated with the Krebs cycle.
Oxidative fluxes are depicted in blue, exchange reactions in orange, anaplerotic fluxes in
red and cataplerotic fluxes in green. ACLy = ATP citrate Lyase, CS =citrate synthase, GDH=
glutamate dehydrogenase, IDHnet= isocitrate dehydrogenase (net), MDH= malate
dehydrogenase, ME= malic enzyme, OGDH= α ketoglutarate dehydrogenase, PC=
pyruvate carboxylase, PCC=propionate CoA carboxylase, PDH= pyruvate dehydrogenase,
PEPCK = phosphoenolpyruvate carboxykinase, SDH= succinate dehydrogenase.
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Anaplerosis and cataplerosis

Figure 2. Anaplerosis and Cataplerosis.
Anaplerotic fluxes are shown in red, cataplerotic fluxes and their biosynthetic products in
green. Anaplerosis is balanced by cataplerosis to maintain mass balance. Cataplerotic
fluxes are important for biosynthesis of many metabolites (green) to maintain glucose and
lipid homeostasis as well as maintenance of Redox Potentials.

The concentrations of Krebs cycle intermediates are relatively constant irrespective of
whether the hepatocyte is in a state of anabolic or catabolic metabolism. During
anabolism, when the Krebs cycles assumes its biosynthetic function, it channels its
designated intermediates, such as OAA or citrate, into specific metabolic pathways,
where they are used as precursors for gluconeogenesis (liver and kidney), lipogenesis
(liver) and glyceroneogensis (adipose tissue) (Figure 2) [3]. The removal of intermediates
from the Krebs cycle for biosynthetic processes is commonly termed cataplerosis. The
two main cataplerotic fluxes are mediated by phosphoenolpyruvate carboxykinase
8

(PEPCK), and malic enzyme (ME), and to a lesser extent ATP citrate lyase (ACLy).
Phosphoenolpyruvate carboxykinase (PEPCK), the main cataplerotic reaction, catalyzes
the formation of phosphoenolpyruvate (PEP) from OAA whereas malic enzyme (ME)
facilitates the conversion of malate to pyruvate. Both cataplerotic fluxes partake in
gluconeogenesis. However, flux through ME is negligible under physiologic conditions
compared to PEPCK [4]. To maintain cycle intermediates at almost constant
concentrations, every carbon efflux from the Krebs cycle needs to replenished by an
equal carbon influx [1, 3]. There are three major carbon entry points into the Krebs cycle.
These three anaplerotic fluxes are mediated by pyruvate carboxylase (PC), glutamate
dehydrogenase (GDH), and propionate CoA carboxylase (PCC). The latter is often
considered to be the major anaplerotic reactions in the liver. PCC catalyzes the
carboxylation of pyruvate into OAA (Figure 2). As illustrated by their different fluxes, both,
anaplerosis and cataplerosis, play important roles in the function of the Krebs cycle and
thus in the regulation of amino acid, glucose, and fatty acid metabolism[3].

9

Reductive carboxylation and ATP citrate lyase
Reductive carboxylation catalyzed by isocitrate dehydrogenase is an important process
for maintaining the intramitochondrial citrate pool which can then be used as a substrate
for fatty acid and cholesterol biosynthesis mediated by ATP citrate lyase. Isocitrate
dehydrogenase catalyzes a reversible step compromised of two biochemical reactions
(Figure 3): 1. A decarboxylation (forward) reaction (IDHf) that converts Isocitrate into aKG
and 2. A reductive (reverse) carboxylation (IDHr) step that converts aKG back into
Isocitrate. Besides its role as an intermediate of the Krebs cycle, Citrate can be
transported from the mitochondrial matrix into the cytosol via mitochondrial citrate carrier
(CiC). In the cytosol, ATP citrate lyase (ACLy) catalyzes the breakdown of Citrate into
cytosolic OAA and acetyl-CoA. The cytosolic OAA is transformed to malate by cytosolic
malate
Dehydrogenase
(MDH),

which

transported

is

back

into

the

mitochondrion

via

CiC in exchange for
citrate. After ligation
with a CoA species
acetate

can

converted
malonyl

be
to

CoA

by

Figure 3. Reverse carboxylation and ATP Citrate Lyase reaction.
The Mitochondrial Citrate Carrier (CiC) transports Citrate out of the
mitochondrial matrix into the cytosol in exchange for Malate. In the
cytosol ACLy facilitates the production of acetyl CoA and Malate from
citrate. The reverse isocitrate dehydrogenase (IDHr) reaction
catalyzes the reductive carboxylation of αKG to citrate.
10

acetyl CoA carboxylase (ACC) and can then be utilized as a building block in fatty acid
synthesis via de novo lipogenesis (DNL) [5-7]. Another fate of acetyl-CoA is histone and
non-histone acetylation through which acetyl CoA can epigenetically modify gene
expression as well as regulate enzyme function [8, 9].

Amino Transferase Exchange rate (Vx)
Aminotransferases
transfer an α-amino
group from an amino
acid to an α-carbon of
a keto acid without any
net carbon conversion
or

net

deamination.

Exchange
(Vx)

reactions

(Figure

Figure 4. Amino Transferase Exchange rate (Vx).
Vx catalyzes the interconversion of Glutamate and αKG.
No net carbon is lost during this reaction.

4)

commonly occur in reversible systems and their directionality depends on the availability
of the reactants. They play an integral role in biosynthetic processes by supplying
intermediates for the Krebs cycle. Another important function of exchange reactions is to
mediate the disposal of toxic nitrogen waste can eventually be detoxified in the Urea
(Ornithine) cycle [9]. The two main aminotransferase reactions that facilitate exchange
between intramitochondrial and cytosolic metabolite pools catalyze the interconversion of
glutamate to αKG as well as OAA to aspartate and vice versa [10]. In contrast to exchange
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reactions, deamination processes lead to net carbon conversion and release of ammonia
when an amino acid is deaminated to a keto acid.

Substrate cycling
Originally
substrate

deemed
cycling

futile,
is

now

considered an important aspect
of

amphibolic

systems.

Substrate

cycling

pathways

replenish

and

maintain

metabolite concentrations and
redox potentials and contribute
to thermogenesis [11-13]. During
substrate cycling two naturally
distinct enzymatic reactions of
opposing metabolic pathways
operate

simultaneously

by

Figure 5. Substrate cycling.
During substrate cycling two naturally distinct enzymatic
reactions of opposing metabolic pathways operate
simultaneously by circumventing an otherwise thermodynamic
unfavorable or irreversible biochemical step. At least one of the
involved cycling reactions results in the hydrolysis of ATP and
a net production and dissipation of heat: ATP + H2O → ADP +
Pi + Heat [1]. Here, pyruvate is converted to OAA via PC. OAA
is transformed to PEP by PEPCK and finally PEP is
phosphorylated back into pyruvate.

circumventing an otherwise thermodynamic unfavorable or irreversible biochemical step
[14]. One important example of substrate cycling is the PEP-pyruvate cycle (Figure 5) at
the intersection of glycolysis and gluconeogenesis. Here, pyruvate is converted to OAA
catalyzed by PC, while OAA is transformed to PEP via PEPCK and back into pyruvate
through pyruvate kinase (PK) [11, 12, 15].
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Regulation of Krebs cycle flux
The major rate limiting steps in the Krebs cycle are the fluxes catalyzed by citrate
synthase, isocitrate dehydrogenase and αKG dehydrogenase. Changes in substrate
availability, and/or molar ratios of NAD+/NADH, ATP/ADP or CoA species, as well as
negative feedback from
their respective products,
can all result in a shift of
their enzymatic equilibria.
For

example,

accumulation of citrate,
succinyl CoA and/or ATP
inhibits citrate synthase,
Figure 6. Regulation of Krebs Cycle metabolism.
The Krebs cycle is regulated by hormones (Glucagon, Insulin),
metabolites, energy states (ATP, ADP) and RedOx potential
(NADH, NAD+). * NADH/NAD dependent reaction.

αKG

whereas
dehydrogenase

is

only

inhibited by succinyl CoA.
Increased NADH/NAD+ or ATP/ADP ratios inhibit all of the dehydrogenase reactions,
including PDH. Additionally, acetyl CoA is a potent allosteric activator of PC [16-22] while
indirectly inhibiting PDH through activation of pyruvate dehydrogenase complex kinase.
Pyruvate, on the other hand, activates PDH through inhibition of pyruvate dehydrogenase
kinase [51]. Endocrine hormones also play a crucial role in controlling enzymatic functions
13

and thus impacting metabolic flux. Insulin suppresses expression of PEPCK while
stimulating pyruvate dehydrogenase phosphatase and thereby indirectly activating PDH
flux, all of which promotes glucose metabolism towards ATP production while it
suppresses endogenous glucose production [23, 24]. Conversely, glucagon stimulates
expression of cytosolic PEPCK [25], thus promoting cataplerotic fluxes for
gluconeogenesis, especially during states of limited exogenous glucose supply, such as
fasting and starvation.

Stable isotope tracer methods
In recent years, increasing emphasis has been placed on studying potential molecular
mechanisms and genetic variations underlying metabolic dysfunction. Whole genome
and exome sequencing, mRNA expression profiling and SNP arrays, to name a few, have
been used to identify genetic targets for early clinical diagnosis and intervention.
However, despite the undisputable place of molecular tests in clinical and scientific
investigation of metabolic and endocrine disorders, they come with their own limitations.
Genetic variants, and expression profiles, similar to measuring metabolite concentrations,
are only a static snapshot of a highly dynamic system. Kinetic investigation of metabolic
fluxes in vivo using stable isotope tracers, on the other hand, give valuable insights into
the dynamic workings of a metabolic system as a whole and how it may change over
time. Thus, metabolic flux analyses (MFA) can serve as a functional readout of
metabolism and add important phenotypical characterization to existing genotypical
information by tracing directionality of chemical reactions within a metabolic pathway and
14

by identifying deviation from a physiologic baseline before and during the development
and progression of disease.

Stable isotope tracers are a safe method to study

metabolism as a whole -at a single or over the course of multiple timepoints- rather than
focusing on individual, static aspects, such as metabolite concentrations and gene
expression profiles [51, 52]. Due to their non-radioactivity, stable isotope based tracer
strategies have gained wide popularity in research studies, especially of the in vivo
kinetics of human and rodent central carbon metabolism since the mid 1980’s [53, 54].
Atoms are made up of three main particles: positively charged protons, uncharged
neutrons and negatively charged electrons. A stable Isotope is a non-radioactive element
Element
Carbon
Hydrogen
Nitrogen
Oxygen

Isotope
12C
13C
1H
2H
14N
15N
16O
17O
18O

Occurrence (%)
98.89
1.11
99.9885
0.115
99.632
0.368
99.757
0.038
0.205

Table 1: Examples of common atoms and their stable isotopes and
their natural abundance.

that differs in number of
neutrons but has the
same number of protons
as

their

counterpart

lighter
[55].

For

instance, carbon 12 is
the

most

abundant

carbon atom in nature. However, up to 1.11% of all carbons have one additional neutron
and occur as carbon 13 (atom mass unit [amu] of 13 compared to an amu of 12 of carbon
12). Table 1 shows examples of atoms and their natural distribution patterns of naturally
occurring stable isotopes. In tracers one or more of the lighter (more abundant) atoms in
the chemical structure of a metabolite is/are replaced by its respective stable isotopes
(label) and therefore differ in mass from its non-labeled counterpart, which is referred to
as a tracee. A prominent tracer strategy is the carbon 13 (13C) tracer method. Herein, 13C
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label is introduced into a metabolic system by exchanging one or more of the commonly
occurring

12C

atom(s) of a metabolite’s carbon backbone with its natural isotope

13C

(Figure 7).
In this thesis we are following the terminology and nomenclature of Seeman et al and the
conventional nomenclature of the International Union of Pure and Applied Chemistry
(IUPAC) [56]: The term isotopologue, indicated by M, describes a molecule that carries n
number of labels (heavy (stable) isotopes) within its structure: M+n (n = 0, 1, 2, 3,…n).
Mass isotopologues differ in molecular weight
due to difference in content of heavy isotopes
but not in difference in molecular structure.
This nomenclature is position non-specific
meaning that it indicates that the molecule is
carrying one or more stable isotope(s) but it
does not indicate its position within the carbon
chain of the molecule. The term isotopomer on
the other hand represents the exact position of
the

heavy

molecule

(isotope)

within

a

molecule’s carbon backbone, i.e., 6-13C1citrate

vs

1-13C1-citrate

[56].

Numbers

Figure 7. Stable isotope tracers.
Examples of carbon numbering and
isotope labeling. Citrate is a 6-carbon
molecule, numbered C1 through C6. The
solid circle denotes a stable isotope
carbon 13 whereas the open circles
indicate carbon 12. An Isotopologue
refers only to the total number of stables
isotopes within a molecule with nonposition specific label information, e.g.,
citrate M+0 (no stable isotope) or citrate
M+1 (one stable isotope). Isotopomer:
position specific label information, e.g.,
6-13C1-citrate which carries one stable
isotope in carbon position six.

preceding the atom indicate the position of the
stable isotope within the molecular structure, while the following superscript indicates the
stable isotope and the subscript following the letter name for the atom indicates the
quantity of heavy isotopes.
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Fractional enrichment of stable isotope tracers
The relative occurrence of a tracer (stable isotope labeled metabolite) to its tracee
(unlabeled metabolite) within a defined metabolite pool, e.g. plasma, is described as the
fractional isotopic enrichment of a metabolite, also referred to as relative abundance of a
stable isotope tracer. This fractional enrichment of a metabolite pool with tracer can be
expressed in many different ways, such as Tracer to Tracee ratio, Molar Percent
Enrichment and Atom Percent Excess (APE%) (Figure 8) [65, 66]. Going forward we will
use the ratio of labeled metabolite (tracer) to its total metabolite pool (unlabeled and
labeled metabolite) expressed as Atom Percent Excess (APE%) [55]:
APE% = (Tracer/(Tracer + Tracee))*100
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Figure 8. Fractional enrichment.
After infusion of a 13C labeled metabolite (tracer, blue circles with 13C) into an unlabeled
metabolite pool (tracee, transparent circles with 12C), the relative enrichment of tracer to
total metabolite pool (tracer + tracee) is expressed as APE% . Since tracer and tracee are
indistinguishable biochemically, they undergo the same physiologic processes in cellular
organisms. F= infusion rate of tracer.

Measuring tracer signal
Even though stable isotope labeled metabolites (tracers) undergo the exact same
physiological processes as their unlabeled counterpart (tracee), the difference in mass
and in quantum-magnetic properties of the heavier isotope can be used to differentiate it
from its lighter naturally more abundant atoms by Mass Spectrometry and Nuclear
Magnetic Resonance spectroscopy, respectively [55, 57].
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Nuclear Magnetic Resonance spectroscopy (NMR)
(for a detailed description see Supplemental Information)

Nuclear Magnetic Resonance spectroscopy (NMR) is a magnetic resonance
spectroscopy (MRS) based, non-invasive analytical technique that allows for dynamic and
static investigation of biochemical composition of tissues and body fluids in vivo and in
vitro. Today, two common types of NMR used in metabolic research are proton- and
carbon-NMR (1H-NMR and
hydrogen atom (1H).

1H

13C-NMR)

[58, 59]. In 1H-NMR the observed nucleus is

-NMR is a popular method due to the high isotopic abundance

of 1H (~99% of all hydrogen atoms) and the comparably easier acquisition of NMR spectra
in comparison to 13C spectra. In 13C-NMR the observed nucleus is 13C, the only MR visible
carbon isotope. Carbon NMR is a useful method to obtain position specific information of
carbon label within an organic molecule. Both,

13C-NMR

and 1H-NMR, come with some

considerable disadvantages and limitations for in vivo studies [60]. For instance 1H-NMR
spectra may be dominated by resonances of highly abundant molecules, such as water
or lipids, and thereby overlap and obscure important peaks of lower abundant metabolites
making exact spectral assignment difficult [61-65]. On the other hand,

13C-NMR

suffers

from limited sensitivity due to low signal to noise ratios, significantly lower magnetogyric
ratio of

13C

compared to 1H, a broad chemical shift and an isotopic abundance of only

1.1% [66]. In addition to its low sensitivity, 13C-NMR is a fairly laborious method requiring
long scan times and metabolite concentrations in the millimolar range [61-65].
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Some of these limitations have been overcome by higher localization accuracy and
improved sensitivity of Proton observed, carbon decoupled/edited NMR spectroscopy
(POCE) [64]. POCE is a 1H-13C heteronuclear editing method which consists of the
acquisition of two spin-echo measurements, one with a broad-band inversion pulse
applied at the

13C

frequency, and the other without the inversion pulse. The difference

between the spectra represents protons bound to 13C at twice the true intensity, while the
sub-spectrum without the inversion pulse represents the protons for 13C-labeled and the
unlabeled compounds, i.e., the total concentrations. 13C decoupling is applied during the
acquisition of the free-induction decays to collapse
complexity while increasing the sensitive of

13C-1H

13C-NMR

couplings, reducing spectral

more than tenfold [64]. However,

its overall application is still limited in vivo by low spectral resolution [65, 99].

Mass Spectrometry (MS)
The first mass analyzer, then called parabola spectrograph, was developed in 1912 by
the English physicist and Nobel Laureate J. J. Thomson, who discovered that the flow of
charged particles can be deflected when exposed to an electromagnetic field. Based on
his discovery Thomson built an instrument that could separate charged particles based
on their mass number and subsequently detected on photographic plates[67]. This
invention made it possible to show evidence of the existence of stable isotopes of an
element by Thomson after their discovery by Frederick Soddy in 1913 [68]. Since its first
development over a century ago Mass analyzers have evolved and today many different
types exist. One of the most prominent Mass analyzers in use is the quadrupole mass
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analyzer

(Figure

9),

which

consists of four parallel circular
or hyperbolic rods. Two opposing
rods

form

electronically

a

pair

and

are

connected.

To

generate an electrodynamic field
a direct current (DC) and a
radiofrequency (RF) are applied
to each pair. While a negative DC
is applied to one pair of rods, a
positive DC voltage is applied to

Figure 9. Mass Spectrometry (MS).
A MS consists of a single mass analyzer (Q1). After the
ion source converted molecules into gas-phase ions by
applying an electrical charge (e-) the mass analyzer is
set to allow metabolites of predefined m/z, e.g. 191
(blue dots) while filtering out metabolites of higher or
lower m/z (red dots), to pass through to a detector which
detects the electrically charged ions.

the other. This causes a shift in
RF phase by 180 degrees between the two pairs. The “magnitude of the electrodynamic
field” is determined by its RF and DC voltage. Only ions of a certain m/z value or a specific
m/z range will resonate with any given combination of DC and RF voltages and thus have
a stable trajectory within the magnetic field to pass through to the detector. Ions, whose
m/z value does not resonate with the electrodymanic field will hit the rods, be neutralized
and eventually removed from the mass analyzer. Mass analyzers can be run in one of
two modes: 1. Scan Mode (SM) and 2. Selective Ion Monitoring Mode (SIM). In Scan
Mode, both, the applied DC and RF voltage are changed in rapid succession to
sequentially identify the constituent ions of a mixture of analytes with varying m/z ratios.
Additionally, quadrupole systems can rapidly switch polarity and thereby monitor various
molecular ions of different polarity with each scan. In SIM mode, the electrokinetic field is
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preset to only allow ions of a preselected m/z ratio through to the detector. This method
is used to look for specific analytes of interest within a sample with very high sensitivity
[55, 69, 70].

Tandem Mass Spectrometry (MS/MS)
An evolution of MS is Tandem Mass Spectrometry, abbreviated as MS/MS, which
provides much higher analytical specificity compared to single MS. In MS/MS two
separated mass analyzers are set up in tandem to perform two independent consecutive
mass analyzer steps back-to-back. The triple quadrupole system is a common
configuration of Tandem Mass Spectrometry (Figure 10). Herein, a total of three
quadrupoles are coupled serially, two of which function as a mass analyzer and one as a
collision cell. The first quadrupole denoted as Q1 is a mass analyzer which moves
precursor ions of a specific m/z range or value towards the second quadrupole, Q2, which
functions as a collision cell and not as a mass analyzer. In this intermediate region of the
tandem mass spectrometer, preselected ions from Q1 are submitted to an inert collision
gas which facilitates collision induced dissociation, or fragmentation, of the precursor or
parent ion into their respective fragments, or daughter ions, which then move on to the
third quadrupole, Q3. This second mass analyzer, like Q1, is set to filter out product (or
daughter) ions of a specific m/z so that they can progress to the detector. The high
analytical specificity of MS/MS stems from its ability distinguish analytes of similar
retention time and m/z ratio by their fragmentation pattern. Fragmentation patterns are
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very unique to individual compounds and highly reproducible thus adding an additional
dimension
accurate

to
ion

identification.
Similar to single
MS, tandem MS
can be run in
different modes.
In

selective

reaction
monitoring (SRM)
Q1 and Q2 are
set to scan for
very
parent
daughter

specific
to

Figure 10. Tandem Mass Spectrometry (MS/MS).
Q1= quadrupole 1 (mass analyzer 1), q2= quadrupole 2 (collision cell),
Q2= quadrupole 2 (mass analyzer 2). A MS/MS system consists of a two
mass analyzers (Q1, Q3) and a collision cell (q2). After the ion source
converted molecules ions by applying the first mass analyzer is set to
allow metabolites of predefined m/z, e.g. 191 (blue dots) to pass through
to the collison cell where a collision gass is applied (Argon, Helium or
Nitrogen gas) which will break the so called parent (precursor) ion into a
daughter (product) ion. At the second mass analyzer product ions of a
predefined m/z, e.g. 111, are allowed to pass through to the detector
while ions of a different m/z are filtered out. The detector measures the
signal from the product ions.

ion

fragments, whereas in multiple reaction monitoring Q1 filters out a specific parent ion
while Q3 is set to scan for multiple product ions generated from the fragmentation of its
respective parent ion in Q2 [70, 71]. Mass spectrometry is a popular tool in metabolic
research due to its high sensitivity, high reproducibility and relatively fast sample
processing time. However, sample analysis can only be performed on in vitro and ex vivo
specimens, making it an invasive method and the sample liable to post-mortem
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degradation if not handled and processed properly. Also, even though Mass spectrometry
can be used to identify isotopologues of different
metabolites, it cannot provide position specific (isotopomeric) label information.

Mass Isotopomer Multi-Ordinate Spectral Analysis (MIMOSA)[71]
As mentioned above, one of the major shortcomings of Mass Spectrometry compared to
Nuclear Magnetic Resonance Spectroscopy is its inability to obtain position specific
(isotopomeric) labeling information of metabolites. This limitation was partly overcome by
the development of Mass Isotopomer Multi-Ordinate Spectral Analysis (MIMOSA) which
expands MS/MS analysis beyond mere measurement of isotopologues. MIMOSA is a flux
analysis platform that allows for stepwise computation of key metabolic flux rates. The
“mass isotopomer” aspect of MIMOSA utilizes the unique precursor to product ion
relationships in MS/MS-based ion fragmentation to identify carbon-specific position of
label. The “multi-ordinate” aspect directly interprets the kinetic transfer of isotope label as
it traverses a metabolic pathway by grouping measurable metabolites, such as citrate,
glutamate and succinate, into isotopomer families according to the metabolic reaction
they originated from (atom fate map). The stoichiometric relationship between those
isotopomer families can then be solved algebraically and the isotopomeric information
deduced [71]. A full description of MIMOSA is exemplified in CHAPTER III.
A comparison of individual strengths and weaknesses of NMR and Mass is shown in
Table (2)
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Sampling
Sample
measurement
Sensitivity

NMR
in vivo, ex vivo, in vitro

High
variable

Mass Spectrometry
ex vivo, in vitro
Different methods for same
samples, e.g. chromatography
columns, polarity
High (nM)
short-long depending on
chromatography
Destructive;
post mortem degradation
Moderate
variable

Limited (40-100)

High (>500)

Yes, limited sensitivity

Yes, high sensitivity
Position-non-specific (MS)
Position-specific (MS/MS with
MIMOSA)

All measurements at
once
Low (mM)

Experimental Time

Moderate to long

Sample Recovery

Non-destructive

Reproducibility
Sample preparation
Number of
detectable
metabolites
Target analysis
Tracer information

Position-specific

Sample Processing
Costs

High

Low to moderate

Table 2. Comparison between NMR and Mass Spectrometry. Table adapted from [83]

Current controversies in stable isotope tracing
Despite being a staple of metabolic research for nearly three and a half decades, stable
isotope tracer methods come with their own liabilities and pitfalls. Three commonly used
tracer methods employed to measure and quantify hepatic metabolism in vivo,

13C-

labeled acetate, lactate, and propionate, have led to highly divergent concepts of basal
hepatic metabolism and have raised concerns about the validity of the data generated
using these tracer methods [72-76]. For instance, depending on the design of the study,
up to a 5-fold difference has been reported in the literature for key basal metabolic fluxes,
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including pyruvate cycling (VPEPCK

and

VPK) and anaplerosis (VPC). These differing

measurements of basal metabolic state have made it impossible to pinpoint the exact
targetable aberrations of hepatic mitochondrial metabolism that play a role in the
development and progression of T2DM, IR and NAFLD [4, 29, 41, 75, 77-79].
The reason for these stark differences in metabolic rates has to do with the complexity
and interrelatedness of metabolism. Due to which metabolic flux analyses require
simplifications derived from multiple assumptions if any conclusions are to be made about
a metabolic system. The degree to which these assumptions are accurate determines
how reliably a metabolic modeling platform can compute metabolic fluxes. Such
assumptions may have been measured or may have been made a priori based on in silico
simulations, educated guesses and mathematical inferences. Oftentimes, assumptions
remain subjective since they have not been experimentally validated with direct
measurements and hence they are susceptible to compounding and analytical errors [74,
75, 77]. Consequently, calculated metabolic rates are highly platform and model
dependent and can vary significantly [80].
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In general, the debate regarding the validity of tracer studies surrounds the choice of
tracer, its primary tissue of uptake and oxidation, as well as possible zonation of its
metabolism within the target tissue and its possible impact on metabolism. Interpretation
and analysis of stable isotope tracer studies are performed under the assumption that a
tracer, regardless of its route of administration, does not alter metabolism, is
predominantly and homogenously taken up and metabolized (oxidized) by the primary
target tissue (liver) without confounding label contribution from secondary tracers. Table
(3) shows a list of common pitfalls associated with tracer studies which are explained in
more detail in the section below
Common Pitfalls of Tracer Studies
1. Tracer modulates metabolism (Tracer Assumption)
2. Failure to reach steady-state, yet using steady state assumption for
metabolic modeling
3. Insensitivity to positional enrichment
4. Ambiguity in isotopomers
5. Reversible metabolic exchange reactions
6. Absent or distant relationship between measured precursor and
product enrichments
7. Post-isolation/post-mortem analyte degradation
8. Insufficient signal-to-noise
9. Metabolic compartmentation and zonation
10. Label dilution
11. Incorrect natural abundance and background correction
12. The requirement for high level technological and analytical expertise
Table 3. Potential shortcomings and pitfalls of in vivo tracer experiments. [2, 5, 14-19]

.
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Tracer Assumption
By definition a tracer is expected to trace a metabolic system without altering it. However,
when a tracer is infused close to its natural turnover rate, the tracer can become a
substrate for the metabolic reactions it is supposed to track, such that by providing mass
to the system, it can impact metabolism. Violation of this tracer assumption, therefore,
can generate widely spurious results. This was clearly demonstrated for glycerol as a
tracer of hepatic gluconeogenesis [91] where endogenous glucose production rates
increased linearly with the rate of glycerol infusion was increased. A similar concern has
arisen in human and rodent studies where

13C-labeled

propionate was used to assess

hepatic metabolism but demonstrated substantial modification of, hepatic pyruvate
cycling, anaplerotic fluxes and mitochondrial metabolism [4, 29, 77, 92, 93].

Likewise,

concerns about 13C-acetate as a tracer method have been raised. For instance, metabolic
models based on labeled acetate use acetate flux (VAC) to calculate Krebs cycle flux
(VTCA). However, acetate infusion contributed up to 25% to overall acetate flux and thus
artificially increased VTCA which in turn led to an erroneously low relative anaplerotic flux
(VANA/VTCA) which was

considered an “investigator- or tracer-perturbed” flux

calculations[29, 74].
Steady State Assumption
Many in vivo studies are designed to determine metabolic fluxes at steady state. These
calculations assume that metabolite concentrations are constant and isotope enrichment
has reached a plateau across all key metabolites by the time samples are taken. At steady
state, mass and isotope balance equations can be derived and solved from the fractional
enrichment data for metabolic flux analysis. If a system is using the steady state
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assumptions but is not at or near steady state the metabolic flux analysis wil generate
erroneous flux rates. Therefore it is essential to experimentally confirm steady state in
such cases [76].
Reversible metabolic exchange reactions and insensitivity to positional enrichment
Exchange reactions catalyze the reversible interconversion of amino and keto acids
without any net carbon loss or gain. Thus, as part of reversible systems exchange reaction
can lead to significant isotopic label dilution within a metabolic pool without contributing
any mass to a metabolic network. When not accounted for in metabolic flux analysis label
dilution from exchange reaction can be mistaken for a net metabolic flux and thereby
overestimate metabolic rates. For example, in vitro studies demonstrated that the dilution
of aKG by the exchange with its reciprocal unlabeled glutamate pool led to subsequent
dilution of citrate through a diluting exchange catalyzed by IDH. When using isotopologue
information only in metabolic flux analysis this dilutional exchange is missed and leads to
an overestimation of reverse carboxylation reaction of IDHr flux [71]. Therefore it is
necessary to obtain position specific labeling information of citrate to measure its
dilutional exchange from aKG directly and correct for it when calculating flux rates of IDH
based on fractional enrichments. Unfortunately, studies that cannot the position specific
labeling information of Krebs cycle intermediates, such as citrate, can easily miss these
fine but important nuances, and hence are liable to spurious flux analysis.
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Post-isolation and post-mortem analyte degradation/metabolism
As an invasive method Mass Spectrometry cannot measure metabolites in vivo and
therefore requires ex vivo tissue samples for analysis following an in vivo tracer study.
However, tissues and their volatile, low abundant metabolites, such as acetyl CoA, OAA,
etc, are highly sensitive to postmortem changes and cell degradation if not processed
rapidly and efficiently. Therefore, ex vivo tissue and plasma samples require rapid in situ
freeze clamping with aluminum tongs pre-chilled in liquid nitrogen prior to further analyses
to avoid spuriously low measurements of enrichments and concentrations these already
low abundant and labile metabolites. For example, studies have shown that hepatic
acetyl-CoA degrades within less than 30 s after collecting liver tissue [81]. Therefore
extreme diligence need to go into post study tissue isolation to avoid postmortem
degradation and spurious flux calculations.

Fast Vx Assumption
Another longstanding concern/debate[94-98] pertains to the amino transferase exchange
rate (Vx) which underlies an assumption used for NMR-based in vivo metabolic flux
calculations. 13C-NMR cannot measure Krebs cycle intermediates directly in vivo because
of their low concentrations. Instead, 13C-NMR can detect the strong 13C signal of aspartate
and glutamate. These amino acids are assumed to be in rapid exchange with Krebs cycle
intermediates, OAA and αKG, respectively. Due to their higher signal they can act as
NMR-observable trapping pools for

13C

label in Krebs cycle intermediates if and only if

the exchange rate of these pools is fast relative to the Krebs cycle flux. A common
30

assumption in modeling oxidative metabolism, then, is that Vx is very rapid exchange of
isotope label between the mitochondrial and cytosolic metabolite pools and thereby
makes glutamate and aspartate labeling a reliable readout of αKG and OAA, respectively.
If Vx exchange is actually slow it would result in marked errors in VTCA and other related
rates [94, 97, 99, 100].

Homogeneity of tracer uptake
In vivo tracer studies generally assume that there is uniform utilization of a tracer by all
cells in a tissue such that an enrichment of the tissue as a whole is the same as the
individual cells. Metabolic zonation pertains to the preferential uptake of a metabolite by
one cell type versus another across a tissue bed. For instance, some tracers are of
sufficiently low concentration and are taken up so avidly by the liver, that the cells on the
periportal side have much higher exposure to tracer than those on the perivenous side.
This results in different enrichments across the hepatic bed that are ‘averaged’ by tissue
homogenization or spectral analysis. Propionate, glycerol and acetate are all subject to
metabolic zonation [73, 101-104]. In the case of propionate, periportal hepatocytes were
shown to take up significantly more tracer than perivenous hepatocytes [101-103]. The
heterogeneity of tracer uptake is particularly problematic when flux estimates are based
on the assumption that a tracer distributes its label evenly across all hepatocytes. By
averaging out high and low labeling signal overall Krebs cycle activity will not only
underestimate metabolic flux analysis but it will also be significantly skewed when any
changes in zonation occur [73, 101, 102, 104]. Another source of a skewed label signal
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has been reported for acetate as a tracer. [13C]acetate undergoes significant dilution in
the splanchnic region before entering the hepatic Krebs cycle, resulting in a heterogenous
tracer pool being taken up into liver liver metabolism. This has reportedly led to lower
enrichments of Krebs cycle intermediates and therefore to an underestimation Krebs
cycle flux [105, 106].

Dilutional influx into the Krebs cycle
At metabolic and isotopic steady state, the relative contribution of a labeled precursor to
product is determined by the ratio of their 13C enrichment ratios. When all of the substrate
is converted into its product the ratio should be 1. However, at intersecting pathways
when more than one substrate contributes to the product, the entry of carbon from an
unlabeled source will dilute (reduce) the precursor to product enrichment ratio
proportionately to its relative contribution to the overall product formation. There for this
precursor to product ratio is particularly helpful for determining if significant dilutional
fluxes, e.g., anaplerosis, or exchange reactions, at metabolic intersections exist.
Moreover, knowledge about the dilution of Krebs cycle intermediates is crucial for
accurate metabolic flux calculation as it directly impacts metabolic flux analysis and can
lead to significant errors in flux calculations when not properly factored into the metabolic
model. For instance, due to the restricted information about individual Krebs cycle fluxes
that can be gleaned from the labeling pattern of NMR observable aspartate and glutamate
pool, dilutional fluxes into the Krebs cycle from anaplerotic sources other than PC or
exchange reactions have not been measured before and rather assumed to be negligible.
Yet, recent in vitro studies of Krebs cycle metabolism have shown reported a significant
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label dilution of Krebs cycle intermediates coming from anaplerotic glutamate influx as
well as from exchange reactions between the Krebs cycle intermediate αKG and the
intracellular glutamate pool [71]. Consequently, omitting dilution of mitochondrial
metabolite enrichments has a significant impact on critical Krebs cycle rates, inasmuch
that it will lead to an underestimation of overall Krebs cycle rate which in turn will result in
an overestimation of reductive carboxylation, PC mediated anaplerosis and substrate
cycling relative to overall Krebs cycle flux .

Label recycling, secondary tracers and isotopomer/isotopologue ambiguity
When a tracer, such as [13C]acetate, is infused systemically, it not only enters the primary
tissue of interest, such as liver, but it will also be taken up by peripheral, extrahepatic
organs, e.g. muscle, where its label can be metabolized and recycled to generate a
secondary tracer, such as [13C]glutamine. The labeled glutamine from muscle can then
enter the systemic circulation and introduce

13C

label into the hepatic Krebs cycle. As a

consequence, the intramitochondrial [13C] glutamate/glutamine pool no longer reflects just
the label originating from [13C]acetate but it is a mixed pool of intra- and extrahepatic
labeling distribution [74]. Thereby leading to overlapping, ambiguous labeling patterns of
key hepatic metabolites confounding metabolic flux analyses (Figure 11). Similar to label
recycling resulting in mixed pools of primary and secondary tracers, another concern
pertaining to tracer studies are ambiguous, non-distinct labeling patterns. The concern
raised about [1- 13C]-acetate was its inability to generate a unique enough labeling pattern
to properly assess anaplerosis in vivo when using the ratio of [1-13C]- to [5-13C]-labeled
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glutamate. For example, [1-13C]acetate generates [5-13C]glutamate with each turn of the
Krebs cycle and the resultant enrichment remains constant at steady state. However, [113C]-glutamate

on the other hand is not equally generated to C5 labeled glutamate as it

needs an additional turn of the Krebs cycle to be made. Moreover, 13C label in C1 position
of glutamate is liable to dilution from anaplerotic PC flux at the level of OAA. Thereby,
erroneously underestimating anaplerosis in vivo [77, 107]. Another examples is [1,2,313C ]lactate.
3

This tracer has been speculated to not fully undergo randomization of label

across fumarase, resulting in lower than expected mass isotpomer distribution in glucose
and hence in underestimation of relative pyruvate cycling and in overestimation of
gluconeogenesis [107]. Table (4) shows a list of primary tracers and their assumed
secondary tracers.
Primary tracer
[13C]acetate
[13C]glucose
[13C]lactate
[13C]propionate

Secondary Tracer (Tissue)
[13C]glutamine (muscle)
[13C]lactate, [13C] CO2 (liver, muscle)
[13C] CO2, [13C]glucose (liver)
[13C]glucose (kidney)

Table 4: Primary tracers and their potential secondary tracers and tissue of origin.
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Figure 11. Label recycling and secondary tracer
Generation of complex primary and secondary labeling pools and patterns of hepatic
metabolites from tracer recycling and tissue cross talk. This results in biased flux
analysis which results in spurious metabolic rates. Label from a tracer not only enters
the primary organ of interest, i.e. the liver, but also other organs where label will get
transferred to subsequent metabolites which then re-enter the systemic circulation
and could potential be recycled in the primary organ of interest and thereby
introducing a secondary more complex labeling pattern.

Incorrect natural abundance and background correction
Since stable isotopes of exist naturally, any metabolite has a certain probability of carrying
one or more stable isotopes in its molecular structure. The heavier isotopes of some
atoms occur at a significant abundance. For instance, in the case of carbon atoms, 1.11%
of all carbons are

13C

with the remainder being

12C

[53, 55]. Therefore, for a metabolite

with n number of carbons, there is a n*1.1% chance of carrying a naturally occurring 13C
label in its carbon backbone, with 2n possible patterns of positional 13C distribution across

35

the entire (asymmetrical) molecule. For example, a six carbon molecule has a probability
of 6.66% of having any one of its 12C carbons naturally being replaced by a 13C.
Since metabolic flux analysis is made based on the relative distribution of isotopic
enrichment from an exogenous tracer to subsequent metabolites throughout a metabolic
pathway [55, 66] the naturally occurring label needs to be taken into consideration and
corrected for. Otherwise, the non-negligible contribution of NA of 13C will lead to spurious
quantitative and qualitative flux estimates of metabolic networks [82-84]. To account for
naturally occurring label, natural abundance (NA) correction need to precede any APE%
based flux calculations. Many different approaches have been developed to account for
NA, such as computation of NA contribution to labeled samples by measuring unlabeled
standards to mathematical NA correction matrices and binomial and multinomial
probability calculations [82]. Regardless of how the NA is computed, it is ultimately
subtracted from the overall measured enrichment of each atom [55, 85, 86]. However,
there are many factors that can impact the accuracy of NA corrections techniques, such
as tracer impurity, imperfect mass spectra with missing peaks and poor signal to noise
intensity, or simply not considering that once an atom is labeled by a tracer it can no
longer carry a natural abundant stable isotope. Especially, in the two latter cases simple
correction for natural abundance by subtraction can lead to overcorrecting and thereby to
negative enrichment data [85, 87]. In addition to naturally occurring isotopes, background
noise in the analyzed sample can confound and artificially raise isotope signal. Therefore
it also needs to be accounted for. To adjust for both, NA and background noise, a common
practice is to use a baseline background (control) sample without any tracer infusion for
background correction and then perform NA correction on the background corrected
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samples by correcting the total tracer enrichment by the natural abundance of the
respective atom. Of note, this approach does not take into account changes in the
metabolic system during which the background enrichment might change. Therefore, this
approach is inadequate for studies in which the system under investigation undergoes
major changes, e.g. during drug intervention, clamp studies or with different diets. In those
cases, control samples that undergo the same systemic change without tracer infusion
need to be obtained simultaneously with the tracer study. Incorrect attribution of label
incorporation into a metabolite either from omitting to correct for background and NA or
from overly correcting for NA will lead to biased qualitative and quantitative flux analysis
[82, 83, 85, 88-90].

Expertise and technological limitations
Both, NMR and MS analysis require high level of expertise for day to day operation,
proper calibration, adjustment of instrumentation settings are vital for accurate analytical
measurements and troubleshooting. Otherwise, false peak detection and assignment can
lead to misinterpretation of data and thus to spurious flux analysis. Technical limitations
of NMR for in vivo studies stem from low sensitivity of 13C-NMR and overlapping 1H-NMR
spectra. For example, in 1H-NMR highly abundant molecules, such as water or lipids, can
overlap and obscure important peaks of lower abundant metabolites making exact
spectral assignment difficult [60-65]. On the other hand,
sensitivity due to the low natural abundance of

13C

13C-NMR

suffers from limited

(1.1%). Therefore, metabolites must

be highly concentrated to detect a measurable signal and to overcome the low signal to
noise ratio of 13C-NMR [66].Thus necessitating metabolite concentrations in the millimolar
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range [55, 65]. Some of these limitations have been overcome by higher localization
accuracy and improved sensitivity of POCE. However, its overall application is still limited
in vivo by low spectral resolution [65, 99]. MS spectrometry is more sensitive than

13C-

NMR, but especially single MS cannot provide position specific label information. This
limitation for MS can be -at least in part- be overcome by MS/MS. Through strategic
fragmentation and the resultant parent daughter fragment relationships of specific
metabolites isotopomeric information can be deduced. However, thus far, many of these
techniques have been restricted to major centers and researchers with expertise in the
area of metabolic studies.

To summarize, misrepresentation of metabolic flux can originate from many different
potential flaws in tracer study design, experimentation and analysis.

Each of the here

proposed shortcomings and potential pitfalls of stable isotope tracer studies, individually
or in any combination, can result -or have resulted- in biased flux analysis and thus in
spurious flux calculations. Therefore, every tracer method warrants careful validation and
diligence in data processing and analysis to establish a “ground truth” of hepatic
metabolism [74, 75, 77, 94-96, 100, 108, 109].
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CHAPTER II: SYSTEMATIC DEVELOPMENT AND VALIDATION
OF GLUTAMINE AS A TRACER OF HEPATIC METABOLISM
Development of [1,2 13C2]-L-Glutamine for in vivo metabolic flux analysis
Many considerations go into the design of an in vivo tracer study for metabolic flux
calculations. A step-wise process was developed to validate [1,2-13C2]-L-glutamine as a
tracer. We systematically and empirically assessed potential fatal pitfalls of glutamine as
tracer that could significantly bias the flux analysis including: 1) Identification of an
infusion rate that does not alter metabolism, 2) Definition of input functions for calculations
and screening for complex secondary labeling patterns, 3) Confirmation of isotopic steady
state, 4) identification of relevant isotopologues and 5) kinetic and steady-state mass
isotopomer analysis of citrate, glutamate, succinate.

Identification of an infusion rate that does not alter metabolism
By definition, a tracer should trace metabolism without altering it (the ‘tracer assumption’).
Hence, the tracer infusion should not significantly impact downstream chemical reactions
or the constituent tracee pool of the metabolic system that is being assessed [74]. An
ideal tracer rate is one that not only leaves metabolic homeostasis unperturbed but still
provides sufficiently detectable label signal across all key metabolites necessary for
metabolic flux analysis (MFA) by MS or NMR [53, 55, 110]. Commonly a tracer infusion
rate is chosen that is a fraction of the endogenous natural turnover rate of its tracee. At
metabolic and isotopic steady state, the turnover rate is a balance between the rate of
appearance and rate of removal of a tracee into and from its designated tracee pool, e.g.,
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glucose in plasma. [53, 55, 110]. Tracer infusion rates can be optimized by first
determining the endogenous turnover rate and then empirically testing different infusion
rates while monitoring the system for changes in metabolic homeostasis, e.g., metabolite
concentrations, hormone secretion, etc. In this manner, the requirement for adequate
signal can be maximized while metabolic impact is minimized.
First, we empirically determined the tracer infusion rates that maximized glutamine
enrichment but minimized the impact on systemic metabolism. Basal glutamine turnover
rates were calculated from primed continuous intravenous infusion of [1,2

13C ]-L2

glutamine in overnight fasted, male Sprague Dawley rats (Figure 12).

Figure 12. Determining endogenous glutamine turnover.
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To identify an infusion rate for L-glutamine that minimally perturbed glucose homeostasis,
we infused “cold” (unlabeled) L-glutamine at three increasing rates, that is, 3-, 6-, and 12µmol/kg/min in 30 minute increments along with a primed continuous infusion [6,6-2H2]glucose to trace the endogenous glucose turnover. The glutamine infusion was started
during and metabolic isotopic steady state of the glucose tracer. We measured plasma
glucose, glycerol and insulin concentrations before and after each 30 mins glutamine
infusion increment (Figure13).

Figure 13. Identifying a tracer infusion rate for glutamine.
To identify an infusion rate for L-glutamine that does not perturb glucose homeostasis we
infused “cold” (unlabeled) L-glutamine at three increasing rates, that is, 3-, 6-, and 12µmol/kg/min along with [6,6-2H2]-glucose to trace endogenous glucose turnover and measured
plasma glucose, glycerol and insulin concentrations before and after each 30 mins glutamine
infusion increment.
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At 3 µmol/kg/min of tracer, the calculated glutamine rate

Glutamine Turnover

of appearance (Ra) was 28±2.5 µmol/kg/min which was
40

Increasing the infusion rate as high as 12 µmol/kg/min
(40% of the endogenous rate) did not impact the

µmol/kg/min

in keeping with prior reports [111, 112] (Figure 14).

30
20
10
0

glutamine Ra (30±1.4 µmol/kg/min) but roughly doubled
the plasma and hepatic glutamine concentration (Figure
15 D, E). The 12 µmol/kg/min infusion also did not
change the steady state concentration of other key
metabolites. Importantly, glutamine infusion did not

3

12

Glutamine Infusion
(µmol/kg/min)

Figure 14. Glutamine Turnover.
Glutamine at an infusion rate of 12
µmol/kg/min does not impact
endogenous glutamine turnover.
Glutamine was infused at a primed
continuous rate of 3 and 12
µmol/kg/min for 120 mins. N=7.

perturb the cytosolic redox state ([NAD+]/[NADH] ratio),
which can be assessed by the pyruvate to lactate ratio because of the rapid equilibrium
across LDH (Figure 15 F)[113]. In a separate experiment, a primed-continuous infusion
of [6,6 2H2]-D-glucose (for measurement of glucose Ra) was followed by the concomitant
step-wise infusion of unlabeled glutamine vs. ½ NS as a control at the same three
rates[55, 110, 114, 115]. Importantly, endogenous glucose Ra as well as plasma glucose
and insulin concentrations were unchanged compared to control (Figure 15 A-C).
Together these data demonstrate that, as a tracer, glutamine infusion as high as 40% of
the endogenous glutamine Ra, does not significantly change whole body glucose
metabolism or redox.
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Figure 15. Developing glutamine as a tracer.
Glutamine infusion rates do not have significant impact on (A) plasma glucose concentration (B) Endogenous
glucose production (C)Plasma insulin concentration (D) Plasma metabolites (E)Liver metabolites (F) Plasma
RedOx state. Even at an infusion of 12umol/kg/min all metabolites remained at steady state. N=6-8
43

Defining input functions and screening for complex secondary labeling patterns
At steady state, systemic infusion of a labeled tracer, such as glutamine, does not interact
with any singular tissue but could enter into the metabolic pathways of any tissue capable
of taking it up. Any tissue that takes up the metabolite then has the possibility to generate
other

13C-labeled

products that can reenter the circulation. These ‘secondary tracers’

have the potential impact metabolite labeling patterns within the tissue of interest. To
investigate if infused

13C

label from glutamine was transferred to other metabolites we

assessed for high likelihood secondary tracers in lactate, pyruvate, lactate, glycerol,
alanine, bicarbonate and short chain fatty acids (SCFA). Importantly, because all of these
metabolites have high turnover rates, they could potentially circulate to other tissues and
be incorporated in metabolic processes that might confound metabolic analysis. As an
extreme case, [1,2-13C2]glutamine was continuously infused for 4 hours at 12 µmol/kg/min

Figure 16.Screening for label recycling.

and then plasma, liver, kidney, muscle and WAT (freeze clamped in situ) were collected
and screened for label distribution (Figure 16).
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Figure 17a: POCE Spectrum of liver: Top trace: Total spectrum
and Bottom Trace: difference spectrum from liver following 4
hours of labeled glutamine infusion.
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Figure 17b: Detail of POCE lactate C3 difference spectrum. A
small enrichment was seen in C3 lactate.
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Figure 17c: Detail of POCE glutamine/glutamate C3 and C4
difference spectrum. There was no discernable enrichment in
glutamine/glutamate C3 and C4 above background, natural
abundance and overlapping spectra.
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Figure 17d: Detail of POCE glutamine/glutamate C2 difference
spectrum. Enrichment of C2 of glutamine and glutamate.
Figure 17. POCE Spectrum of liver.
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In the tissue and plasma extracts,
heteronuclear Proton Observed
Carbon Edited (POCE)
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18). This indicates, that in addition

Figure 18. Screening for secondary tracers by GC-MS.
No unexpected label recycling was Identified in short
chain fatty acids, glycerol or glucose.

to [1,2-13C2] glutamine,
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[3-13C] lactate must be considered in the model. The spectra for glutamine/glutamate C3
and C4 showed no discernable enrichment with heavy overlap from other metabolites,
such as β-hydroxy butyrate.

Metabolite

13C

Label Position

Tissue

Alanine

C3

Liver

Lactate

C3

Liver

Glu/Gln

C2

Liver, Plasma

Glycerol

none

none

Propionate

none

none

SCFA

none

none

BOHB

none

none

Table 5. Label distribution.
Label distribution after a 4 hour infusion of [1,2-13C2]-L-glutamine. No complex secondary labeling
patterns were generated by [1,2 13C2]-L-glutamine. Glu/Gln = glutamate, glutamine; SCFA = short
chain fatty acids; BOHB = beta hydroxy butyrate.
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Determination of isotopic steady state
One of the goals of in vivo kinetic studies is to infuse a tracer until a constant isotope
enrichment is reached. This is also referred to as plateau enrichment (Ep), isotopic
equilibrium or isotopic steady state and is crucial for metabolic modeling. At steady state
net flux is zero, meaning that all influxes equal all effluxes and thus the pool sizes are
constant. At isotopic and metabolic steady state mass balance and isotope balance
equations can be solved for metabolic flux analysis (MFA) and the in vivo kinetics, such
as turnover rates, of metabolites can be assessed (Figure 19).

Figure 19.Steady States.
Panels show infusion (F) of 13C label (tracer) into a 12C metabolite pool (tracee). The overall concentration
of metabolites does not change with the tracer infusion. At steady state the rate of appearance (Ra) equals
the rate of disappearance (Rd) and a plateau enrichment (Ep) of isotope label is achieved within the
metabolite pool. During a primed continuous infusion the Ep approximates a square wave function. Left
Panel: A shows the metabolic pool before and during the primed continuous tracer infusion D-F. A: no
tracer infusion; B-C: primed bolus; D-E: continuous infusion. Metabolic Steady State:A-E; Isotopic Steady
State (Ep): E. Right Panel shows the measurement of metabolite concentrations before (A) and during
tracer infusion (B-D) and at steady state (D).
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After confirming that at a glutamine infusion rate of 12 μmol/kg/min plasma and liver
metabolite concentration did not change (we administered [1,2-13C2]-L-glutamine as a
primed continuous infusion to ensure detectable tracer signal within key metabolites and
to characterize their plasma and tissue isotope build up curves and plateau enrichments.
The ability to track evolution of fractional enrichments of plasma metabolites during a
tracer infusion by serial blood draws is relatively straight forward. In order to assess
temporal build up of label in liver metabolites, hepatic tissue was isolated from timed
cohorts of different animals (Figure 20).

Figure 20. Determining isotopic build up curves and steady states for [1,2-13C2] L-glutamine.

Plasma samples following the primed-continuous infusion of [1,2-13C2]-L-glutamine
displayed an approximately square wave pattern for M+2 Glutamine that was at steady
state by 15 minutes with an enrichment of 25%. This plateau enrichment remained stable
for the duration of the 2h experiment (Figure 21 top panel).
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Figure 21.Isotopic steady state.
[1,2 13C2]-L-Glutamine label reaches steady state within less than 60 mins across all
metabolites in plasma (top) and liver (bottom). Glutamine was infused at a primed continuous
rate of 12 umol/kg/min. N=6-8.

Plasma and hepatic Glutamine enrichments were fully equilibrated within minutes of
50

starting the infusion (Figure 21). Glucose was a dominant secondary metabolite and its
M+1 isotopologue exponentially increased to a plateau within one hour to a value of 2%.
No significant M+2 glucose was detected. M+1 pyruvate, lactate, alanine, and glutamate
all trailed the glucose enrichments at a lower percentage. Similarly, extra- and
intramitochondrial metabolites/intermediates downstream from glutamine reached their
stable fractional enrichment plateaus within less than 60 mins of the glutamine tracer
infusion (Figure 21). The fast equilibration of

13C

label with whole body Krebs cycle

metabolism was indicative of a prompt succession of consecutive reactions where isotope
label traversed the entire Krebs cycle to reach equilibrium rapidly.

Identification of relevant isotopologues
The M+2 glutamine tracer is deaminated to M+2 glutamate that enters the Krebs Cycle
as M+2 αKG via the GDH reaction. Doubly labeled αKG was then decarboxylated to M+1
succinate via OGDH and further metabolized to M+1 malate, citrate, and αKG. Then,
through aminotransferase exchange M+1 αKG produced M+1 glutamate. Any remaining
13C

label that had traversed the oxidative Krebs cycle was then lost to CO2 during the

decarboxylation reaction of OGDH. Thus, after one full traverse of the Krebs cycle

13C-

label from doubly labeled glutamine did not contribute to subsequent turns past αKG. The
other fate for M+2 αKG was reductive carboxylation to M+2 citrate catalyzed by IDHr.
Next, M+2 citrate is metabolized to M+0 acetyl CoA and M+2 malate by the ACLy
reaction. No higher isotopologue species, such as M+3 citrate or malate were observed.
Table 6 shows the complete list of measured isotopologues.
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Metabolite

Isotopologue

APE% SEM (+/-)

M1

1.12 (0.13)

M2

25.18 (1)

M1

2.32 (0.28)

M2

6.76 (0.63)

M1

5.24 (0.46)

M1

2.95 (0.19)

M2

0.24 (0.05)

M1

2.6 (0.36)

M2

0.13 (0.07)

Glutamine

Glutamate

Succinate

Malate

Aspartate

M1

2.2 (0.24)

Citrate
M2

3.13 (0.45)

Pyruvate

M1

0.58 (0.11)

PEP

M1

1.15 (0.56)

Lactate

M1

0.48 (0.09)

Table 6. Steady state enrichments.
Steady State enrichments (APE%) of all LC/MS observed isotopologues. Data are the
mean (SEM) of n=8
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Mass isotopomer analysis of citrate, glutamate, and succinate

Some mitochondrial metabolites, such as OAA, succinyl CoA and acetyl CoA are difficult
to measure directly due to various reasons, including their overall low abundance,
compartmentalization (cytosol vs mitochondrial matrix), as well as analytical difficulties
stemming from high volatility, instability and fast degradation during processing or
complex mass spectrometry fragmentation patterns [71, 116]. Others can be measured
but because they are in rapid equilibrium (e.g., oxaloacetate<->malate<->fumarate,
citrate<->aconitate<->isocitrate), they provide limited additional information. Due to the
resultant distinct

13C

labeling pattern of Krebs cycle intermediates at steady state, key

intermediates can be grouped into unique isotopologue and isotopomer families based
on their precursor/product fragment relationships as described by Alves et al. using the
MIMOSA strategy. Figure (22) shows the complete initial theoretical fate map of all
possible isotopologues and isotopomers of all key Krebs cycle and constituent
metabolites.
Through stepwise elimination of superfluous isotopologue and isotopomer species along
with positional deconvolvement of citrate, glutamate, and succinate the theoretical fate
map could be simplified to an actual “observed” fate map (Figure 24) and the information
could then be used as key inputs for specific metabolic flux analyses (CHAPTER III).
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Figure 22. Theoretical carbon fate map.
Theoretical carbon fate map expected from [1,2-13C2]glutamine tracer strategy. V =
metabolic flux. Isotpologues/isotopomers are grouped based on the enzymatic reaction it
originated from indicated by subscript after metabolite name. ACLY = ATP citrate lyase,
CS = citrate synthase, IDHr/f = isocitrate dehydrogenase (reverse/forward), OGDH = alpha
ketoglutarate dehydrogenase, PC = pyruvate carboxylase, PDH = pyruvate
dehydrogenase, SDH = succinate dehydrogenase.
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1.1 Deconvolvement of citrate
Citrate isotopologues are grouped into distinct families based on stoichiometric labeling
patterns and their inherent precursor/product relationships mediated by specific
enzymatic reactions. For instance, citrate isotopomers can be grouped into stoichiometric
families based on their generation via CS (e.g., condensation of labeled or unlabeled OAA
with labeled or unlabeled acetyl-CoA). Similarly, ligation of labeled or unlabeled αKG with
labeled or unlabeled CO2 can batch affect labeling patterns via the IDHr reaction. Citrate
has a prochiral center which is recognizable by enzymes but not by the mass
spectrometer. Fragmentation of a citrate parent ion can generate a pro-S and pro-R
daughters. During 191/111 citrate fragmentation, carbons C1 and C5 are lost with equal
probability. The probabilities citrate families occupancy can be determined from the
stoichiometry of isotopologues generated from enzymatic racemization of precursors.
Likewise, known probabilities of parent-daughter fragmentation patterns can be used to
compute the occupancy of each isotopomer family. Table 7 shows the predicted
fragmentation patterns based on the initial theoretical fate map (Figure 22). Obviously,
this is too complicated to find a unique distribution of isotopologues into families.
Fortunately, using information from initial NMR and MS analysis of the samples as well
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Table 7. Theoretical parent daughter.
Parent daughter fragmentation patterns of citrate predicted from the theoretical fate map. IDHr:
reverse Isocitrate Dehydrogenase, PDH: Pyruvate Dehydrogenase, CS: Citrate Synthase,
CSPC: Citrate Synthase with label originating from Pyruvate Decarboxylase, CSACLy: Citrate
Synthase with label originating from Pyruvate Decarboxylase

as following the kinetics of labeling, many of the theoretically possible families can be
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eliminated to provide a much simpler distribution of family occupancies (Figure 24, at the
end of this chapter).
For instance, from the absence of observed citrate isotopologues m/z >193, any families
containing members with M+3, M+4, M+5 and M+6 citrate can be eliminated due to the
fact that we did not measure any citrate 194 or higher m/z parent ions. Since M+2 citrate
was the most enriched of the citrate isotopologues, then in the absence of measured M+3
citrate, labeled CO2 is unlikely to interfere with rate calculations in the liver. A measured
citrate 193/112 to 193/113 ratio of ~1 ruled out significant family e (which has a ratio of
1/3) that would occur from the recycling of M+2 malate from ACLy back into citrate via
CS. Lack of detectable succinate M+2 also ruled out significant [3,6-13C2]-citrate or
significant combinations M+1 acetyl CoA with M+1 OAA. Regarding the latter, this should
not be surprising since the highest predicted combination based on the measured
isotopologues is less than 0.02% enriched.
From the remaining parent daughter fragments, only one M+2 family (family a) and
three citrate M+1 families (families b, c and d) were observed (Table 8).
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With these limited possibilities, practical information for flux determinations can be
obtained from the fragment deconvolvement which is discussed below.

Table 8. Observed citrate isotopologues and their respective.
Citrate Isotopomer Families grouped based on their original enzymatic reaction and
eliminating other family members based on precursor/product enrichment. IDHr: reverse
Isocitrate Dehydrogenase, PDH: Pyruvate Dehydrogenase, CS: Citrate Synthase, CSPC
Citrate Synthase with label originating from Pyruvate Decarboxylase

Citrate M+3 to M+6
Citrate 194 or higher m/z ions were not detected and eliminated any citrate families
containing these isotopologues from the carbon fate map. Therefore,

13C

enrichment of

the CO2 pool and combinatorial labeling was negligible and did not contribute significantly
to labeling patterns through IDHr or PC.

Citrate M+2
[1,2-13C2]citrate which originates from reverse IDH. IDHr catalyzes the production of
[(1,2)-13C2]citrate from [1,2-13C2]αKG coming from [(1,2)-13C2]glutamate. The malate/OAA
M+2 isotopomers (denoted as [(1,2)(3,4)-13C2]OAA) originated only from citrate M+2
through the ACLy reaction. However, due to its low abundance, malate/OAA M+2 did not
contribute any measurable label to citrate through CS as indicated by the 1:1 ratio of
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193/112 to 193/113. An excessive deviation from this ratio would come from [(3,4)13C ]malate
2

being converted to [(3,6)-13C2]citrate that would otherwise increase the pool

of citrate 193/113 relative to 193/112. Mal M+2 enrichment was slightly higher than Asp
M+2 indicating equilibrium across OAA. Citrate isotopologue family cita was the only
observed citrate M+2 family.
cita = 2*193/112 = 2*193/113 = citrate M+2

Citrate M+1
Isotopologue family citc originates from the condensation of oxaloacetate M+1 with
unlabeled acetyl CoA through CS. Isotopologue family citb originates from condensation
of unlabeled oxaloacetate with labeled acetyl CoA through PDH. Isotopologue family citd
originates from anaplerotic flux through PC. Using the 111 daughter, family citb+d are
computationally indistinguishable using the 111 fragment and despite having different
positional probabilities collectively denoted as [(2)(3)(4)-13C1]citrate without assignment
of a probability to any individual position. The contribution of the cit families to the 192/112
species are:
•

192/112 = citb + ¾ citc + citd

Since citb+d are indistinguishable then:

•

citb+d = 192/112 – ¾ citc
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Isotopologue Family citc originates from labeled OAA generated by the oxidative Krebs
cycle and unlabeled acetyl CoA and represents [(1)(6)-13C1]citrate with equal probability
of C1 and C6. We take advantage of the fact that only family c generates the M+1
fragment 192/111.
•

citc = 4*192/111

With that, the size of family citb+d can be solved by substituting citc with 4*192/111 since
there are 3 192/112 generated for every 192/111:
•

citb+d = 192/112 - 3*192/111 = CitM+1 - 4*192/111
Given the low predicted flux of VPDH relative to VPC in the liver, citb+d is expected to

dominate the citb+d signal. Family citc represents the first turn of the TCA cycle and its
apparent size is anticipated to be large, but it will be further impacted by reductive
exchange reactions as well as any unexpected C5 label. In the liver, there was an
undetectably low amount of labeled bicarbonate (see above), therefore reductive
exchange across IDH will dilute (rather than augment) the M+1 enrichment with from loss
13C ]citrate
1

of label in [6
precursor [1,2

to bicarbonate to form citrate M+0. Since by comparing the

13C ]glutamate
2

enrichment relative to its unique product [1,2

13C ]citrate
2

we can directly measure the amount of reverse exchange flux (defined below as ΦGlu->Cit),
this information can be used to correct the size of the [(1),(6)

13C ]citrate
1

pool before

solving for the corrected citc* family size.
•

citc* = citc * (1+ ΦGlu->Cit)
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In contrast, any C5 label coming from PDH will over-estimate this pool size by contributing
to the generation of the 192/111 parent/daughter. In this case, there will be an expansion
of the M+1 pool size. Because of the overall enrichment of acetyl CoA is low (and C2
lactate/pyruvate/alanine enrichments demonstrated to be low by NMR) and the PDH is
generally small relative to CS, this is expected to be small and left uncorrected in this
study.
Thus, the equations for citrate devolvement used in this study are:
•

cita = 2*193/112 = 2*193/113 = citrateM+2

•

citb+d = citM+1 - citc*

•

citc* = citc * (1 + φGlu→Cit)

For the purpose of calculating sequential precursor product relationships (see Φ
calculations below), when there are different numbers of carbons, it is valuable to
assess the same carbons in a precursor relative to its product. For instance, citrate has
6 carbons but loses C6 following decarboxylation to aKG/glutamate. So, the relevant
comparison in the oxidative direction is [(1)(2)(3)(4)(5) 13C1]citrate to glutamateM+1 (since
glutamate only has 5 carbons). Since after correcting for reductive exchanges across
IDH, for citc* = C1 + C6, then it possible to calculate [(1)(2)(3)(4)(5) 13C1]citrate as
follows:
•

½citc* = [1 13C1]citrate = [6 13C1]citrate

•

citb+d = [(2),(3),(4) 13C1]citrate

since [5 13C1]citrate is small then:
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•

[(1),(2),(3),(4),(5) 13C1]citrate = citb+d + ½citc*

5.2 Deconvolution of Glutamate Isotopomers
If it is made by the Krebs cycle, the carbon backbone of glutamate originates from
intramitochondrial OAA (C2-4) and pyruvate-derived acetyl-CoA (C4,5). During
fragmentation in the mass spectrometer, the 41 Da daughter fragment specifically isolates
the carbons from the acetyl CoA moiety of glutamate (Alves et al.). Any

13C

label entry

via PDH into the Krebs cycle will result in either the daughter fragment of 42 [(4)(5) 13C1]
or 43 [(4,5)

13C ]-glutamine.
2

On the other hand, label generated within the Krebs cycle

passing through OAA will yield any of the following parent/daughter pairs: 147/41, 148/41,
149/41 (considering only cases where acetyl CoA is unlabeled). The M+1 glutamate
species that originate within the Krebs cycle are [(1)(2)(3)-13C1]-L-glutamate whose label
came from [(2)(3)(4)-13C1]OAA, and [4-13C1]-L-glutamate which formed from the
condensation of [2-13C1]acetyl CoA with M+0 OAA. This acetyl CoA species originated
from peripheral [3-13C1]lactate which was confirmed by NMR analysis. [5-13C1]glutamate
was not observed by NMR, nor [2-13C1]alanine, pyruvate or lactate which ruled out that
there was substantial [5-13C1]glutamate. Moreover, significant label in C5 of glutamate
would have skewed the overall citrate 193/112 to 193/113 ratio in favor for 193/112 (but
the ratio approximated unity). The glutamate parent-daughter ion pairs measured to
evaluate these labeling patterns are as follows (of the ones screened only those in black
were observed:

•

Glutamate C4,5 isotopologues (PDH flux):
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GluC4,50 = [(4),(5) 13C0]glutamate = Σ(146/41, 147/41, 148/41, 149/41)
GluC4,51 = [(4),(5) 13C1]glutamate = Σ(147/42, 148/42, 149/42,150/42)
GluC4,52 = [(4,5) 13C2]glutamate = Σ(148/43, 149/43, 150/43, 151/43)

•

Glutamate C1-3 isotopologues (CS flux):

GluC1,2,30= [(1),(2),(3)-13C0]glutamate = Σ(146/41, 147/42, 148/43)
GluC1,2,31= [(1),(2),(3)-13C1]glutamate = Σ(147/41, 148/42, 149/43)
GluC1,2,32= [(1,2), (1,3), (2,3)-13C2]glutamate = Σ(148/41, 149/42, 150/43)
GluC1,2,33= [(1,2,3)-13C3]glutamate = Σ(149/41, 150/42, 151/43)

Based on the observed distribution of citrate isotopomer families reflecting OAA
enrichment, only GluC1,2,32= [(1,2)-13C2]glutamate was observed. Similarly, only GluC4,51 =
[(4) 13C1]glutamate reflecting AcCoA enrichment were observed
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5.3 Deconvolvement of Succinate Isotopomers
Succinate is a symmetric mitochondrial metabolite. Unlike some other Krebs cycle
intermediates, under most conditions it is almost exclusively formed within the Krebs
cycle. 13C-label traversing the Krebs cycle is evenly reflected across the symmetry plane
of succinate. Taking advantage of its fragmentation pattern, succinate loses either C1 or
C4 with equal probability resulting in the 117/73 fragment. In general, if there is an even
distribution of

13C

labels with equal probability of M+1 enrichment in all four carbons of

succinate we expect a 3:1 118/74 to 118/73 fragment ratio. Similarly, if label is only found
in the C1 or C4 position we would expect a 1:1 ratio of the 118/74 to 118/73 fragments.
Any deviation from these ratios (along with the isotopomeric information of citrate and
glutamate) can be used to deduce the proportional contribution of different sources of
label, for example, as an indirect readout of PC carbon entry. Since we cannot obtain
position-specific label information from the malate fragment, deconvolvement of
succinate is needed to calculate PC flux. As depicted in Figure 23, two succinate M+1
families exist, that is [(1)(4)- 13C1]succinate and [(2)(3)- 13C1]succinate. The only source of
[(1)(4)- 13C1]succinate is through OGDH whereas [(2)(3)- 13C1]succinate originates from
[(2)(3)-13C1]malate/OAA during sequential forward reactions of the Krebs cycle:
anaplerotic PC-derived 13C carbons give rise to malate/OAA M+1 (equally as [2-13C1]- or
[3-13C1]OAA/malate due to the racemic scrambling of the [3-13C1]OAA label across the
irreversible reactions of fumarase and SDH). While the label of [2-13C1]OAA will become
C1 or C4 of succinate, the label of [3-13C1]-OAA will be C2 or C3 of succinate. These OAA
labeling patterns can give rise to the [(1)(2)(3)(4)- 13C1]succinate labeling family. There
was virtually no succinate M+2 generated from [(1,2)-13C2]glutamine within the forward
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turn of the Krebs cycle which aided in ruling out higher isotopomeric glutamate and
thereby citrate species, such as [(2,3)(2,4)(2,5)(3,4)(3,5)(4,5)-13C2]glutamine.

Succinate M+1
[(1)(4)-13C1]succinate = 2*118.0 / 73.0
[(2)(3)-13C1]succinate = 118/ 74-118/ 73

5.4 Deconvolvement of malate isotopomers
Since the fragmentation of malate results in the of loss of H2O leaving the carbon
backbone intact, only isotopologue and not isotopomeric information can be gleaned from
the fragment analysis of malate. The isotopomers, however, can be deduced from the
deconvolution of glutamate and citrate considering that SDH is irreversible. Given that
succinate M+2 was not observed, then all M+2 malate originates from citrate M+2 through

Figure 23. Succinate families.
Organizing succinate isotopomers into succinate families based on their origin within the Krebs
cycle.
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ACLy. The following malate isotopologues/isotopomers are reported with positional
distributions not distinguishable except the M+2 isotopomers which are racemic:

[(1)(2)(3)(4)13C1]malate = 134/116
[(1,2)(3,4)13C2]malate =

135/117

5.5 Deconvolution of aspartate isotopomers

During the fragmentation of aspartate the H2O is lost and thereby does not provide
positional information. At isotopic equilibrium with malate and fumarate the carbons of
OAA are racemized between positions 1 and 4 as well as carbon 2 and 3. Aspartate and
malate share OAA as a common intermediate. Therefore, the similar isotopic build up
curves of M+1 Malate and Aspartate as well as M+2 malate and aspartate suggest
isotopic equilibrium between these two intermediates across OAA.

In summary, MIMOSA allowed for a straightforward interpretation of label information
generated by [1,2-13C2]glutamine (Figure 24) and by grouping key metabolites into
distinct isotopomer families based on the enzymatic reaction that catalyzed their
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production (Table 9) generated more refined input functions for metabolic flux analysis
(CHAPTER III) than would be possible by isotopologue information alone. As expected,
all of the isotopomer families reached steady state within less than one hour (Figure 25)
and therefore measurements from our 60 mins time points were used for metabolic flux
analysis in the following chapter.

Figure 24. Observed carbon fate map.
Observed carbon fate map from [1,2-13C2]-L-glutamine tracer strategy after stepwise
elimination of isotopologues and isotopomers of citrate, glutamate, malate by MIMOSA
deconvolution. V = metabolic flux. Isotpologues/isotopomers families are based on the
enzymatic reaction they originated from (indicated by subscript after metabolite name).
ACLy = ATP citrate lyase, CS = citrate synthase, IDHr/f = isocitrate dehydrogenase
(reverse/forward), OGDH = alpha ketoglutarate dehydrogenase, PC = pyruvate
carboxylase, PDH = pyruvate dehydrogenase, SDH = succinate dehydrogenase.
67

Isotopologue
Family

Isotopologue

Isotopomer

Calculation
(Precursor/Product Fragments)

Malate
Mala+b
Malc

M+1
M+2

Cita
Citc*
Citb+d
Citb+½c+d
Citc

M+2
M+1
M+1
M+1
M+1

Glua
Gluc+d
Glub

M+2
M+1
M+1

Suca
Sucb

M+1
M+1

[(1)(2)(3)(4)13C1]malate
[(1,2)(3,4)13C2]malate
Citrate
[(1,2)13C2]citrate
[(1),(6)13C1]citrate
[(2)(3)(4)(6)13C1]citrate
[(1)(2)(3)(4)(5)13C1]citrate
[(1)(6)13C1]citrate
Glutamate
[(1,2)13C2]glutamate
[(1)(2)(3)13C1]glutamate
[(4)13C1]glutamate
Succinate
[(1)(4)13C1]succinate
[(2)(3)13C1]succinate

134/116
135/117
2*193/112

4*192/111*(1 + ΦGlu->Cit)
192/112 -3*192/111
citb+d + ½citc
4*192/111

148/41
147/41 + 148/42
147/42 + 148/42
2*118/73
118 / 74 -118 / 73

Table 9. Summary of all isotopomers.
A summary of all isotopomeric deconvolvement of the observed isotopologues by MIMOSA as described
in the text.
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Mala+b

Isotopomer Families

Malc
Cita

15

APE%

Citb+d
Citc*

10

Citb+½c+d
Glua
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Gluc+d
Glub

0
0

20
40
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Suca
Sucb

Figure 25.Build up curves of isotopomeric families.
The time dependent isotopic build up curves for all isotopomer families shows that
they all reach steady state within less than 60 mins of the primed continuous infusion
of [(1,2)13C2]glutamine.
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CHAPTER III: CHARACTERIZING BASAL HEPATIC KREBS
CYCLE METABOLISM AND ASSESSING ASSUMPTIONS AND
CONTROVERSIES
Assumptions in metabolic modeling
Stable isotope based tracer methods are a safe and popular method to study metabolism.
However, current tracer methods used for metabolic flux analysis of in vivo hepatic
metabolism have led to highly controversial concepts of key basal metabolic fluxes, such
as pyruvate cycling (VPEPCK and VPK) and anaplerosis (VPC) [4, 29, 41, 75, 77-79]. These
controversies stem from the fact, that all in vivo tracer-based metabolic modeling
techniques rely on assumptions. Since not all parameters of a metabolic system are
directly measurable/observable in vivo due to technical or analytical limitations, and given
the complexity and interrelatedness of metabolic networks, metabolic flux analyses
require simplifications derived from multiple assumptions. The most common
assumptions are that the system is in metabolic and isotopic steady state (for an endpoint
study), tracer uptake is homogenous across an entire tissue without being diluted or
impacting metabolism or generating complex secondary tracer signals.
When these assumptions remain unvalidated, inaccuracies can introduce significant
biases into the final metabolic flux analysis. Given the importance of accurate
measurements of hepatic metabolism, in order to identify its role in the development and
progression of insulin resistance, T2DM, obesity and NAFLD as well as to discover novel
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therapeutic targets then the resolution of uncertainties surrounding key assumptions is
crucial for future in vivo studies of hepatic metabolism.

Experimental design to measure relative and absolute Krebs cycle rates
To experimentally assess individual Krebs cycle fluxes and to validate the assumptions
listed in Table (3) with direct measurements we performed primed continuous infusions
of [1,2-13C2]glutamine and measured the steady state fractional enrichment of key Krebs
cycle intermediates. The isotopomeric enrichment data was used to numerically solve
mass and isotope balance equations written for metabolic flux analysis (Figure 26). The
position-specific

labeling

information

obtained

from

our

mass

isotopomer

deconvolvement of citrate, glutamate and succinate by MIMOSA (described in CHAPTER
II) were used for direct measurement of previously assumed isotope exchange rates (Vx)
and Krebs cycle dilutions (Φs) along with individual rates for oxidative, anaplerotic and
cataplerotic fluxes.
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Figure 26. Primed continuous infusion for steady state MFA.
For metabolic flux analysis [1,2-13C2]glutamine was infused and steady state sample were
obtained at 60 mins as previously determined.

Positional carbon transfer

The evaluation of the positional transfer of labeled carbons across sequential metabolites
within the Krebs cycle and adjacent pathways is fundamental for our metabolic flux
analysis. Citrate is a symmetric molecule but it contains a prochiral center which is
stereochemically distinguishable by enzymes. The pro-R arm contains carbons 1, 2, 3
and 6 from OAA while the pro-S arm consists of carbons 4 and 5 contributed by acetylCoA generated either via β-oxidation or PDH reaction. Subsequently the pro-S arm will
become C4 and C5 of glutamate during the IDH reaction. Thus, based on the prochirality
of citrate, isotopomers generated by PDH, PC or CS flux can be distinguished.
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Metabolism of [1,2-13C2]glutamine leads to the formation of [1,2-13C2]glutamate which
enters the Krebs cycle via GDH as [1,2-13C2]αKG. Doubly labeled αKG undergoes two
fates: decarboxylation of its C1 to [(1)(4)-13C1]succinate via OGDH or [1,2-13C2]citrate
catalyzed by IDHr. [(1)(4)-13C1]succinate generates [(1)(4)-13C1]OAA/malate which
condenses with acetyl CoA to form citrate. Label in C1 position of pyruvate is lost during
the decarboxylation reaction of PDH or re-introduced into C2 and C3 position of OAA
through PC. Additionally, any ligation of labeled CO2 catalyzed by PC can generate any
of the following OAA species: [2,4-13C2]OAA, [3,4-13C2]OAA, [1,2-13C2]OAA or [1,313C ]OAA
2

along with their respective citrate isotopologues. Additional contribution to the

overall malate isotopologue pool (M+2) comes from citrate that is metabolized by ACLy
to cytosolic malate (C1,2,3,6) and acetyl CoA (C4,5).

Assessment of dilutional fluxes

At metabolic and isotopic steady state, the relative contribution of a pathway to a specific
product can be determined by the

13C

enrichment (φ) ratio of precursor A to product B

(φAB). For instance, in a unidirectional reaction if a labeled precursor is the sole substrate
converted to a specific product, the enrichment ratio between product and precursor will
approach 1 at steady state. If additional substrates from other pathways, contribute to the
same product, then the relative contribution of the labeled precursor and the additional
unlabeled substrate(s) will be less than or equal to the total enrichment of the product and
result in an enrichment of product to labeled precursor ratio of less than 1. The discrete
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entry of unlabeled carbon from confluent, intersecting pathways can be described as
follows:

𝐴𝐴

φ𝐴𝐴 → 𝐵𝐵 = 𝐵𝐵 ≤ 1

and the relative contribution from unlabeled metabolites can then be defined as 1-φAB.
This is particularly helpful to determine if significant dilutional fluxes, e.g., anaplerosis,
and/or exchange reactions, exist.

Results
As shown in Figure (27), there was significant serial dilution across consecutive
metabolites as the

13C

label traversed the Krebs cycle (Figure 27, top panel) with a

remarkable total drop of 70% in the plateau enrichment after one full turn at 60 mins
(Figure 27, bottom panel). Because C6 is lost during the IDH reaction, then this indicates
a ~35% dilution of label by unlabeled metabolites in equilibrium with different steps of the
cycle. This sequential dilution indicated significant influx of unlabeled carbons from
multiple confluent, intersecting pathways into the Krebs Cycle. The time to half max
enrichment was calculated for each by fitting to a single exponential. The difference in t1/2
for for glutamate M+2 and glutamate M+1 was about 10 minutes, indicating that >5 full
turns of the cycle by 60 minutes consistent with being at isotopic steady state.
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Figure 27. Sequential Hepatic Metabolite.
At isotopic steady state there was serial label dilution across all Krebs cycle
intermediates (top panel). The evolution of glutamate M+2 into M+1 glutamate in vivo
during a full turn of the Krebs cycle (bottom panel). Curves were fit to a single
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exponential and t1/2 shown by vertical dashed lines.

In addition to anaplerotic fluxes another source of label dilution in reversible systems are
“isotopic exchange reactions” which transfer isotopic label between metabolites without
net carbon conversion leading to label dilution. Aminotransferase exchange reactions
associated with the Krebs cycle catalyze the interconversion of glutamate and αKG as
well as OAA and aspartate [10]. The kinetic measurements of the aminotransferase
exchange reaction VX in vivo were made by comparing the temporal build up curves of
glutamate vs succinate positional isotopomers. Unfortunately, the deconvolvement does
not provide exact carbon matching between glutamate and succinate. Since the observed
equilibration between glutamate and succinate was fast relative to the TCA cycle, [C(1,2)13C ]glutamate
2

was compared to succinate M+1([(1)(4)

13C ]succinate
1

= 2*118/73).

During the early time points, C2 enrichment of the succinate C1 and C4 isotopomers by
coming from tracer glutamine and then glutamate. Here the contributions of [5
13C ]glutamate
1

were small (as shown above) and [2 13C1]glutamate derived from PC flux

would be small and late making the comparison a reasonable surrogate for the transfer
of glutamate enrichment into the Krebs cycle. The temporal isotopic build up curves
between these two isotopologues were superimposable and not significantly different,
confirming a fast exchange of label from the cytosolic glutamate into the mitochondrial
matrix pool of aKG (Figure 28).
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Figure 28. Amino Transferase Exchange reaction (Vx).
Amino Transferase Exchange reaction (Vx) catalyzes a rapid exchange between cytosolic and
intramitochondrial metabolites. Isotope build up curves of Glutamate M+2 and Succinate M+1.
No statistical significant difference between both lines.
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Metabolic flux analysis (MFA)
In metabolic modeling studies, the labeling rate of each intermediate depends on the
precursor enrichments, enzyme kinetics, the metabolic flux through the system and its
respective pool size [67]. Atom fate maps provide information about individual reactions
within a pathway but do not give information about flux. To determine relative fluxes a
steady state a metabolic flux analysis is performed using the measured fractional tracer
enrichments. The concept of metabolic flux analysis and modeling is based on
mathematical formalisms[71, 117-121]. Herein, from steady state relationships differential
equations can be derived to describe the rate of change of enrichment of a labeled
metabolite arising from a metabolic inflow/influx minus the outflow/efflux of the product.
This is described in the following reaction:

𝑬𝑬𝑬𝑬

𝑬𝑬𝑬𝑬

𝑨𝑨 �� 𝑩𝑩 �� 𝑪𝑪

where A is the substrate that is converted into product B and then into C. The reactions
are catalyzed by enzyme E1 and then E2 respectively. The general mass and isotope
balance equations describing the change in the concentration of B is:

Mass Balance:

𝑑𝑑[𝐵𝐵 ]
𝑑𝑑𝑑𝑑

= 𝑉𝑉𝐸𝐸1 − 𝑉𝑉𝐸𝐸2

If A is an enriched tracer (A*), then the change in the isotope balance of the fractional
enrichment of B* over time is described by:

Isotope Balance:

𝑑𝑑[𝐹𝐹𝐹𝐹𝐵𝐵∗ ]
𝑑𝑑𝑑𝑑

= 𝐹𝐹𝐹𝐹𝐴𝐴∗ * 𝑣𝑣𝐸𝐸1 - 𝐹𝐹𝐹𝐹𝐵𝐵∗ * 𝑣𝑣𝐸𝐸2
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Of note, exchange reactions do not contribute to or consume mass (i.e., no net carbon
conversion) and therefore do not need to be accounted for in mass balance equations.
However, they contribute label and therefore need to be factored into isotope balance
equations.

Phi (φ) ratios
To determine the relative carbon contribution to a metabolic reaction we derived first order
differential equations describing the transfer of label from a

13C

enriched substrate to its

product as described above.
At metabolic and isotopic steady-state, the fractional enrichment of

13C

label is constant

and therefore the relative contribution of E1 to E2 can be described as the phi (φ) ratio of
precursor to product 𝜑𝜑𝜑𝜑 → 𝐵𝐵 where the relative contribution of the input relative to the

output is equal to the enrichment of the product to its precursor and therefore can be
solved for by
𝑉𝑉

𝜑𝜑𝜑𝜑 → 𝐵𝐵 = 𝑉𝑉𝐸𝐸1 =
𝐸𝐸2

𝐹𝐹𝐹𝐹𝐵𝐵∗

𝐹𝐹𝐹𝐹𝐴𝐴∗
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Based on the above principle preliminary phi (φ) ratio relationships were established for
our metabolic flux analysis as follows:
Mass Balance of anaplerosis and cataplerosis
𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

At steady state:

Thus:

𝑑𝑑𝑑𝑑

= VSDH+ VPC + VACLy– (VCS + VPEPCK)

VSDH+ VPC + VACLy= VCS + VPEPCK

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆 +𝑉𝑉𝑃𝑃𝑃𝑃 +𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶 +𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

=1

We make the following definitions of fractional fluxes:
FSDH:
FACLy:
FPC:

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝐶𝐶𝐶𝐶 +𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴

𝑉𝑉𝐶𝐶𝐶𝐶 +𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝑃𝑃𝑃𝑃

𝑉𝑉𝐶𝐶𝐶𝐶 +𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

= 𝑓𝑓𝑠𝑠

= 𝑓𝑓𝑐𝑐

= 𝑓𝑓𝑝𝑝

The sum of the fractional fluxes then equals 1.

Rearranging to solve for 𝑓𝑓𝑝𝑝

𝑓𝑓𝑠𝑠 + 𝑓𝑓𝑝𝑝 + 𝑓𝑓𝑐𝑐 = 1
𝑓𝑓𝑝𝑝 = 1 - 𝑓𝑓𝑠𝑠 - 𝑓𝑓𝑐𝑐

Solving for 𝑓𝑓𝑐𝑐

Since malate and OAA are in isotopic equilibrium across all carbons, we can substitute

malate for OAA.
Then isotope balance for malate M+2 is:
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𝑑𝑑(𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀+2)
𝑑𝑑𝑑𝑑

= 𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆 (Succ M + 2) + 𝑉𝑉𝑃𝑃𝑃𝑃 (Pyr M + 2) + 𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 (Cit M + 2) −
(Mal M + 2)(𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )

At steady state:
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆 (SuccM + 2) + 𝑉𝑉𝑃𝑃𝑃𝑃 (Pyr M + 2) + 𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 (Cit M + 2) = (Mal M + 2)(𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )

Since there was no detectable M+2 succinate or pyruvate, this simplifies to:
𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 (Cit M + 2) = (𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )(Mal M + 2)

Rearranging:
𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴

𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀

=

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀+2
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2]

Substituting previously defined variables and relationships
𝒇𝒇𝒄𝒄 =

𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴+𝟐𝟐
𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪[𝟏𝟏,𝟐𝟐]

𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴

= 𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝒄𝒄

𝒂𝒂

81

Solving for 𝑓𝑓𝑠𝑠

Isotope balance for malate M+1:

𝑑𝑑(Mal𝑀𝑀+1 )
= 𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆 (Succ𝑀𝑀+1 ) + 𝑉𝑉𝑃𝑃𝑃𝑃 (Pyr𝑀𝑀+1 ) + 𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 ��(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶�
𝑑𝑑𝑑𝑑
− (Mal𝑀𝑀+1 )(𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )
At steady state:
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆 (Succ𝑀𝑀+1 ) + 𝑉𝑉𝑃𝑃𝑃𝑃 (Pyr𝑀𝑀+1 ) + 𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 ��(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶� = (Mal𝑀𝑀+1 )(𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )
Divide by 𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀

(Pyr𝑀𝑀+1 )𝑉𝑉𝑃𝑃𝑃𝑃
(Succ𝑀𝑀+1 )𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆
��(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶�𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
+
+
= (Mal𝑀𝑀+1 )
(𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 ) (𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )
(𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )

Substitute fraction relations

fs(SuccM+1) + (1 -fc – fs)(PyrM+1) + fc(�(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶 1) = MalM+1
Expand
fs(SuccM+1) + PyrM+1 – fc(PyrM+1)- fs(PyrM+1) +
fc(�(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶) = MalM+1
Combine terms
fs(SuccM+1 - PyrM+1) + fc(�(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶 - PyrM+1) = MalM+1 - PyrM+1
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Solve for fs
fs = ((MalM+1 - PyrM+1) + fc(PyrM+1 - �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))/(SuccM+1 - PyrM+1)

[Note: New isotopomer definition assuming C5 enrichment is negligible]

�(1)(2)(3) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶 =

(1− �(4) 13C1 �𝐺𝐺𝐺𝐺𝐺𝐺)

�(1)(2)(3)(4)(5) 13C1 �𝐺𝐺𝐺𝐺𝐺𝐺

* �(1)(2)(3)(4)(5) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶

1
�(1)(2)(3) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶 + 𝐶𝐶𝐶𝐶𝐶𝐶𝑐𝑐 = �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶
2

�(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶 =

(1 − (147/42 + 148/42))
∗ (192/112 − 192/111) + 2 ∗ 192/111
𝐺𝐺𝐺𝐺𝐺𝐺𝑀𝑀+1

The derivation of all the equations used to generate mass isotopomer
measurements for each label are based on the study by Alves et al. [71] and are
presented in part below ( for all fluxes relative to CS). The full derivations are shown in
more detail in the Supplemental Information.

Establishing PDH relative to CS
𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝐶𝐶𝐶𝐶

=

𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+1𝑃𝑃𝑃𝑃𝑃𝑃
𝜑𝜑𝐶𝐶𝐶𝐶𝐶𝐶→𝐺𝐺𝐺𝐺𝐺𝐺

÷ PyrM+1

Establishing IDHf relative to CS
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Mass Balance:
Rearrange:

𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

= VCS + VIDHr - VACLy - VIDHf

𝑑𝑑𝑑𝑑

VCS + VIDHr = VACLy + VIDHf

𝑉𝑉𝐶𝐶𝐶𝐶

Solve:

+

𝑉𝑉𝐶𝐶𝐶𝐶

1+

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

=

=1-

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

=

=

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝑦𝑦
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶

+

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶

+

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

+

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

= 1-

(Mal M+2 − Cit M+2)

(Cit M+2 − Glu M+2)

(Mal M+2 − Cit M+2)

(Cit M+2 − Glu M+2)

Mass Balance:

VIDHnet = VIDHf - VIDHr

Isotope Balance:

dCitM+2/dt = aKGM+2*VIDHr – CitM+2*VIDHf

Because Vx is fast::

aKGM+2 = GluM+2

Substitute:

GluM+2*VIDHr = CitM+2*VIDHf

Rearrange:

VIDHf = VIDHr(GluM+2/CitM+2)

Substitute for VIDHr:

VIDHf = (VIDHf- VIDHnet) (GluM+2/CitM+2)
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Solve:

VIDHf/VIDHnet = GluM+2/CitM+2/(GluM+2/CitM+2 - 1)

Net IDH flux is the difference between forward and reverse IDH flux:

Mass Balance

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

=

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

-

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

From the above established relationships the following relative fluxes can be
established

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝐶𝐶𝐶𝐶

=

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

-

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Establishing SDH relative CS
From the above fluxes relative to VSDH fluxes relative to CS can be established as

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

=

𝑓𝑓𝑐𝑐
𝑓𝑓𝑠𝑠

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

= ( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷
[1,2]

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

)
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𝑉𝑉𝑃𝑃𝑃𝑃

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

=

𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑓𝑓𝑝𝑝
𝑓𝑓𝑠𝑠

= (1-

= (1-

(

(𝑀𝑀𝑀𝑀+1 − 𝑓𝑓𝑐𝑐 ∗ 𝐶𝐶𝐶𝐶𝐶𝐶[(2)(3)(4)(6)] +𝑃𝑃𝑀𝑀+1 )− 𝑃𝑃𝑀𝑀+1 )
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

= ( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷ (

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

[1,2]

)* ( 𝐺𝐺𝐺𝐺𝐺𝐺

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝑙𝑙𝑛𝑛 𝑀𝑀+2)

)) *
− 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

)

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

= 1-

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂

)

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶)))

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2]

Succ 𝑎𝑎

𝑎𝑎 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑏𝑏 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑐𝑐+𝑑𝑑

(1-

=1-

[1,2]

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

– 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷

)+

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)

Succ (1)(4)

= 1- 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺+2

𝑂𝑂𝑂𝑂𝑂𝑂 +𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺+1

86

Establishing SDH relative to CS
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Equation:

=

𝑉𝑉𝐶𝐶𝐶𝐶

1

𝑉𝑉𝐶𝐶𝐶𝐶
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Solve:
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆
𝑉𝑉𝐶𝐶𝐶𝐶

= 1 ÷ ((

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀+2
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2]

(1-

)÷(

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)) *

)+

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

))

Establishing PC relative to CS

𝑉𝑉𝑃𝑃𝑃𝑃

Equation:

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉

= 𝑉𝑉 𝑃𝑃𝑃𝑃 ÷
𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Solve:
𝑉𝑉𝑃𝑃𝑃𝑃
𝑉𝑉𝐶𝐶𝐶𝐶

= ( (1-

�(MalM+1 – PyrM+1)+ fc�PyrM+1 – �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶��
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

– 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷
[1,2]
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((
(

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))

(1-

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)) *

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

))÷ ( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷
[1,2]

)+

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

))

Establishing Prop relative to CS

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

Equation:

𝑉𝑉𝐶𝐶𝐶𝐶

=

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

÷

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Solve:
𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝐶𝐶𝐶𝐶

Succ (1)(4)

= (1- 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺+2

𝑂𝑂𝑂𝑂𝑂𝑂 +𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺+1

(

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

÷ ( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 )) ÷
[1,2]

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(1-

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)) *

)+

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)
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Establishing GDH relative to CS
𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺

Equation:

Solve:

𝑉𝑉

𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺
𝑉𝑉𝐶𝐶𝐶𝐶

(

= ((1-

𝑉𝑉𝐶𝐶𝐶𝐶

= 𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺 ÷

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑆𝑆𝑆𝑆𝑆𝑆

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)* ( 𝐺𝐺𝐺𝐺𝐺𝐺

Succ 𝑎𝑎

𝑎𝑎 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑏𝑏 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑐𝑐+𝑑𝑑

)) ÷

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))

(1-

)+

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2]

)) *
− 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)

Since at steady state anaplerosis is equal to cataplerosis

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀
𝑉𝑉𝐶𝐶𝐶𝐶

=

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶

=

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉

÷ 𝑉𝑉 𝐶𝐶𝐶𝐶

𝑆𝑆𝑆𝑆𝑆𝑆

Establishing ACLy relative to CS
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𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴

Equation:

𝑉𝑉𝐶𝐶𝐶𝐶

=

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

÷

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Solve:
𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

= (( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷ �
𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

[1,2]

�(MalM+1 – PyrM+1)+ fc�PyrM+1 – �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶��

( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 )) ÷ ((
(1-

[1,2]

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2]

�÷

)) *
− 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

)+

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)

After mass and isotope balance equations were derived for the glutamine labeling
strategy for key reactions of the Krebs cycle we were able to numerically solve these
equations from the measured enrichment data to calculate specific relative fluxes. From
the high-resolution position-specific label analysis provided by POCE, and

13C

NMR,

along with the direct deconvolution of citrate, glutamate and succinate isotopomers by
our analytical platform MIMOSA, tracing of isotopomer distributions along metabolic
networks was made possible [71, 80, 122] (see CHAPTER II). Incorporation of positionspecific isotopomeric information into the analysis (in addition to the more general position
non-specific isotopologue data), in principle, improves the estimations of metabolic fluxes
than possible with isotopologue data alone [71, 118]. We calculated relevant
mitochondrial oxidative (IDH, OGDH, SDH), anaplerotic (PC, PCC, GDH), cataplerotic
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fluxes (PEPCK+ME) and de novo lipogenesis (ACLy) as well as the transaminase
exchange rate (Vx) relative to citrate synthase (CS)[71].

Relative Krebs cycle fluxes
The cyclic sequence of Krebs cycle reactions begins when acetyl-CoA undergoes an aldol
condensation with oxaloacetate (OAA) to form citrate. This first committed step of the
Krebs cycle is catalyzed by citrate synthase (CS). Three major oxidative reactions of the
Krebs cycle are catalyzed by isocitrate dehydrogenase (forward reaction, IDHf), αKG
dehydrogenase, and succinate dehydrogenase. All of these reactions have previously not
been measured individually in vivo due to sensitivity limitations of in vivo

13CNMR

which

made position specific labeling information inaccessible for direct measurements.
Therefore, the individual oxidative reactions of the Krebs cycle have been grouped with
CS and reported as one overarching rate, that is, VTCA. With position specific labeling
information of key Krebs cycle intermediates it was possible to calculate rates for each of
these oxidation reactions relative to CS. Furthermore, our isotopomeric MFA enabled us
to estimate rates for all three key anaplerotic (PC, GDH, PCC) and the major cataplerotic
flux through PEPCK in addition to the ACLy reaction.
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Figure 29. Relative Krebs cycle fluxes.
(a) Overview over Krebs cycle fluxes (b) oxidative fluxes, (c, d) anaplerotic fluxes, (e)
cataplerotic fluxes, including ACLy flux (f). Glutamine was infused at a primed continuous rate
12 umol/kg/min for 60 mins. N=8.
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Dilutional influx into the Krebs cycle is considered anaplerotic when balanced by a
cataplerotic efflux. The progressive dilution of

13C

signal across sequential Krebs cycle

intermediates described above was consistent with significant carbon contribution coming
from anaplerosis. The three anaplerotic fluxes stemmed from 1) propionate (VPCC) at
approximately 20%, 2) pyruvate (VPC), which accounted for 75% and 3) glutamate (VGDH)
contributing the remaining 5% of total anaplerotic fluxes (Figure 29 c,d). All of which were
balanced by cataplerotic flux through PEPCK+ME (29 e), that plays an important role in
gluconeogenesis and pyruvate cycling. Substrate cycling is mediated by the simultaneous
occurrence of two opposing enzymatic reactions leading to the net hydrolysis of ATP.
Pyruvate cycling begins with the conversion of pyruvate to OAA by PC (anaplerosis). OAA
undergoes metabolism through PEPCK into PEP which subsequently cycles back into
pyruvate through pyruvate kinase [15]. Pyruvate cycling is the difference between
cataplerosis through PEPCK and anaplerosis mediated by PC. The rate of PEPCK sets
the maximum rate of pyruvate re-cycling. Figure shows that the relative rate of pyruvate
carboxylase is close to the same rate as CS whereas PEPCK is only 1.5 or 1.2 times the
rate of CS (Figure 29 e) which indicates that the pyruvate cycling rate is substantially
smaller than measured using the propionate tracer strategy and more consistent with
previously reported rates using lactate as a tracer [4]. Additionally, our metabolic flux
analysis deomonstrated that each of the three measured oxidative steps, IDH, ODGH
and SDH, are work at distinct rates (Figure 29 b) and adjust to adjacent anaplerotic and/or
cataplerotic pathways.
Isocitrate dehydrogenase catalyzes two half reactions where decarboxylation
converts isocitrate into aKG (referred to as IDHf) as well as reductive carboxylation to
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convert aKG back into isocitrate (IDHr). The latter reaction has been suggested to be an
important step in de novo lipogenesis (DNL) where ATP Citrate Lyase (ACLy) catalyzes
citrate conversion into cytosolic malate and acetyl CoA (though this suggestion to date
has only considered the unidirectional reactions). ACLy contributes significantly to basal
hepatic metabolism (Figure 29 e). IDH is commonly treated as one reversible reaction.
However, distinct rates for IDHf and IDHr lead to an overall net flow (IDHnet) towards the
oxidative reaction (Figure 29 b, 30).

Figure 30. Reductive carboxylation.
Isotope build up curves of glutamate M+2  citrate M+1 malate M+2, reflect flux through
reductive carboxylation and ATP citrate lyase, respectively.
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Absolute Krebs cycle rates (“Bootstrapping”)
From the relative rates
the absolute Krebs cycle
rates can be calculated
if there is a known flux
rate to link it to. Here this
was

done

by

bootstrapping

the

relative fluxes onto the
externally
absolute
endogenous
production

measured
rate

of

glucose
(EGP,

glucose Ra) [15, 123].

Figure 31. Absolute rates for all Krebs cycle fluxes.

Under the assumption
that during fasting all gluconeogenic flux comes from PEPCK absolute rates and that
glycerol and fructose made small or fixed contributions, rates relative to CS were
determined by “strapping” steady-state relative fluxes of VPEPCK+ME/VCS onto the direct
measurements. All other absolute fluxes were then calculated in relation to VCS (Figure
31) [4, 15].
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1

Absolute Fluxes
𝑉𝑉
𝑉𝑉
𝑉𝑉𝐶𝐶𝐶𝐶 = EGP ÷ 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
= EGP * 𝑉𝑉 𝐶𝐶𝐶𝐶 = 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 ∗
𝑉𝑉
𝐶𝐶𝐶𝐶

2
3
4
5
6
7
8
9
10
11

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼

VIDHf = 𝑉𝑉𝐶𝐶𝐶𝐶 *

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼

VIDHr = 𝑉𝑉𝐶𝐶𝐶𝐶 *

VIDHnet = 𝑉𝑉𝐶𝐶𝐶𝐶 *
VSDH = 𝑉𝑉𝐶𝐶𝐶𝐶 *

VSDH = 𝑉𝑉𝐶𝐶𝐶𝐶 *

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

VPEPCK = 𝑉𝑉𝐶𝐶𝐶𝐶 *

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃

VPCC = 𝑉𝑉𝐶𝐶𝐶𝐶 *

VGDH = 𝑉𝑉𝐶𝐶𝐶𝐶 *
VPC = 𝑉𝑉𝐶𝐶𝐶𝐶 *

𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑃𝑃𝑃𝑃
𝑉𝑉𝐶𝐶𝐶𝐶

VACLY = 𝑉𝑉𝐶𝐶𝐶𝐶 *

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶

Lastly, we not only determined absolute rates for each key step of the Krebs cycle, from
the dynamic data points we also calculated the time it takes to complete one full turn of
the cycle which is accomplished when the [1-13C]glutamate isotopomer is made from [1,213C ]
2

glutamate with half the enrichment lost from C6 citrate at the IDH step. The

difference in the half max time for each of those two isotopomers reflects the full circuit
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which was actually completed in only approximately 13 minutes (Figure 32). Therefore,
within one hour the Krebs cycle completes five full turns which further corroborates that
under proper tracer condition full label equilibration across all key intermediates can be
achieved in approximately 60 minutes.
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Figure 32. One full turn of the Krebs cycle.
A full turn of the Krebs cycle is signified by the difference in the half max time for M+2 vs M+1
glutamate. A full Krebs cycle circuit was completed within approximately 13 minutes.

Discussion
Just as Hans Krebs predicted almost seven decades ago, the Krebs cycle stands in the
center of attention of the scientific community in an attempt to explain the origin and
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progression of many diseases in mankind. To date numerous research studies have
demonstrated that mitochondrial oxidative and biosynthetic metabolism play an integral
role in the pathogenesis and development of insulin resistance, type 2 diabetes mellitus,
NAFLD and obesity [27-39]. To accurately identify how and to what extend mitochondrial
oxidative and biosynthetic fluxes are involved in these common disorders accurate
measurements of absolute and relative Krebs cycle fluxes in health and disease are of
utmost importance. Recent stable isotope research, both in rodents and humans, of
hepatic metabolism at basal state and in disease models has led to vastly inconsistent/
incongruent and controversial results. For instance, anaplerosis through PC has been
reported to be approximately 1.4 times the rate of the Krebs cycle by one group while
another measured anaplerotic flux through PC at approximately 5 times the Krebs cycle
rate, yet with minimal overall impact on flux into gluconeogenesis [41, 107, 124, 125].
Similarly, substrate cycling has been in the center of the controversial debate regarding
basal hepatic metabolism [109]. There has been a four to five-fold difference between
published rates pyruvate cycling depending on the study [74-77, 116, 125]. If anaplerosis
and substrate cycling were truly manifold faster than the Krebs cycle turns, these fluxes
would put the metabolic system into a precarious thermodynamic state/situation. For
example, PEP-pyruvate cycle at the intersection of glycolysis and gluconeogenesis. Here,
pyruvate is converted to OAA catalyzed by PC, while OAA is transformed to PEP via
PEPCK and back into pyruvate through pyruvate kinase (PK) with an overall consumption
of 1 molecules of ATP which at a fast pace would overwhelm the direct ATP production
of the Krebs cycle [11, 12, 15]. Moreover, the change in RedOx state would likely expose
to the cell to oxidative stresses and eventually cell damage and apoptosis/death.
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Therefore, previously reported rates of anaplerosis being approximately 1.4 times the rate
of the Krebs cycle and pyruvate cycling making up only a small fraction of anaplerosis
makes physiologic sense [4, 116, 126]. Recent in vitro studies have challenged the
paradigm of excessively fast anaplerotic and cycling fluxes by showing that the
overestimation of pyruvate cycling in metabolic modeling is related to limited isotopomeric
that leads to substantial miscalculations of key metabolic fluxes, such as anaplerosis and
VTCA [71]. Here, in our study, we show that the rates for anaplerosis in vivo are much
closer to the overall rate of CS and that pyruvate cycling is just a fraction of Krebs cycle
metabolism. By obtaining direct isotopomeric information of all key Krebs cycle
intermediates we were able to develop a much more constraint metabolic model of all
oxidative and biosynthetic fluxes and thereby estimate fluxes much closer to their
physiologic rates.
Moreover, we could show that there is significant label dilution into Krebs cycle from two
additional sources, besides PC, which are glutamate and propionate. Previously not
measured in vivo and deemed metabolically negligible, these dilutional fluxes, when not
considered in the metabolic model, will lead to significant underestimation of the VTCA.
An uncorrected, falsely low, rate of VTCA will artificially increase all fluxes relative
to it, e.g., anaplerosis and pyruvate cycling. While in turn, as part of a modeling vicious
cycle, overestimation of pyruvate cycling further contributes to the underestimation of
Krebs cycle flux, as mentioned before. An additional important finding of our flux analysis
is that summarizing all oxidative reactions as VTCA is an oversimplification of and misses
fine nuances of Krebs cycle metabolism. Our position-specific tracking of kinetic label
transfer demonstrates that actually each oxidative step within the Krebs cycle is a series
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of individual enzymatic reactions that adjusts to its adjacent anaplerotic fluxes rather than
one steady circular sequence of metabolic steps.
Finally, from the isotopomeric information obtained with MIMOSA, we were able to directly
assess aminotransferase exchange, Vx, which has been in the center of longstanding
debates pertaining to NMR-based in vivo metabolic flux calculations [94-98]. While
13CNMR

is a method for non-invasive measurements of hepatic metabolism, 13C labeled

tracers have limited sensitivity given their overall low concentrations and makes direct
assessment of multiple Krebs cycle intermediates a challenge in vivo. Instead, 13C NMR
relies on the highly abundant

13C

signal of aspartate and glutamate. These amino acids

are assumed to be in rapid exchange through aminotransferase exchange reactions (VX)
with the Krebs cycle intermediates OAA and αKG, respectively. Due to their higher
abundance glutamate’s and aspartate’s can act as NMR-observable trapping pools for
13C

label in Krebs cycle intermediates. Since Vx has never been measured in vivo before,

all of

13CNMR

metabolic flux calculations and modeling is based on the underlying

assumption that the isotopic exchange rate between glutamate and αKG as well as OAA
and aspartate mediated is fast relative to the Krebs cycle flux and thus makes glutamate
and aspartate a kinetic component of the Krebs cycle [94-98]. If Vx exchange were slow
and unadjusted for, it would result in marked errors in calculation of VTCA, and other
related rates, such as anaplerosis [94, 97, 99, 100]. Taking advantage of our direct
measurement of Krebs cycle intermediates and their positional labeling information we
were able to directly assess the isotope exchange rate and thereby validate this key
assumption which forms the basis of all in vivo

13C

NMR flux calculations and show that
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glutamate and aKG are in rapid exchange. As such label information of glutamate is a
reliable readout of Krebs cycle metabolism.

CHAPTER IV: CROSS VALIDATION OF MIMOSA FLUX
ANALYSIS WITH KINETIC MODELING
Due to experimental and methodological limitations (some of which are described above),
not all flux parameters of a metabolic system can always be measured directly and solved
manually as described above. To derive additional pertinent fluxes that capture otherwise
experimentally unobservable fluxes, more comprehensive metabolic flux models were
constructed mathematically with the help of metabolic modeling software [127].

A

metabolic flux model was constructed mathematically with the modeling software CWave
[128] whose computational modeling process consists of a syntactic approach employing
a series of coupled differential equations written to describe the metabolic system under
investigation[99, 129-132]. CWave derived algebraic equations for all metabolic reactions
and then solved them numerically from experimentally determined isotope patterns (see
Supplemental Information). These measured enrichment data serve as input functions to
stochastically compute kinetic and steady state metabolic flow and simulate the unknown
(unmeasured) parameters of the atom fate map [110, 117, 133, 134]. Figure (33) shows
the metabolic model of the Krebs cycle and its constituent pathways in its entirety
including all enzymatic reactions that CWave computed from the isotopologue and
isotopomeric data. The position specific information generated by our MIMOSA analysis
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provided important constraints to the dynamic model which allowed for precise relative
flux analysis with tight standard deviation (Table 10).

Figure 33. Kinetic metabolic model (CWave).
Schematic of the reactions modeled by CWave. From the isotopomeric and isotopologue
date generated by MIMOSA, CWave modeled all metabolic rates of the Krebs cycle and
adjacent pathways with high confidence. A description of all reactions and abbreviations is
provided in detail in the Method Chapter.

The computational model of kinetic and steady state fluxes modeled by CWave provided
an opportunity to not only expand but also to cross-validate the metabolic flux analysis
performed with MIMOSA. Comparing relative metabolic fluxes both models showed
strong congruency between their respective analysis and confirmed that 1) VICDHr, the
reductive component of IDH is slower than the oxidative reaction (VICDHf) of IDH leading
to a net IDH flux (IDHnet) of approximately 18 umol/kg/min, 2) VACLy relative to VCS,
contributes significantly to basal hepatic metabolism. 3) pyruvate cycling was much
slower than previously reported with PC much closer to the rate of CS and PEPCK only
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1.2 times the rate of CS, 4) the Amino Transferase Exchange rate (Vx) converting
glutamate to αKG is extremely fast and thereby makes the cytosolic glutamate pool a
kinetic component of the intramitochondrial Krebs cycle whereas 5) the reaction catalyzed
by GDH designated as VGDH is much slower as VX (Table 10).
The only difference between the MIMOSA generated steady state model and the kinetic
model created by CWave was the relative rate for PDH (VPDH/VCS).

In contrast to

MIMOSA CWave uses enrichment data from pyruvate to calculate PDH flux. However,
direct measurements of pyruvate and its fractional enrichment are difficult due to
pyruvate’s poor signal to noise ratios in the mass spectra. Therefore, relative flux
calculations of PDH by CWave suffer from the imprecise data input of pyruvate
enrichment.
MIMOSA flux calculations, on the other hand, takes advantage of the fact that the acetylCoa moiety of glutamate (C4, C5) originates from pyruvate C2 and C3: pyruvate C2, C3
acetyl-CoA C1, C2 glutamate C4,C5. Through strategic fragmentation of glutamate in
the tandem MS glutamate’s m/z 41 daughter fragment consists of its C4, C5 of the
glutamate carbon backbone which represents the acetyl-CoA moiety coming from
pyruvate. Any fractional enrichment of pyruvate can be deduced from the enrichment in
the m/z 41 daughter fragment:
Glutamate C4,5 isotopologues (PDH flux):
GluC4,50 = [C4,5 13C0]Glutamate = Σ(146/41, 147/41, 148/41, 149/41)
GluC4,51 = [C4,5 13C1]Glutamate = Σ(147/42, 148/42, 149/42,150/42)
GluC4,52 = [C4,5 13C2]Glutamate = Σ(148/43, 149/43, 150/43, 151/43)
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Since glutamate spectra have an excellent signal to noise ratio its measurement is much
more precise and reliable than pyruvate. Hence, using the enrichment of C4,C5 glutamate
as a surrogate input function for metabolic flux analysis results in much more robust rate
estimates.
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Relative Rate

Steady State Model

CWave Kinetic Model

Mean

SD

Fitted

SD

%

(+/-)

%

(+/-)

VPC/VCS

115.35

(42.3)

90

(10.43)

VProp/VCS

32.72

(8.89)

26.4

(5.54)

V(PEPCK+ME)/VCS

157.20

(45.22)

116.5

(20.56)

VPDH/VCS

48.55

(22.91)

94.7

(3.83)

VIDHr/Vcs

81.3

(23.78)

94.4

(14.6)

VIDHf/Vcs

163.69

(32.96)

163.9

(16.34)

VOGDH/VCS

82.39

(11.52)

69.5

(6.92)

VSDH/VCS

115.12

(18.76)

95.5

(9.51)

VACLy/VCS

17.6

(11.5)

30.5

(3.82)

Table 10.Comparison of steady state and kinetic model.
Comparison of relative rates calculated by MIMOSA Metabolic Model vs CWave Kinetic. Both
models showed high congruence with no significant differences between flux rates except for
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PDH.

CHAPTER V: ASSESSING PITFALLS OF COMMON TRACER
STRATEGIES
Existing tracer strategies have led to highly divergent concepts of hepatic metabolism. To
better understand the origins of the differences in reported metabolic flux rates we
systematically evaluated three of the common tracer strategies for potential liabilities and
shortcomings in tracing hepatic metabolism. To this end we performed primed continuous
infusion of each “unlabeled/cold” tracer at their respective previously reported infusion
rates:

L-glutamine (12 μmol/kg/min), L-lactate (40 μmol/kg/min), L-propionate (55

μmol/kg/min) [29, 74, 92, 107, 116, 135]. Di-deuterated-Glucose was co-infused as a
tracer for glucose metabolism along with each unlabeled “cold” tracer. Plasma samples
were taken at 0, 30, 60, and 120 min for measurement of plasma glucose, alanine,
pyruvate, and insulin concentrations as well as glucose enrichments for turnover analysis.
At the end of the study, freeze-clamped livers were obtained to measure hepatic
metabolites Results were compared to our glutamine tracer strategy (Figure 34, top
panel). We then performed separate experiments where we co-infused [1,2-13C2]-Lglutamine as a tracer of mitochondrial metabolism along with either cold acetate, lactate
or propionate to assess whether these existing tracer strategies have an impact
metabolism (Figure34, bottom panel).
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Figure 34. Assessing tracer liabilities.
Top Panel: Assessing the impact of acetate, glutamine, lactate and propionate on
glucose homeostasis and plasma and liver metabolites during a full length infusion..
Bottom Panel: Assessing the impact of acetate, lactate and propionate on metabolic
fluxes using [1,2-13C2]-L-glutamine as a tracer strategy.

As shown in Figure 35 (top panels) compared to glutamine, which did not perturb glucose
homeostasis, acetate, lactate and propionate all significantly increased endogenous
glucose production and plasma insulin levels. Furthermore, lactate and propionate also
raised glucose concentration significantly from baseline. Additionally, all three tracers
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increased key metabolites in liver and plasma significantly (Figure middle panels)
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Figure 35. Contemporary tracers impact glucose metabolism.
All commonly used tracers impacted glucose homeostasis and liver metabolism. Acetate,
glutamine, lactate and propionate were infused as a primed continuous infusion and (a) plasma
glucose concentration, (b) endogenous glucose production, (c) plasma insulin concentration, (d)
plasma metabolites, (e) liver metabolites were measured. Control group was infused with 1/2NS
instead of a cold tracer. N=7-10.
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compared to glutamine and thereby perturbed metabolic steady state. Their impact on
metabolism was further corroborated by their impact on absolute and relative fluxes in the
liver (Figure 36 and 37). Compared to glutamine studies acetate increased anaplerosis
and cataplerosis, respectively (VPC and VPEPCK+ME), whereas lactate predominantly
increased PDH flux. Propionate on the other hand mainly pushed oxidation in the distal
half of the Krebs cycle thereby increasing cataplerotic fluxes (PEPCK+ME).
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112

CHAPTER VI: DISCUSSION AND FUTURE APPLICATIONS
Over the past decades, stable isotope based metabolic flux analysis has given us a
unprecedented glimpse into the system-wide dynamics of in vivo mitochondrial
metabolism that often expanded well beyond the static and isolated snapshots of
metabolism yielded by molecular studies, such as metabolomics, RNAseq, and whole
genome sequencing [51, 136]. For instance, metabolic flux analyses demonstrated that
dysregulated hepatic oxidative and anaplerotic Krebs Cycle fluxes along with increased
cataplerotic flux into biosynthetic pathways contribute significantly to hyperglycemia and
dyslipidemia manifesting in NAFLD, insulin resistance, and type 2 diabetes mellitus [27,
40-43]. However, at the same time stable isotope-based tracer methods have led to highly
divergent and controversial conclusions and concepts of these hepatic Krebs Cycle fluxes
[4, 29, 41, 75, 77-79]. It is impossible that minor differences in experimental setup – such
as potential differences in the microbiome between animals studied at two different
universities – could lead to an up to 5-fold difference in pyruvate cycling measured with
13C-propionate

and lactate as a tracer[4, 41, 42]. The reason for the discrepancies is

based in erroneous/spurious flux calculations that occur due to problematic tracer study
design and implementation [10, 71, 72, 74, 84, 86, 107, 137]. Unbiased measurements
of basal metabolic fluxes through the Krebs cycle and adjacent pathways are crucial for
our understanding and investigation of the etiology and progression of obesity, NAFLD,
insulin resistance, and diabetes mellitus.
Stable isotope metabolic flux analyses provide a safe and elegant method to study minute
changes of highly dynamic metabolic systems and can serve as a critical means of
assessing target engagement when identifying novel therapeutic and curative targets
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[60]. Even though a “one size fits all” tracer method may not exist, herein, we reported
the systematic development of [1,2-13C2]-L-glutamine as a novel tracer strategy that has
been systematically validated to provide an unencumbered interrogation of basal hepatic
Krebs cycle metabolism and to help solving several of its existing controversies by
identifying many of the challenges and shortcomings of existing tracer methods.

[1,2-13C2]-L-glutamine generated mass isotopomers interrogate in vivo hepatic
metabolism with minimal tracer interference
A metabolic isotope tracer is a molecule which is subject to the same physiological
processes as its respective tracee but does not interfere with metabolism. One of the
most common concerns regarding stable isotope tracer studies pertains to potential
violations of this “Tracer assumption”: Stable isotope-based tracers are not completely
mass-less compared to radioisotopes whose radioactive signal can be readily detected
even at minuscule concentrations. Signal sensitivity for stable isotopes, on the other
hand, is much lower resulting in poor signal to noise ratios. To overcome this insensitivity
issue, oftentimes high and rapid infusion rates are necessary to achieve measurable
fractional enrichments and thus discernable signal to noise ratios [55]. When infused at
rates close to the natural turnover of its tracee, a tracer can add significant mass to the
system and shift the equilibrium of the reactions it is supposed to trace. Thereby it can
violate tracer assumptions and invalidate its putative tracer function. This change in
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enzyme kinetics will ultimately impact metabolic homeostasis. Therefore, it is prudent to
find an infusion rate for a stable isotope tracer that does not interfere with its endogenous
turnover to avoid perturbing the metabolic system under investigation, yet is high enough
to introduce sufficient fractional enrichment of the tracer into the Krebs Cycle and its
constituent pathways. We empirically tested multiple infusion rates for [1,2-13C2]-Lglutamine until we identified a rate which allowed for a robust transfer of label from our
tracer to downstream traces. Thus, providing measurable signal intensity of key metabolic
intermediates, yet without pushing glucose or glutamine metabolism, as demonstrated by
a lack of differences in plasma glucose, glycerol, insulin concentrations and endogenous
glucose and glutamine turnover rates. Additionally, at our infusion rate (12 mmol/kg/min),
tracer signal reached isotopic steady state across all key plasma and liver metabolites
quickly and reliably without sacrificing labeling signal. Due to the high costs of isotope
tracers and the possible effects of extended infusion times on subjects’ comfort and
metabolism, a shorter duration of infusion, as is possible with [1,2-13C2]-L-glutamine, is
preferred by many investigators.

[1,2-13C2]-L-glutamine provides distinct mass spectra amenable to MIMOSA
An inherent limitation of stable isotope-based approaches has been the restricted number
of metabolites and isotopomers that can be measured by either NMR or Mass
Spectrometry alone. Scarcity of directly measurable fractional enrichment of key
metabolites make a metabolic flux model reliant on the accuracy of its underlying
assumptions and in silico approximations of the unknown parameters. However, making
the right assumptions can be complicated by complex and at times overlapping labeling
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patterns leading to ambiguity of the data used for in silico simulation and subsequent
stable isotope-based flux analysis. Complex and ambiguous mass spectra commonly
stem from choice of tracer, position of label within the tracer’s carbon backbone,
distribution of label across one or multiple turns of the Krebs cycle and label recycling in
the form of “secondary tracers,” thereby leading to complex, labile axiomatic
dependencies on higher order algebraic equations needed to approximate flux through a
metabolic system. For example, the more complex the mathematical analysis the more
liable it is to perpetuating and compounding experimental and analytical errors which in
turn will result in erroneous flux calculations.

[1,2-13C2]-L-glutamine generated

distinguishable isotopomer and isotopologue species of key metabolites that were free of
any overlapping, convoluted primary or secondary labeling schemes and thus amenable
for novel application of our in vivo analytical platform MIMOSA [71]. Due to the lack of
any ambiguity of quantitative and qualitative tracer and tracee measurements at isotopic
dynamic and steady state, we were able to directly interpret the carbon-specific kinetic
flow of isotope label across sequential key metabolites and along intersecting metabolic
pathways. The unambiguous fractional enrichment patters provided the necessary input
functions to directly solve and calculate all key metabolic fluxes through first order
differential equations.
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Not all Krebs cycle fluxes are equal
Due to its low sensitivity, in vivo

13CNMR

cannot detect label signal from Krebs cycle

intermediates directly. Instead, it relies on measuring signal from higher abundant,
cytosolic metabolites, such as Aspartate and Glutamate, that are in direct exchange with
Krebs cycle intermediates (OAA and αKG, respectively). Since the actual Krebs cycle
intermediates are “invisible” to NMR, all oxidative reactions of the Krebs cycle have
traditionally been reported and for metabolic modeling purposes simplified as one circular
flux pathway, the rate of which is often denoted as VTCA. Combining the glutamine tracer
approach with our MS/MS based MIMOSA, we were able to trace individual steps of the
Krebs cycle and calculate relative rates for all of its major metabolic reactions. We found
that all oxidative Krebs cycle fluxes are not equal and collapsing them into one singular
rate is an oversimplification. For instance, succinate dehydrogenase flux (VSDH) is about
15% larger than citrate synthase flux (VCS) whereas VOGDH, and isocitrate dehydrogenase
net (VIDHnet) are only ¾ of CS. These different oxidative rates exemplify the fact that the
Krebs cycle must be viewed as a series of individual reactions that adjust to their adjacent
anaplerotic and cataplerotic fluxes accordingly to maintain mass balance. This is of
particular importance when tracer studies are designed to interrogate only parts of the
Krebs Cycle, but the data are used to make estimates about the Krebs Cycle rate as a
whole or about proximal flux rates, such as VCS.

117

There are three major anaplerotic entry points into the Krebs cycle
Another crucial finding pertains to anaplerotic (dilutional) fluxes. The importance of
assessing and accounting for all anaplerotic fluxes properly is underlined by the
successive dilution of label across Krebs cycle intermediates with one turn of the Krebs
cycle. One implicit assumption that goes into the calculations of most metabolic models
of hepatic metabolism is that there is no dilution of label as the cycle turns. However, our
data demonstrated that there is significant sequential dilution of label through one turn of
the Krebs cycle. As a matter of fact, tracer enrichment was reduced by approximately
70% through one full turn of the Krebs cycle. In addition to the commonly reported
anaplerotic flux through PC we found significant anaplerotic contribution from two other
sources, that is, glutamate and propionate. These anaplerotic fluxes have previously been
regarded as negligible. However, while PC still accounted for 75% of all anaplerotic
fluxes, anaplerosis from propionate constituted approximately 20% and glutamate
approximately 5%. The unexpectedly large anaplerotic flux from propionate underlines
that there is significant contribution from endogenous propionate, most likely coming from
gut fermentation, to hepatic metabolism in the basal state. Assuming minimal dilution of
label as it traverses the Krebs cycle and omitting to factor it into flux calculations,
especially when using surrogate metabolites as input functions for metabolic modeling,
will result in spuriously low VTCA rates and spuriously high cataplerotic fluxes, such as
PEPCK, by falsely attributing a reduction in the tracer to downstream tracee ratio to low
activity of oxidative reactions rather than to dilutional flux.
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Isocitrate consists of two distinct reactions and ACLy contributes significantly to
basal hepatic metabolism
Isocitrate dehydrogenase catalyzes the step in the Krebs cycle between Isocitrate and
αKG. IDH’s enzymatic function is often simply described as one reversible exchange
reaction. However, our data demonstrated that this simplification does not hold true. IDH
catalyzes rather two very distinct, independent enzymatic steps: an oxidative (forward)
reaction (IDHf) converts Isocitrate to αKG and a reductive carboxylation (reverse) reaction
(IDHr) which carboxylates αKG to Isocitrate. Since IDHf flux exceeds IDHr, there is an
overall net flux (IDHnet) towards aKG. However, the significant reverse carbon flow from
αKG to Isocitrate and ultimately to Citrate at baseline is of tremendous importance for two
reasons: First, IDHr is a crucial step in one of the anabolic functions of the Krebs cycle
because it provides Citrate for ATP Citrate Lyase. ACLy catalyzes the cleavage of citrate
into cytosolic malate and acetate which after activation to acetyl CoA is used as a building
block for the biosynthesis of lipids in the process of de novo lipogenesis (DNL) and
cholesterol in the mevalonate pathway. Previously thought to predominantly occur in the
fed state [5, 6] we are showing here that flux through ACLy makes up almost 20% of basal
hepatic metabolism in the fasted state. While DNL might mainly occur in the fed state
during a surplus of fuel substrates, hepatic cholesterologenesis is reciprocal to
exogenous cholesterol intake and highest at night during fasting with the majority of basal
endogenous cholesterol production coming from the liver [138{Schroor, 2019 #822]}.
Thus, explaining significant ACLy contribution at baseline. Moreover, acetyl-CoA is not
only an important substrate for lipid and cholesterol production but a vital building block
in ketogenesis and an allosteric activator of PC, a key step in gluconeogenesis [31-37].
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In the prolonged fasted state, the brain relies heavily not only on endogenous glucose
production but on alternative fuels such as ketone bodies when exogenous glucose
supplies diminish. Ketones can easily cross the blood-brain barrier and can be used as
energy sources in the central nervous system. Besides its direct role as a metabolite in
energy metabolism, AcCoA
is

also

substrate

an
for

important
histone

acetylation and thus an vital
epigenetic regulator of DNA
[139].
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Figure 38. ACLy's role in basal metabolism.
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lipogenesis,
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modulation.

pool of malate and therefore of OAA, which serves as something of a metabolic hub that
links the Krebs cycle to gluconeogenesis. Depending on the tracer strategy and analytical
platform, significant flux through ACLy can bias the interpretation of relative fluxes when
only measuring malate or its trapping pool (aspartate). Falsely attributing all of malate’s
fractional enrichment to VTCA and not correcting for VACLy will result in spurious oxidative
rates. Overall, under fasting conditions, reductive carboxylation and ACLy appear to play
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a much more important role in cell homeostasis than previously assumed and flux through
these mitochondrial nodes needs to be factored into accurate flux analysis.

Glutamate is a kinetic component of the Krebs cycle due to rapid exchange
reaction Vx
An important base assumption of

13CNMR

based metabolic modeling pertains to the

aminotransferase exchange rate (VX) between the cytosolic glutamate and the
intramitochondrial αKG pool. Due to its low sensitivity, NMR cannot measure Krebs cycle
intermediates directly and relies on measurements of high abundance surrogate
metabolites that are trapping pools for low abundance intermediates, such as glutamate
for αKG. An inherent assumption of most NMR metabolic modeling schema is that Vx is
so fast that glutamate becomes a kinetic component of the Krebs cycle and an immediate
readout of αKG labeling [94, 96, 99, 100]. Inaccuracy of this assumption, i.e., if the
exchange reaction is not significantly faster than the Krebs cycle or varies substantially
under different conditions, would mean that VX needs to be determined separately for
each experimental condition to calculate accurate Krebs cycle reactions by NMR. One
reason we chose glutamine as a tracer method is its strategic entry point into Krebs cycle
which allowed for an unprecedented direct kinetic measurement of VX in vivo. Tracing the
kinetic transfer of label between specific glutamate and succinate isotopomers we were
able to show that glutamate is indeed in fast exchange with the intramitochondrial
metabolite pool and

13C

label equilibrates within less than ~5-10 minutes. These data

thereby validate the assumption that signal from labeled glutamate is a reliable readout
of αKG enrichments and thus can be used as a surrogate input function in metabolic
modeling of the mitochondrial metabolism.
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Glucose serves as an extramitochondrial trapping pool
An additional advantage of our tracer strategy is that glucose is a trapping pool for [1,213C ]-L-glutamine
2

and thereby serves as a convenient systemic readout of hepatic

glucose production that is easily accessible for minimally invasive clinical testing. Tracing
glucose labeling would allow for assessment of changes in gluconeogenic fluxes which
are often altered in fatty liver and diabetes mellitus.

[1,2-13C2]-L-glutamine minimizes uncertainties of metabolic modeling and shows
strong congruencies between MIMOSA and computational analysis
Many assumptions about unknown parameters regarding label distribution and
transformation are inherent in the development of isotope fate maps and ultimately in
metabolic modeling. Oftentimes elaborate series of mathematical equations are
necessary to approximate individual reactions of a metabolic system. The elaborate
scope of direct isotopic measurements provided by [1,2-13C2]-L-glutamine in conjunction
with MIMOSA provided a solid foundation that could be used as inputs for mathematical
modeling software CWave [128]. Thus, assumption about unknown parameters could be
replaced by directly measured fractional enrichments of key metabolites. CWave was
able to compute the full panoply of Krebs cycle isotopomers, calculate absolute and
relative metabolic fluxes with high certainty and thereby construct a highly constrained,
comprehensive metabolic flux model. The metabolic flux analysis performed with CWave
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was used to cross-validate the flux calculations made with MIMOSA. We found high
congruency between the data output from both modeling approaches. Most modeling
software requires powerful processors and a certain level of expertise. Showing that our
initial “manual” metabolic flux analysis was highly consistent with the computational
output underlines the robustness of our approach and offers a “user-friendly” alternative
for investigators performing isotope studies.

Absolute Krebs cycle rates were calculated by bootstrapping relative rates on
EGP
Absolute Krebs cycle rates were determined by “bootstrapping” an externally measured
absolute rate, such as endogenous glucose production (EGP, glucose Ra) onto relative
metabolic rates derived from steady state equations [15, 123]. Under the assumption that
during fasting all gluconeogenic flux comes from PEPCK, absolute rates for CS were
determined by back-calculating from direct measurements of EGP multiplied by relative
fluxes of VPEPCK+ME/VCS. All other absolute fluxes were then calculated using their ratio
relative to VCS [4, 15]. Relative metabolic fluxes give insight into the fractional contribution
of one metabolic flux/reaction relative to another, e.g., VSDH to VCS, which is informative
for determining directionality of metabolic processes and relative contribution of one
pathway to another. However, when both fluxes increase or decrease proportionately,
relative fluxes remain the same even though the overall metabolic flux has changed. For
instance, even though flux through PEPCK might not be statistically significantly
increased relative to CS in clinically latent insulin resistance because CS rate increased
simultaneously, but absolute flux through gluconeogenesis might already be significantly
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elevated and herald ensuing diabetes mellitus. Therefore, measuring both flux rates and
ratios will complete the metabolic picture and bridge their respective shortcomings.

Liabilities of existing tracer methods
Applying our glutamine tracer strategy, we investigated the root cause of the controversial
concepts of basal hepatic metabolism. Unlike in vitro systems that are closed and more
controllable, in vivo systems are open and susceptible to systemic physiologic changes
that could impact metabolism in the tissue of interest. The liver as a central organ of
glucose, lipid and amino acid metabolism is specifically sensitive to minute changes in
substrate concentrations and hormone levels. Therefore, accounting for a tracer’s specific
liabilities and comprehensively validating it for the metabolic study at hand is extremely
important to avoid spurious results. To investigate potential liabilities of current tracer
methods that have led to recent metabolic controversies, we applied a doubly labeled
glutamine strategy as an independent tracer method and assessed all absolute and
relative Krebs cycle rates after infusion of unlabeled L-acetate, L-lactate, or L-propionate
at one of their reported infusion rates [29, 74, 92, 107, 116, 135]. We found that, unlike
glutamine, all three contemporary tracer methods impacted glucose homeostasis and
central carbon metabolism. Acetate is activated to acetyl CoA which is an allosteric
activator of PC [16-22] and pyruvate dehydrogenase complex kinase [140] consequently
increasing anaplerotic flux and decreasing substrate flux into the oxidative part of the
Krebs cycle. Accordingly, our absolute and relative flux analysis showed that acetate
increased anaplerosis and cataplerosis (VPC and VPEPCK+ME, respectively). In contrast,
lactate predominantly increased PDH flux. These data stand to reason because lactate
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is converted to pyruvate which in turn activates PDH through inhibition of pyruvate
dehydrogenase kinase [51]. Increased PDH and decreased PEPCK activity might further
be amplified by the elevated insulin levels we observed during the Lactate infusion
because pyruvate dehydrogenase phosphatase is stimulated by insulin [23]. Propionate
increased oxidation in the distal half of the Krebs cycle, thereby pushing cataplerotic
fluxes (VPEPCK+ME) and substrate cycling. Propionyl-CoA, the activated propionate
species, has been described as a potent activator of PC and identified to play a role in
increasing EGP [4, 141]. Our data along with previous [4, 142, 143] studies also
demonstrated that propionate at commonly used infusion rates significantly increased
concentrations of Krebs cycle intermediates. The resultant metabolic push into the distal
part of the Krebs cycle leads to increased flux through malate dehydrogenase/ME which
decreases the NAD+/NADH molar ratio. Reduced levels of NAD+ can lead to decreased
flow through PDH and increased pyruvate cycling and gluconeogenesis. Taken together,
these data shed light on possible explanations for the divergence of concepts of hepatic
metabolism. Different tracers have their respective strengths tracing specific aspects of
metabolism; however, here we have shown that if not carefully validated these tracers
can push and alter metabolism. Thereby, it is crucial to validate that the key assumption
of stable isotope tracing: the tracer must simply trace but not direct the metabolic fate of
label in order to avoid spurious flux rate calculations. Moreover, some changes were not
obvious from relative rates alone but became significant when absolute rates were
assessed. This further highlights the importance of taking a comprehensive approach
when investigating metabolism rather than relying on isolated aspects.
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Potential pitfalls of glutamine as a tracer
We have not yet fully validated glutamine as a tracer of Krebs cycle flux in tissues other
than the liver. Even though we did not find any unexpected secondary labeling patterns
from glutamine in kidney, muscle, or WAT, its effect on mitochondrial metabolism in those
tissues still needs to be assessed. The ideal infusion rate may vary based on the condition
under investigation. For example, a tracer is more likely to provide substrate and violate
tracer assumptions under conditions of prolonged starvation than in fed, substrate-replete
animals, so ideally one should validate the infusion rates under their conditions of interest.
For instance, the kidney is reported to be a major site of Glutamine metabolism, where
Glutamine is avidly taken up and used as a preferred substrate for gluconeogenesis.
Therefore, glutamine could potentially violate tracer assumptions when used to model
renal metabolism, particularly under prolonged fasting conditions where the renal
contribution to gluconeogenesis likely increases[144]. Another possible shortcoming is
that glutamine has not been evaluated for multiple tracer approaches. Since stable
isotope tracer are not completely massless, infusing labeled glutamine along with other
labeled tracers might have a cumulative mass effect resulting in potential violation of
tracer assumptions. Therefore, adjustments might need to be made to the infusion rate.
Another potential pitfall pertains to the bootstrapping method. Under prolonged fasting
conditions additional contribution to GNG can come from other sources, such as glycerol,
in which case PEPCK flux cannot be used as the sole relative flux related to EGP. Lastly,
the overall enrichment of plasma glucose coming from [1,2-13C2]glutamine was fairly low
and might not be high enough to be used for future NMR studies to assess substrate
contributions to glucose production when infused at our proposed infusion rate.
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Concluding remarks
The Krebs cycle is a multifaceted pathway and plays a central role in the etiology and
progression of some of the most common metabolic and endocrine diseases, all of which
have reached epidemic proportions in our society. Previous stable isotope tracer methods
meant to elucidate the underlying metabolic flux aberrations of insulin resistance, T2DM,
and NAFLD have resulted in many controversies regarding central carbon metabolism
and call for a critical assessment of stable isotope tracer methodology. The identified
limitations ranged from interference of the tracer with metabolism, insufficient or too
complicated tracer enrichments, to technical and analytical shortcomings. To address
these issues, we empirically developed and comprehensively validated [1,2-13C2]-Lglutamine as a novel tracer method that in conjunction with our analytical platform
MIMOSA expanded the scope of traceable metabolites and added isotopomeric
information to the metabolic flux analysis. This approach allowed for direct calculation of
previously inaccessible Krebs cycle reactions, such as individual oxidative, anaplerotic
and exchange reactions, some of which have never been measured before in vivo. This
study highlights that many of the current assumptions of in vivo metabolic modeling in
use for metabolic modeling need to be revised and critically revisited. For instance, one
novel insight gleaned from our experiments is that label entering the Krebs cycle
undergoes sequential dilution at distinct metabolic intersections, such as PCC and GDH.
Moreover, ACLy flux contributes significant mass to Malate even under basal conditions.
When these significant fluxes are neglected in MFA because only isolated reactions are
assessed and used as readouts of the entire cycle, the analysis is liable to miss important
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qualitative and quantitative aspects of mitochondrial metabolism and generate
misconceptions.

[1,2-13C2]-L-glutamine

provided

a

comprehensive

and

holistic

interrogation of Krebs Cycle metabolism in vivo that can be employed to investigate some
of medicine’s most pervasive problems, such as diabetes mellitus, NAFLD and obesity.
Therefore, we anticipate it will aid in identifying novel diagnostic and therapeutic targets
as well as enable us to identify the underlying metabolic predisposition and progression
of NAFLD to NASH and hepatocellular cancer.

Future Applications
Going forwards we extend our [1,2-13C2]-L-glutamine strategy to measure basal
mitochondrial metabolism in additional tissues in vivo, such as adipose tissue, kidney and
muscle with the intention to expand our metabolic model from the liver to whole body
metabolism. By studying isolated organs we get great insights about individual metabolic
aspect, but might miss the bigger picture, especially considering that different organs
contribute to metabolism in various ways. Understanding the metabolic cross-talk and
relative contribution of each organ might hold the answers to some of the unsolved
problems in medicine.
Additionally, we will apply our glutamine tracer strategy to study hepatic metabolism in
disease models of obesity, NAFLD and hepatocellular cancer to identify early metabolic
aberrations that can be targetable for early diagnostic, preventive and/or curative
interventions.
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CHAPTER VI: MATERIALS AND METHODS

Rodent studies
Sprague-Dawley rats (~250+/-25g) were purchased from Charles River Laboratories and
fed normal chow ad lib (Harlan-Teklad 2018). All animal protocols were approved by the
Yale University Animal Care and Use Committee (IACUC) prior to performance. Rats
underwent surgery under general isoflurane anesthesia to place polyethylene catheters
in the left carotid artery (advanced into the proximal aorta) and right jugular vein (PE50,
PE90, and PE50 tubing, respectively, Instech Solomon). After 1 week of recovery post
surgery, rats were acclimated to the infusion room the night before the infusion study and
fasted overnight. Studies began at 8 A.M to avoid contributions of the diurnal cycle to the
phenotypes observed. Rats were unrestrained in their cages (Figure 41). At the end of
each study each rat was euthanized by intravenous pentobarbital injection. Tissues, such
as livers, kidneys, white adipose tissue (WAT), and muscle, were freeze-clamped in situ
using tongs pre-chilled in liquid N2 and stored at -80°C for later analysis [133-135].
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All infusion studies
were

done

as

primed-continuous
infusions
pointed

(unless
out

otherwise) into the
arterial

catheter,

either by infusion of a
labeled tracer alone
Figure 39. Set up of rat infusion study.
Tracer Infusion Study Setup. Sprague -Dawley rats are unrestrained
in clean cages. Tracer is infused through a central arterial catheter
and plasma samples are obtained through a jugular venous
catheter.

or as a co-infusion of
a labeled and an
unlabeled

(“cold”)

tracer candidate. All
isotopes were obtained from Cambridge Isotopes. ”Cold” tracers were purchased from
Sigma Aldrich. The prime lasted for 5 mins and was 5x the basal infusion rate, followed
by the described basal infusion rate for the remainder of the study. Blood samples were
drawn through the venous catheter at baseline (before tracer infusion) and at multiple
time points throughout and at termination of the study [136]. Blood samples were
immediately transferred to a heparin-coated tube (Beckman Coulter), centrifuged at
maximum rpm for 0.5 min, and plasma stored at -80°C. Tissue samples were obtained at
each endpoint. Tracer infusion rates were based on published studies. For each study,
4-8 rats were studied per time point per label based on power calculations from pilot
experiments. Time points measurements included a baseline at time 0 (prior to infusion
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of label), followed by three to four early time points (e.g., 5, 10, 15, 30 minutes) to define
the shape of the build-up curves and 3-4 late time points (e.g., 90, 120 minutes) to define
isotopic steady and metabolic state. Secondary tracer generation was investigated by
continuous infusion of labeled tracer for 240 mins.

Liquid Chromatography -Mass Spectrometry/Mass Spectrometry Analysis
For MS analysis approximately 100mg of frozen tissue was lyophilized overnight in prechilled 1.7mL Eppendorf tubes. The lyophilized samples were then vortexed in ice cold
extraction buffer (50:50 MeOH and ddH2O) in a precooled centrifuge (4°C) and spun at
maximum speed for 10 mins. The supernatant was transferred into a Nanosep filter tube
and centrifuged for 1 hour at maximum speed in a precooled centrifuge. The filtrate was
subsequently transferred to a new pre-chilled Eppendorf tube. 1 ml of ice cold ddH2O
was added and then frozen in -80C. Once the sample was frozen the Eppendorf was
placed in the Lyophilizer overnight. The lyophilized samples were resuspended in 50 ul
of 50uM D4T spiked ddH20 and then transferred into 96 Well Plates for MS analysis.
Reconstituted samples were injected onto a Hypercarb column (3 μm particle size, 3x150
mm, Thermo Fisher Scientific) at a flow rate of 1 mL/min and separated isocratically.
Mobile Phase consisted of an aqueous phase (5% Ammonium formate, 20 ul EDTA,
0.03% acetyl acetone) and an organic phase (60% acetonitrile, 35% IPA (HPLC grade),
5% ammonium formate).

Samples ionized by electrospray into an ABSCIEX 5500

QTRAP equipped with a SelexION for differential mobility separation (DMS) was acquired
using multiple reaction monitoring (MRM). Retention times are confirmed with known
standards and peaks integrated using Multiquant (ABSCIEX) using the individual MRM
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transition pairs (Q1/Q3) and mobile phase composition for each metabolite and fragment
identities were confirmed using

13C-labeled

standards. The atomic percent excess

(APE%) was calculated as the quotient between each Q1/Q3 area and the sum of all
Q1/Q3 areas from each metabolite multiplied by 100 after correction for background and
isotopomer matrix to account for natural abundance carbons for possible parent/daughter
ion combination of the positive matrix for each MRM. Isobaric signals were eliminated by
DMS spectroscopy. The following settings: 1. Collision Cell Exit Potential (CXP), Collision
Energy (CE), Declustering Potential (DP), Entrance Potential (EP), Separation Voltage
(SV)-Compensation Voltage (CoV) were optimized for each metabolite studied and are
detailed below. 2. MRM transition pairs (Q1/Q3), carbons analyzed in each fragment,
mobile phase and M+n refers to the molecular weight (M) plus number of 13C (n).
Validation of LC-MS measurement of positional enrichment of TCA intermediates: LC-MS
measurements of glutamate, glutamine, acetate, lactate, aspartate and glucose were
compared with the positional 13C labeling of these amino acids measured by POCE-NMR.

LC-MS/MS and DMS Settings
1. Approximate Collision Cell Exit Potential (CXP), Collision Energy (CE), Declustering
Potential (DP), Entrance Potential (EP), Separation Voltage (SV)-Compensation Voltage
(CoV) pair for each metabolite studied. 2. MRM transition pairs (Q1/Q3), carbons
analyzed in each fragment, mobile phase and M+n refers to the molecular weight (M) plus
number of 13C (n).
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DMS settings:

Mode

Metabolite

Q1

Q3

Time
DP
(mins)
60
-40
30
-40
60
-40
50
-60
30
-35
30
-40
60
-40
100
-40
30
-30

Negative

Aspartate
Citrate
Glutamate
Glutamine
Succinate
Lactate
Malate
Phosphoenolpyruvate
Pyruvate

132
191
146
145
117
89
133
167
87

88
111
128
127
73
89
115
79
87

Alanine
Carbamoyl
Phosphate
Urea

90
140

90
79

5
15

61

61

30

EP

CE

CXP SV

CoV

-10
-10
-10
-5
-13
-10
-5
-10
-6

-16
-17
-15
-15
-15
-8
-15
-14
-6

-8
-10
-12
-8
-8
-5
-11
-6
-7

3400
3600
3400
3400
3400
3400
3400
2800
3000

-53
-7.25
-53
-58
-63
-53
-47
-37.5
-47

40
-17

8
-10

6
-18

15
-9

2400
1500

-14
-2

90

6

7

12

500

-2

Positive

Metabolite isotopologues and their parent/daughter ion m/z in MS/MS:
Metabolite
Alanine

Aspartate

CarbamoylP

Isotopologue
M+0
M+1
M+2
M+3
M+0
M+1
M+2
M+3
M+4
M+0
M+1

Q1/Q3
90/90
91/91
92/92
93/93
132/115
133/116
134/117
135/118
136/119
140/79
141/80

Daughter
C1,2,3

C1,2,3,4

C1
133

Citrate

M+0
M+1

191/111
192/111

C1,2,3,4,6
C2,3,4,5,6

192/112
M+2

193/112
193/113

M+3

194/113
194/114

M+4

195/114
195/115

Glutamate

Glutamate

Glutamine

Lactate

M+5

196/115
196/116

M+6

197/116

M+0
M+1
M+2
M+3
M+4
M+5
M+0
M+1
M+1
M+2
M+2
M+2
M+3
M+3
M+4
M+4
M+5
M+0
M+1
M+2
M+3
M+4
M+5
M+0
M+1
M+2
M+3

146/128
147/129
148/130
149/131
150/132
151/133
146/41
147/41
147/42
148/41
148/42
148/43
149/41
149/42
150/42
150/43
151/43
145/127
146/128
147/129
148/130
149/131
150/132
89/89
90/90
91/91
92/92

C1,2,3,4,5

C4,5

C1,2,3,4,5

C1,2,3
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Malate

PEP

Pyruvate

Succinate

Urea

M+0
M+1
M+2
M+3
M+4
M+0
M+1
M+2
M+3
M+0
M+1
M+2
M+3
M+0

133/115
134/116
135/117
136/118
137/119
167/79
168/79
169/79
170/79
87/87
89/89
90/90
91/91
117/73

M+1
M+1
M+2
M+2
M+3
M+4
M+0
M+1

118/73
118/74
119/74
119/75
120/76
121/76
61/61
62/62

C1,2,3,4

C1,2,3

C1,2,3

C123
C234

C1

Gas Chromatography-Mass Spectrometry Analysis
Whole blood was spun down and plasma was separated. After spiking with [2-13C1]Glycerol (100 uM) as an internal standard, 20ul of plasma was used for plasma
glucose/glycerol

derivatization

with

1:1

acetic

anhydride:pyrimidine,

following

Ba(OH)2/ZnSO4 deproteinization. GC-MS analysis of plasma samples was performed
with a Hewlett-Packard 5890 gas chromatograph (HP-1 capillary column, 12 m x 0.2 mm
x 0.33 Mm film thickness) interfaced to a Hewlett-Packard 5971A Mass Selective Detector
operating in the positive chemical ionization mode with methane as the reagent gas.
Selected ion monitoring was used to determine glucose enrichment and glycerol
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concentration. Ions with m/z 200 and 202 were monitored for glucose enrichment and m/z
145 and 146 for glycerol concentrations. The glycerol concentration was calculated from
the mass-to-charge ratio (m/z) of 145/146 signal.

Plasma glucose concentrations
Plasma glucose concentrations were measured enzymatically using the YSI 2700 Select
Biochemistry Analyzer (Yellow Springs Instruments, Yellow Springs, OH) or Analox
Instruments. The glucose measured is based on the following glucose oxidase reaction:
β- D-Glucose + O2  H2O2 + D-Gluconic acid. Hydrogen peroxide diffuses toward the
platinum anode in the probe assembly where it gives rise to the probe signal current.

Plasma insulin concentrations
Insulin concentrations were measured using the ALPCO Rat Insulin ELISA, a sandwich
type immunoassay. The 96-well microplate is coated with a monoclonal antibody specific
for insulin. The standards, controls, and samples were added to the microplate wells with
the conjugate. The microplate was then incubated at room temperature on a microplate
shaker at 700-900 rpm. After completion of the first incubation, the wells were washed
with Wash Buffer and blotted dry. TMB Substrate was added, and the microplate
incubated a second time at room temperature on a microplate shaker at 700-900 rpm.
Once the second incubation was completed, Stop Solution was added, and the optical
density (OD) measured by a spectrophotometer at 450 nm. The intensity of the color
generated is directly proportional to the amount of insulin in the sample.
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Calculation of endogenous turnover production (Tracer Dilution Model)
Rates of basal endogenous turnover were determined as the ratio of the rate of the tracer
infusion (μmol.kg-1.min-1) to the plasma APE of the tracer minus the tracer infusion rate
(corrected for its enrichment) Infusion rate (µmol/kg/min) * (Infusate APE/Sample
corrected APE-1). Endogenous glucose production (EGP) was determined from steady
state plasma enrichments after a primed continuous infusion of [6,6-(D2)]-D-glucose
(μmol.kg-1.min-1), whereas endogenous glutamine turnover was calculated from a
primed continuous infusion of [1,2-13C2]-L-glutamine (3 and 12 μmol.kg-1.min-1)[102]

NMR Analysis
Approximately 150 mg of tissue was homogenized with 0.1 M HCl/methanol (2:1 vol/wt)
followed by extraction with ethanol followed by centrifugation at 20,000×g. Heavy metals
were removed from the supernatant on Chelex-100 columns. Samples were then
lyophilized for long-term storage at −80 °C or resuspended in 500 μL of phosphatebuffered (50 mM, pH 7.0) D2O/H2O (85/15%) solution (Cambridge Isotopes, Andover,
MA) solution containing 3-trimethylsilyl[2,2,3,3-D4]-propionate (0.25 mM), as a chemical
shift reference. The samples from each rat were measured individually at 11.75 T on a
Bruker AVANCE vertical bore NMR spectrometer (Bruker Corp., Billerica, MA, USA) using
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1H-13C heteronuclear editing[50]. Spectral fitting was performed with NMRWizard [137].
Briefly, the heteronuclear editing method consists of the acquisition of two spin-echo
measurements, one with a broad-band inversion pulse applied at the 13C frequency, and
the other without the inversion pulse. The difference between the spectra represents
protons bound to

13C

(at twice the true intensity), while the sub-spectrum without the

inversion pulse represents the protons for 13C-labeled and the unlabeled compounds (i.e.,
the total concentrations).

13C

decoupling was applied during the acquisition of the free-

induction decays to collapse

13C-1H

couplings, reducing spectral complexity while

increasing sensitivity. An 8-ms echo time, 20-s repetition time, 12-ppm sweep width, and
32 768 complex data points were used.

Natural abundance correction of MRM fragments
As described previously [61], natural abundance was adjusted based on the value of
1.1%. A corrected isotopomer matrix, 𝐼𝐼’(Pm,Dn), was generated to account for the

presence of natural abundance carbons for each possible parent/daughter ion
combination of the positive matrix 𝐼𝐼(Pm,Dn):
𝐼𝐼’(Pm,Dn) = I(Pm,Dn) ∗ (1 + 𝑘𝑘( 𝑝𝑝 – 𝑚𝑚)) − I(Pm-1,Dn)∗ 𝑘𝑘(( 𝑝𝑝 – 𝑑𝑑) – (𝑚𝑚 − 𝑛𝑛 – 1) − I(Pm-1,Dn-1)∗ 𝑘𝑘 (𝑑𝑑 – (𝑛𝑛 – 1))

𝑝𝑝 is the total number of carbons in the parent ion

𝑑𝑑 is the total number of carbons in the daughter ion
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𝑚𝑚 is the number of 13C in the parent ion

𝑛𝑛 is the number of 13C in the daughter ion

𝐼𝐼 is the peak area corresponding to parent ion with mass P from 0 → 𝑝𝑝 and daughter ion
with mass D from 0 → 𝑑𝑑

𝑘𝑘 is 0.011 (the natural abundance of 13C in the environment)
𝑚𝑚 − 𝑛𝑛 ≤ 𝑝𝑝 – 𝑑𝑑

Statistical analysis
All data are reported as mean ± SEM (or ±SD as indicated). Comparisons of metabolic
parameters were made by a One-Way ANOVA corrected for multiple comparisons using
Dunnett’s test or Two-Way ANOVA corrected for multiple comparisons using Tukey's
multiple comparisons test. P<0.05 was considered significant (*p<0.05, **p<0.005,
***p<0.0005 and ****p<0.00005). Analyses were conducted with GraphPad Prism v7.0.
For NMR studies Mean and standard deviations were calculated for each of the fluxes
determined under basal conditions using Monte Carlo analysis [24].

Figures and Cartoons
All graphs were made with GraphPad Prism or Microsoft Excel. Cartoons were made with
BioRender.
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SUPPLEMENTAL INFORMATION
S1. Nuclear Magnetic Resonance Spectroscopy (NMR)

Nuclear Magnetic Resonance spectroscopy (NMR) is a magnetic resonance
spectroscopy (MRS) based, non-invasive analytical technique that allows for dynamic and
static investigation/analysis of metabolic/biochemical composition of tissues and body
fluids in vivo and in vitro. NMR takes advantage of the quantum property of spin. First
described by Bloch and Purcell in 1946 [59], nuclei with an odd mass or odd atomic
number can spin around their own axis and thereby create their own magnetic field,
referred to as magnetic moment (magnetization). Without an orienting field the direction
of the magnetic momentum is random. However, when an external, constant,
homogeneous magnetic field is applied the magnetic momentum of the nuclei will align
with the magnetic field. The alignment can either be parallel (α spin state) or anti-parallel
(β spin state) to the external magnetic field. The α spin state, also called ground state, is
a lower energy state compared to the β spin state, also called excited state. The difference
in distribution between the α and β spin state generates a measurable magnetization
along the z-axis. However, the difference in magnetic moments between parallel and antiparallel nuclei is extremely small (~0.01%) which explains the overall low sensitivity of
NMR. When aligned in the external magnetic field, the magnetic moment of the nucleus
will tip on the xy-axes at a specific angle (angular momentum) to the external magnetic
field and precess (rotate) around its spin axis. The resonance frequency at which a
nucleus rotates is called Larmor frequency (LF). The LF is directly proportional to the
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external magnetic field strength, B0, and the intrinsic magnetic properties of the respective
nucleus (γ-gyromagnetic ratio) and thus characteristic to each NMR visible nucleus. The
precession of each nucleus in the magnetic field is random and therefore out of phase.
This is the reason why there is naturally no observable net magnetic signal in the xyplane. To obtain a measurable signal that identifies a specific nucleus a radiofrequency
transmitter is used to apply a radiofrequency pulse sequence to the magnetic field. Nuclei
in the α spin state that precess at a Larmor frequency identical to the frequency of the
pulse sequence will transition out of their alignment with the magnetic field into the higher
energy β spin state and precess in phase. This leads to an observable magnetic signal
perpendicular to the external magnetic field in the xy axis. Once the RF pulse ends the
nuclei relax back to their original thermodynamic equilibrium and the amplitude of the
magnetization signal slowly decreases. This process is called Free Induction Decay (FID).
The relaxation time (RT) is the period over which the emitted signal decays. There are
two different relaxation times, T1 and T2, spin-lattice (longitudinal) time and spin-spin
(transverse) Time, respectively. T1 describes the return of the magnetic momentum along
the z axis, which is the direction of the applied magnetic field and T2 describes the return
of the magnetic momentum in the xy plane. Differences in relaxation times are an
important factor in signal intensity. The amplitude of the emitted signal and its FID is
recorded/detected by a radio frequency receiver. The decaying signal of each nucleus is
an oscillation of magnetization as it attenuates over time. The oscillation signal, which is
equal to the precession frequency of a nucleus, forms a unique FID curve that functions
as an identifiable nuclear fingerprint. The FID curve over time is then converted into signal
intensities over frequency by a process called Fourier Transformation. Important factors
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that impact the precession frequency of a nucleus are the chemical and electronic
properties of its molecular environment. For instance, adjacent nuclei and chemical bonds
can increase or decrease the precession frequency of a nucleus. The resultant chemical
shift in NMR peaks from a known reference frequency is called spin-spin (or J-) coupling.
Sometimes chemical shift can lead to a multitude of peaks on the NMR spectrum, all of
which reflect the different frequency components of a nucleus within its chemical
environment and thus aid in identifying a molecular structure and position specific label
information by NMR. The chemical shift is dimensionless and expressed in parts per
million (ppm) [55, 57].

S1.1 NMR CWave kinetic modeling

The following analytical process was used in CWave: first order differential input-output
equations describing each reaction of the metabolic pathway were used to calculate
metabolic fluxes and transport. Metabolic model parameters were obtained from nonlinear least squares fitting of the experimental data set and iteratively adjusted. With each
set of iterative parameters (IP) a simulated flux model was generated. The uncertainties
of the parameters were calculated by Monte Carlo simulation. Herein, simulations of the
initial flux model were run iteratively while adding noise to the parameters. The mean of
the noise is normalized to zero with a standard deviation that reflect the difference
between the experimental data and the simulated data. Every simulated data set was
least squares fitted to calculate the SD for each parameter of the metabolic model. This
process was repeated thousands of times until the variation of IPs consistently reached
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a narrow value [99, 127]. Thus from the time course of label appearance and the plateau
enrichments, kinetic constants of transport along with absolute and relative metabolic
rates of all key metabolic fluxes describing the Krebs cycle and its constituent metabolic
pathway were computed [127].

Table S1. Summary table of all metabolites and reactions included in the mathematical model
used for flux analysis computed by CWave.
Metabolite

Rate

AcCoA

Acetyl COA

ACL

ATP Citrate Lyase

Asp

Aspartate

bOx

Beta oxidation

Cit

Citrate

CS

Citrate Synthase

Glc

Glucose

GlyHex

Glycolysis-Hexokinase

Gln

Glutamine

GlcTriNeo

Gluconeogensis

Glyceraldehyde
Glu

Glutamate

GlyTri
Phosphatedehydrogenase

Glycerol
Glyc3p

3
ICDHfor

Isocitrate dehydrogenase, reverse

Phosphate
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KG

α Ketoglutarate

ICDHrev

Isocitrate dehydrogenase, reverse

Glycerol

Glycerol

KGDH

α Ketoglutarate dehydrogenase

Lac

Lactate

LDHrev

Lactate dehydrogenase, reverse

LacBlood

Lactate in blood

MDHfor

Malate dehydrogenase, forward

Lip

Lipids

MDHrev

Malate dehydrogenase, reverse

ME

Malic Enzyme

PC

Pyruvate carboxylase

Oxaloacetate,
OAAc
cytosolic

Oxaloacetate,
OAAm
mitochondrial

Phosphoenolpyr
PEP

Phosphoenolpyruvate

uvate

cytosolic

Phosphoenolpyruvate
Prop

kinase,

PEPCKc

Propionate

kinase,

PEPCKm
mitochondrial

Pyr

Pyruvate

PDH

Pyruvate dehydrogenase

Urea

PK

Pyruvate kinase

Urea
(HCO3)
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Suc

Succinate

SDHfor

Succinate dehydrogenase, forward

Vx_AspOAA Exchange
c

rate

Aspartate

and

Oxaloacetate, cytosolic

Vx_AspOAA Exchange

rate

Aspartate

m

Oaxolacetate, mitochondrial

Vglugln

Glutaminase

and

Aspartate
Vx_GluKG
Aminotransferase

Vglycerol

Glycerol kinase

Vlac

Lactate dehydrogenase, forward

Vprop

Propionyl-CoA carboxylase

Vx_OAAAsp Exchange
c

Aspartate

and

Oxaloacetate, cytosolic

Vx_OAAAsp Exchange
m

rate

rate

Aspartate

and

Oxaloacetate, mitochondrial
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Table S2.Summary of all reactions computed mathematically by CWave model

Source



Product

Rate

AcCoA



Cit

CS

Asp



OAAc

Vx_AspOAAm

Asp



OAAm

Vx_AspOAAc

Cit



KG

ICDHfor

Cit



AcCoA

ACL

Cit



OAAm

ACL

Glc



Glyc3p

GlyHex

Gln



Glu

Vgln

GlnBlood



Gln

VglnNet

Glu



Gln

Vglugln

Glu



KG

Vx_GluKG
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OAA

PC

148

S1.2 CWave equations

Mass balance equations in CWave are as follows:

Acetyl-CoA
dAcCoAm/dt = PDH + bOx – CS

Aspartate
dAsp/dt = Vx_OAAAspm - Vx_AspOAAm

Citrate
dCitrate/dt = CS + ICDHrev - [ICDHfor + ACL]

Glutamate
dGlu/dt = Vx_KGGlu + Vgln - [GluOut + Vx_GluKG]
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Glycerol 3 Phosphate
dGlyc3p/dt = GlcTriNeo + Vglycerol - [GlyTri + GlcNeo]

αKG
dKG/dt = ICDHfor + Vx_GluKG - [Vx_KGGlu + ICDHrev + KGDH]

Lactate
dLacPyr/dt = PK + Vlac - [PDH + PC]

Malate
dOAAmMal/dt = PC + Vx_AspOAAm + ACL + 0.5SDH + 0.5SDH - [Vx_OAAAspm +
PEPCK + CS]

OAA
dOAAc/dt = ACL – ACL

PEP
dPEP/dt = + GlyTri + PEPCK - [PK + GlcTriNeo]
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Succinate
dSuc/dt = + Vprop + KGDH – SDH

Isotope balance equations used in CWave are as follows:

Acetyl CoA
dAcCoAm2/dt

=

PDH(LacPyrC3/LacPyr)

+

bOx(IsotNA0/IsotNA)

+

PDH(LacPyrC1,3/LacPyr) - CS(AcCoAm2/AcCoAm)
1. dAcCoAm0/dt = - CS(AcCoAm0/AcCoAm{1})

2. dAcCoAm1/dt

=

PDH(LacPyr2/LacPyr)

+

bOx(IsotNA0/IsotNA)

+

bOx(IsotNA0/IsotNA)

+

PDH(LacPyr1,2/LacPyr) - CS(AcCoAm1/AcCoAm)

3. dAcCoAm1,2/dt

=

PDH(LacPyr2,3/LacPyr)

+

PDH(LacPyr1,2,3/LacPyr) - CS(AcCoAm1,2/AcCoAm)
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Aspartate
1. dAsp1/dt = Vx_OAAAspm(OAAmMal1/OAAmMal) - Vx_AspOAAm(Asp1/Asp)

2. dAsp2/dt = Vx_OAAAspm(OAAmMal2/OAAmMal) - Vx_AspOAAm(Asp2/Asp)

3. dAsp3/dt = Vx_OAAAspm(OAAmMal3/OAAmMal) - Vx_AspOAAm(Asp3/Asp)

4. dAsp4/dt = Vx_OAAAspm(OAAmMal4/OAAmMal) - Vx_AspOAAm(Asp4/Asp)

5. dAsp1,2/dt = Vx_OAAAspm(OAAmMal1,2/OAAmMal) - Vx_AspOAAm(Asp1,2/Asp)

6. dAsp1,3/dt = Vx_OAAAspm(OAAmMal1,3/OAAmMal) - Vx_AspOAAm(Asp1,3/Asp)

7. dAsp1,4/dt = Vx_OAAAspm(OAAmMal1,4/OAAmMal) - Vx_AspOAAm(Asp1,4/Asp)

8. dAsp2,3/dt = Vx_OAAAspm(OAAmMal2,3/OAAmMal) - Vx_AspOAAm(Asp2,3/Asp)

9. dAsp2,4/dt = Vx_OAAAspm(OAAmMal2,4/OAAmMal) - Vx_AspOAAm(Asp2,4/Asp)

10. dAsp3,4/dt = Vx_OAAAspm(OAAmMal3,4/OAAmMal) - Vx_AspOAAm(Asp3,4/Asp)

11. dAsp1,3,4/dt

=

Vx_OAAAspm(OAAmMal1,3,4/OAAmMal)-

Vx_AspOAAm(Asp1,3,4/Asp)
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12. dAsp1,2,3/dt

=

Vx_OAAAspm(OAAmMal1,2,3/OAAmMal)

-

Vx_OAAAspm(OAAmMal1,2,4/OAAmMal)

-

Vx_OAAAspm(OAAmMal2,3,4/OAAmMal)

-

Vx_OAAAspm(OAAmMal1,2,3,4/OAAmMal)

-

Vx_AspOAAm(Asp1,2,3/Asp)

13. dAsp1,2,4/dt

=

Vx_AspOAAm(Asp1,2,4/Asp)

14. dAsp2,3,4/dt

=

Vx_AspOAAm(Asp2,3,4/Asp)

15. dAsp1,2,3,4/dt

=

Vx_AspOAAm(Asp1,2,3,4/Asp)

Citrate

1. dCitrate1/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal4/OAAmMal)

+

ICDHrev(KG1/KG0/Urea) - [ICDHfor + ACL](Citrate1/Citrate)

2. dCitrate2/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal3/OAAmMal)

+

ICDHrev(KG2/KG)0/Urea) - [ICDHfor + ACL](Citrate2/Citrate)
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3. dCitrate3/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal2/OAAmMal)

+

ICDHrev(KG3/KG)0/Urea) - [ICDHfor + ACL](Citrate3/Citrate)

4. dCitrate4/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal0/OAAmMal)

+

ICDHrev(KG4/KG)0/Urea) - [ICDHfor + ACL](Citrate4/Citrate)

5. dCitrate5/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal0/OAAmMal)

+

ICDHrev(KG5/KG)0/Urea) - [ICDHfor + ACL](Citrate5/Citrate)

6. dCitrate6/dt

=

CS(AcCoAm0/AcCoAm(OAAmMal1/OAAmMal)

+

ICDHrev(KG0/KG)1/Urea) - [ICDHfor + ACL](Citrate6/Citrate)

7. dCitrate1,2/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal3,4/OAAmMal)

+

ICDHrev(KG1,2/KG)0/Urea) - [ICDHfor + ACL](Citrate1,2/Citrate)

8. dCitrate1,3/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal2,4/OAAmMal)

+

ICDHrev(KG1,3/KG)0/Urea) - [ICDHfor + ACL](Citrate1,3/Citrate)

9. dCitrate1,4/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal4/OAAmMal)

+

ICDHrev(KG1,4/KG)0/Urea) - [ICDHfor + ACL](Citrate1,4/Citrate)
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10. dCitrate1,5/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal4/OAAmMal)

+

ICDHrev(KG1,5/KG)0/Urea) - [ICDHfor + ACL](Citrate1,5/Citrate)

11. dCitrate1,6/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal1,4/OAAmMal)

+

ICDHrev(KG1/KG)1/Urea) - [ICDHfor + ACL](Citrate1,6/Citrate)

12. dCitrate2,3/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal2,3/OAAmMal)

+

ICDHrev(KG2,3/KG)0/Urea) - [ICDHfor + ACL](Citrate2,3/Citrate)

13. dCitrate2,4/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal3/OAAmMal)

+

ICDHrev(KG2,4/KG)0/Urea) - [ICDHfor + ACL](Citrate2,4/Citrate)
14. dCitrate2,5/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal3/OAAmMal)

+

ICDHrev(KG2,5/KG)0/Urea) - [ICDHfor + ACL](Citrate2,5/Citrate)

15. dCitrate2,6/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal1,3/OAAmMal)

+

ICDHrev(KG2/KG)1/Urea) - [ICDHfor + ACL](Citrate2,6/Citrate)
16. dCitrate3,4/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal2/OAAmMal)

+

ICDHrev(KG3,4/KG)0/Urea) - [ICDHfor + ACL](Citrate3,4/Citrate)
17. dCitrate3,5/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal2/OAAmMal)

+

ICDHrev(KG3,5/KG)0/Urea) - [ICDHfor + ACL](Citrate3,5/Citrate)

155

18. dCitrate3,6/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal1,2/OAAmMal)

+

ICDHrev(KG3/KG)1/Urea) - [ICDHfor + ACL](Citrate3,6/Citrate)

19. dCitrate4,5/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal0/OAAmMal)

+

ICDHrev(KG4,5/KG)0/Urea) - [ICDHfor + ACL](Citrate4,5/Citrate)

20. dCitrate4,6/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal1/OAAmMal)

+

ICDHrev(KG4/KG)1/Urea) - [ICDHfor + ACL](Citrate4,6/Citrate)

21. dCitrate5,6/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal1/OAAmMal)

+

ICDHrev(KG5/KG)1/Urea) - [ICDHfor + ACL](Citrate5,6/Citrate)

22. dCitrate1,2,3/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal2,3,4/OAAmMal)

+

ICDHrev(KG1,2,3/KG)0/Urea) - [ICDHfor + ACL](Citrate1,2,3/Citrate)

23. dCitrate1,2,4/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal3,4/OAAmMal)

+

ICDHrev(KG1,2,4/KG)0/Urea) - [ICDHfor + ACL](Citrate1,2,4/Citrate)

24. dCitrate1,2,5/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal3,4/OAAmMal)

+

ICDHrev(KG1,2,5/KG)0/Urea) - [ICDHfor + ACL](Citrate1,2,5/Citrate)
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25. dCitrate1,2,6/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal1,3,4/OAAmMal)

+

ICDHrev(KG1,2/KG)1/Urea) - [ICDHfor + ACL](Citrate1,2,6/Citrate)

26. dCitrate1,3,4/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal2,4/OAAmMal)

+

ICDHrev(KG1,3,4/KG)0/Urea) - [ICDHfor + ACL](Citrate1,3,4/Citrate)

27. dCitrate1,3,5/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal2,4/OAAmMal)

+

ICDHrev(KG1,3,5/KG)0/Urea) - [ICDHfor + ACL](Citrate1,3,5/Citrate)

28. dCitrate1,3,6/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal1,2,4/OAAmMal)

+

ICDHrev(KG1,3/KG)1/Urea) - [ICDHfor + ACL](Citrate1,3,6/Citrate)

29. dCitrate1,4,5/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal4/OAAmMal)

+

ICDHrev(KG1,4,5/KG)0/Urea) - [ICDHfor + ACL](Citrate1,4,5/Citrate)

30. dCitrate1,4,6/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal1,4/OAAmMal)

+

ICDHrev(KG1,4/KG)1/Urea) - [ICDHfor + ACL](Citrate1,4,6/Citrate)

31. dCitrate1,5,6/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal1,4/OAAmMal)

+

ICDHrev(KG1,5/KG)1/Urea) - [ICDHfor + ACL](Citrate1,5,6/Citrate)

32. dCitrate2,4,6/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal1,3/OAAmMal)

+

ICDHrev(KG2,4/KG)1/Urea) - [ICDHfor + ACL](Citrate2,4,6/Citrate)
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33. dCitrate2,3,4/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal2,3/OAAmMal)

+

ICDHrev(KG2,3,4/KG)0/Urea) - [ICDHfor + ACL](Citrate2,3,4/Citrate)

34. dCitrate2,3,5/dt = CS(AcCoAm1/AcCoAm)(OAAmMal2,3/OAAmMal)
+ ICDHrev(KG2,3,5/KG)0/Urea) - [ICDHfor + ACL](Citrate2,3,5/Citrate)

35. dCitrate2,3,6/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal1,2,3/OAAmMal)

+

ICDHrev(KG2,3/KG)1/Urea) - [ICDHfor + ACL](Citrate2,3,6/Citrate)

36. dCitrate2,4,5/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal3/OAAmMal)

+

ICDHrev(KG2,4,5/KG)0/Urea) - [ICDHfor + ACL](Citrate2,4,5/Citrate)

37. dCitrate2,5,6/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal1,3/OAAmMal)

+

ICDHrev(KG2,5/KG)1/Urea) - [ICDHfor + ACL](Citrate2,5,6/Citrate)

38. dCitrate4,5,6/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal1/OAAmMal)

+

ICDHrev(KG4,5/KG)1/Urea) - [ICDHfor + ACL](Citrate4,5,6/Citrate)

39. dCitrate3,4,6/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal1,2/OAAmMal)

+

ICDHrev(KG3,4/KG)1/Urea) - [ICDHfor + ACL](Citrate3,4,6/Citrate)
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40. dCitrate3,5,6/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal1,2/OAAmMal)

+

ICDHrev(KG3,5/KG)1/Urea) - [ICDHfor + ACL](Citrate3,5,6/Citrate)

41. dCitrate1,2,3,4/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal2,3,4/OAAmMal)

+

ICDHrev(KG1,2,3,4/KG)0/Urea) - [ICDHfor + ACL](Citrate1,2,3,4/Citrate)

42. dCitrate1,2,3,5/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal2,3,4/OAAmMal)

+

ICDHrev(KG1,2,3,5/KG)0/Urea) - [ICDHfor + ACL](Citrate1,2,3,5/Citrate)

43. dCitrate1,2,4,6/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal1,3,4/OAAmMal)

+

ICDHrev(KG1,2,4/KG)1/Urea) - [ICDHfor + ACL](Citrate1,2,4,6/Citrate)

44. dCitrate1,2,5,6/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal1,3,4/OAAmMal

+

ICDHrev(KG1,2,5/KG)1/Urea) - [ICDHfor + ACL](Citrate1,2,5,6/Citrate)

45. dCitrate1,3,4,6/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal1,2,4/OAAmMal)

+

ICDHrev(KG1,3,4/KG)1/Urea) - [ICDHfor + ACL](Citrate1,3,4,6/Citrate)

46. dCitrate1,3,5,6/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal1,2,4/OAAmMal)

+

ICDHrev(KG1,3,5/KG)1/Urea) - [ICDHfor + ACL](Citrate1,3,5,6/Citrate)

47. dCitrate2,3,4,6/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal1,2,3/OAAmMal)

+

ICDHrev(KG2,3,4/KG)1/Urea) - [ICDHfor + ACL](Citrate2,3,4,6/Citrate)
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48. dCitrate2,3,5,6/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal1,2,3/OAAmMal)

+

ICDHrev(KG2,3,5/KG)1/Urea) - [ICDHfor + ACL](Citrate2,3,5,6/Citrate)

49. dCitrate1,2,4,5/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal3,4/OAAmMal)

+

ICDHrev(KG1,2,4,5/KG)0/Urea) - [ICDHfor + ACL](Citrate1,2,4,5/Citrate)

50. dCitrate1,2,4,5,6/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal1,3,4/OAAmMal)

+

ICDHrev(KG1,2,4,5/KG)1/Urea) - [ICDHfor + ACL](Citrate1,2,4,5,6/Citrate)

51. dCitrate3,4,5/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal2/OAAmMal)

+

ICDHrev(KG3,4,5/KG)0/Urea) - [ICDHfor + ACL](Citrate3,4,5/Citrate)

52. dCitrate2,4,5,6/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal1,3/OAAmMal)

+

ICDHrev(KG2,4,5/KG)1/Urea) - [ICDHfor + ACL](Citrate2,4,5,6/Citrate)

53. dCitrate1,3,4,5/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal2,4/OAAmMal)

+

ICDHrev(KG1,3,4,5/KG)0/Urea) - [ICDHfor + ACL](Citrate1,3,4,5/Citrate)

54. dCitrate1,4,5,6/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal1,4/OAAmMal)

+

ICDHrev(KG1,4,5/KG)1/Urea) - [ICDHfor + ACL](Citrate1,4,5,6/Citrate)
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55. dCitrate2,3,4,5/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal2,3/OAAmMal)

+

ICDHrev(KG2,3,4,5/KG)0/Urea) - [ICDHfor + ACL](Citrate2,3,4,5/Citrate)

56. dCitrate3,4,5,6/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal1,2/OAAmMal)

+

ICDHrev(KG3,4,5/KG)1/Urea) - [ICDHfor + ACL](Citrate3,4,5,6/Citrate)

57. dCitrate1,3,4,5,6/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal1,2,4/OAAmMal)

+

ICDHrev(KG1,3,4,5/KG)1/Urea) - [ICDHfor + ACL](Citrate1,3,4,5,6/Citrate)

58. dCitrate1,2,3,4,5/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal2,3,4/OAAmMal)

+

ICDHrev(KG1,2,3,4,5/KG)0/Urea) - [ICDHfor + ACL](Citrate1,2,3,4,5/Citrate)

59. dCitrate2,3,4,5,6/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal1,2,3/OAAmMal)

+

ICDHrev(KG2,3,4,5/KG)1/Urea) - [ICDHfor + ACL](Citrate2,3,4,5,6/Citrate)

60. dCitrate1,2,3,6/dt

=

CS(AcCoAm0/AcCoAm)(OAAmMal1,2,3,4/OAAmMal)

+

ICDHrev(KG1,2,3/KG)1/Urea) - [ICDHfor + ACL](Citrate1,2,3,6/Citrate)

61. dCitrate1,2,3,4,6/dt

=

CS(AcCoAm2/AcCoAm)(OAAmMal1,2,3,4/OAAmMal)

+

ICDHrev(KG1,2,3,4/KG)1/Urea) - [ICDHfor + ACL](Citrate1,2,3,4,6/Citrate)

62. dCitrate1,2,3,5,6/dt

=

CS(AcCoAm1/AcCoAm)(OAAmMal1,2,3,4/OAAmMal)

+

ICDHrev(KG1,2,3,5/KG)1/Urea) - [ICDHfor + ACL](Citrate1,2,3,5,6/Citrate)
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63. dCitrate1,2,3,4,5,6/dt

=

CS(AcCoAm1,2/AcCoAm)(OAAmMal1,2,3,4/OAAmMal)

+

ICDHrev(KG1,2,3,4,5/KG)1/Urea) - [ICDHfor + ACL](Citrate1,2,3,4,5,6/Citrate)

Glutamate

1. dGlu1/dt

=

Vx_KGGlu(KG1/KG)

+

Vgln(IsotNA0/IsotNA)

-

[GluOut

+

+

Vgln(IsotNA0/IsotNA)

-

[GluOut

+

+

Vgln(IsotNA0/IsotNA)

-

[GluOut

+

+

Vgln(IsotNA0/IsotNA)

-

[GluOut

+

+

Vgln(IsotNA0/IsotNA)

-

[GluOut

+

Vx_GluKG](Glu1/Glu)

2. dGlu2/dt

=

Vx_KGGlu(KG2/KG)

Vx_GluKG](Glu2/Glu)

3. dGlu3/dt

=

Vx_KGGlu(KG3/KG)

Vx_GluKG](Glu3/Glu)

4. dGlu4/dt

=

Vx_KGGlu(KG4/KG)

Vx_GluKG](Glu4/Glu)

5. dGlu5/dt

=

Vx_KGGlu(KG5/KG)

Vx_GluKG](Glu5/Glu)
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6. dGlu1,2/dt = Vx_KGGlu(KG1,2/KG) + Vgln(GlnLiver1,2/GlnLiver) - [GluOut +
Vx_GluKG](Glu1,2/Glu)

7. dGlu1,3/dt

=

Vx_KGGlu(KG1,3/KG)

+

Vgln(IsotNA0/IsotNA)

- [GluOut

+

+

Vgln(IsotNA0/IsotNA)

- [GluOut

+

+

Vgln(IsotNA0/IsotNA)

- [GluOut

+

+

Vgln(IsotNA0/IsotNA)

- [GluOut

+

Vx_GluKG](Glu1,3/Glu)

8. dGlu1,4/dt

=

Vx_KGGlu(KG1,4/KG)

Vx_GluKG](Glu1,4/Glu)

9. dGlu1,5/dt

=

Vx_KGGlu(KG1,5/KG)

Vx_GluKG](Glu1,5/Glu)

10. dGlu2,4/dt

=

Vx_KGGlu(KG2,4/KG)

Vx_GluKG](Glu2,4/Glu)
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1. dGlu2,5/dt

=

Vx_KGGlu(KG2,5/KG)

+

Vgln(IsotNA0/IsotNA)

- [GluOut

+

+

Vgln(IsotNA0/IsotNA)

- [GluOut

+

+

Vgln(IsotNA0/IsotNA)

- [GluOut

+

+

Vgln(IsotNA0/IsotNA)

- [GluOut

+

Vx_GluKG](Glu2,5/Glu)

2. dGlu3,4/dt

=

Vx_KGGlu(KG3,4/KG)

Vx_GluKG](Glu3,4/Glu)

3. dGlu3,5/dt

=

Vx_KGGlu(KG3,5/KG)

Vx_GluKG](Glu3,5/Glu)

4. dGlu4,5/dt

=

Vx_KGGlu(KG4,5/KG)

Vx_GluKG](Glu4,5/Glu)

5. dGlu1,2,3/dt = Vx_KGGlu(KG1,2,3/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu1,2,3/Glu)

6. dGlu1,2,4/dt = Vx_KGGlu(KG1,2,4/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu1,2,4/Glu)

7. dGlu1,3,4/dt = Vx_KGGlu(KG1,3,4/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu1,3,4/Glu)

8. dGlu1,2,5/dt = Vx_KGGlu(KG1,2,5/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu1,2,5/Glu)
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9. dGlu1,3,5/dt = Vx_KGGlu(KG1,3,5/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu1,3,5/Glu)

10. dGlu1,4,5/dt = Vx_KGGlu(KG1,4,5/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu1,4,5/Glu)

11. dGlu2,3,4/dt = Vx_KGGlu(KG2,3,4/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu2,3,4/Glu)

12. dGlu2,3,5/dt = Vx_KGGlu(KG2,3,5/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu2,3,5/Glu)

13. dGlu2,4,5/dt = Vx_KGGlu(KG2,4,5/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu2,4,5/Glu)

14. dGlu3,4,5/dt = Vx_KGGlu(KG3,4,5/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu3,4,5/Glu)

15. dGlu1,2,3,4/dt = Vx_KGGlu(KG1,2,3,4/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu1,2,3,4/Glu)
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16. dGlu1,2,3,5/dt = Vx_KGGlu(KG1,2,3,5/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu1,2,3,5/Glu)

17. dGlu1,2,4,5/dt = Vx_KGGlu(KG1,2,4,5/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu1,2,4,5/Glu)

18. dGlu1,3,4,5/dt = Vx_KGGlu(KG1,3,4,5/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu1,3,4,5/Glu)

19. dGlu2,3,4,5/dt = Vx_KGGlu(KG2,3,4,5/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu2,3,4,5/Glu)

20. dGlu1,2,3,4,5/dt = Vx_KGGlu(KG1,2,3,4,5/KG) + Vgln(IsotNA0/IsotNA) - [GluOut +
Vx_GluKG](Glu1,2,3,4,5/Glu)

Glycerol 3 Phosphate

1. dGlyc3p1/dt = GlcTriNeo(PEP1/PEP) + Vglycerol(IsotNA0/IsotNA) - [GlyTri +
GlcNeo](Glyc3p1/Glyc3p)
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2. dGlyc3p2/dt = GlcTriNeo(PEP2/PEP) + Vglycerol(IsotNA0/IsotNA) - [GlyTri +
GlcNeo](Glyc3p2/Glyc3p)

3. dGlyc3p3/dt = GlcTriNeo(PEP3/PEP) + Vglycerol(Glycerol3/Glycerol) - [GlyTri +
GlcNeo](Glyc3p3/Glyc3p)

4. dGlyc3p1,2/dt = GlcTriNeo(PEP1,2/PEP) + Vglycerol(IsotNA0/IsotNA) - [GlyTri +
GlcNeo](Glyc3p1,2/Glyc3p)

5. dGlyc3p1,3/dt = GlcTriNeo(PEP1,3/PEP) + Vglycerol(IsotNA0/IsotNA) - [GlyTri +
GlcNeo](Glyc3p1,3/Glyc3p)

6. dGlyc3p2,3/dt = GlcTriNeo(PEP2,3/PEP) + Vglycerol(IsotNA0/IsotNA) - [GlyTri +
GlcNeo](Glyc3p2,3/Glyc3p)

7. dGlyc3p1,2,3/dt = GlcTriNeo(PEP1,2,3/PEP) + Vglycerol(IsotNA0/IsotNA) - [GlyTri +
GlcNeo](Glyc3p1,2,3/Glyc3p)
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αKG
1. dKG0/dt = - [Vx_KGGlu + ICDHrev + KGDH](KG0/KG)

2. dKG1/dt

=

ICDHfor(Citrate1/Citrate)

+

Vx_GluKG(Glu1/Glu)

+

ICDHfor(Citrate1,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1/KG)

3. dKG2/dt

=

ICDHfor(Citrate2/Citrate)

+

Vx_GluKG(Glu2/Glu)

+

ICDHfor(Citrate{2,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG2/KG)

4. dKG3/dt

=

ICDHfor(Citrate3/Citrate)

+

Vx_GluKG(Glu3/Glu)

+

ICDHfor(Citrate3,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG3/KG)

5. dKG4/dt

=

ICDHfor(Citrate4/Citrate)

+

Vx_GluKG(Glu4/Glu)

+

ICDHfor(Citrate4,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG4/KG)

6. dKG5/dt

=

ICDHfor(Citrate5/Citrate)

+

Vx_GluKG(Glu5/Glu)

+

ICDHfor(Citrate5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG5/KG)

7. dKG1,2/dt

=

ICDHfor(Citrate1,2/Citrate)

+

Vx_GluKG(Glu1,2/Glu)

+

ICDHfor(Citrate1,2,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,2/KG)

8. dKG1,3/dt

=

ICDHfor(Citrate1,3/Citrate)

+

Vx_GluKG(Glu1,3/Glu)

+

ICDHfor(Citrate1,3,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,3/KG)
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9. dKG1,4/dt

=

ICDHfor(Citrate1,4/Citrate)

+

Vx_GluKG(Glu1,4/Glu)

+

ICDHfor(Citrate1,4,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,4/KG)

10. dKG1,5/dt

=

ICDHfor(Citrate1,5/Citrate)

+

Vx_GluKG(Glu1,5/Glu)

+

ICDHfor(Citrate1,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,5/KG)

11. dKG2,3/dt

=

ICDHfor(Citrate2,3/Citrate)

+

Vx_GluKG(Glu2,3/Glu)

+

ICDHfor(Citrate2,3,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG2,3/KG)

12. dKG2,4/dt

=

ICDHfor(Citrate2,4/Citrate)

+

Vx_GluKG(Glu2,4/Glu)

+

ICDHfor(Citrate2,4,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG2,4/KG)

13. dKG2,5/dt

=

ICDHfor(Citrate2,5/Citrate)

+

Vx_GluKG(Glu2,5/Glu)

+

ICDHfor(Citrate2,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG2,5/KG)

14. dKG3,4/dt

=

ICDHfor(Citrate3,4/Citrate)

+

Vx_GluKG(Glu3,4/Glu)

+

ICDHfor(Citrate3,4,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG3,4/KG)

15. dKG3,5/dt

=

ICDHfor(Citrate3,5/Citrate)

+

Vx_GluKG(Glu3,5/Glu)

+

ICDHfor(Citrate3,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG3,5/KG)
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16. dKG4,5/dt

=

ICDHfor(Citrate4,5/Citrate)

+

Vx_GluKG(Glu4,5/Glu)

+

ICDHfor(Citrate4,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG4,5/KG)

17. dKG1,2,3/dt

=

ICDHfor(Citrate1,2,3/Citrate)

+

Vx_GluKG(Glu1,2,3/Glu)

+

ICDHfor(Citrate1,2,3,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,2,3/KG)

18. dKG1,2,4/dt

=

ICDHfor(Citrate1,2,4/Citrate)

+

Vx_GluKG(Glu1,2,4/Glu)

+

ICDHfor(Citrate1,2,4,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,2,4/KG)

19. dKG1,2,5/dt

=

ICDHfor(Citrate1,2,5/Citrate)

+

Vx_GluKG(Glu1,2,5/Glu)

+

ICDHfor(Citrate1,2,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,2,5/KG)

20. dKG1,4,5/dt

=

ICDHfor(Citrate1,4,5/Citrate)

+

Vx_GluKG(Glu1,4,5/Glu)

+

ICDHfor(Citrate1,4,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,4,5/KG)

21. dKG1,3,4/dt

=

ICDHfor(Citrate1,3,4/Citrate)

+

Vx_GluKG(Glu1,3,4/Glu)

+

ICDHfor(Citrate3,4,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,3,4/KG)

22. dKG1,3,5/dt

=

ICDHfor(Citrate1,3,5/Citrate)

+

Vx_GluKG(Glu1,3,5/Glu)

+

ICDHfor(Citrate1,3,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,3,5/KG)
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23. dKG2,3,4/dt

=

ICDHfor(Citrate2,3,4/Citrate)

+

Vx_GluKG(Glu2,3,4/Glu)

+

ICDHfor(Citrate2,3,4,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG2,3,4/KG)

24. dKG2,3,5/dt

=

ICDHfor(Citrate2,3,5/Citrate)

+

Vx_GluKG(Glu2,3,5/Glu)

+

ICDHfor(Citrate2,3,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG2,3,5/KG)

25. dKG2,4,5/dt

=

ICDHfor(Citrate2,4,5/Citrate)

+

Vx_GluKG(Glu2,4,5/Glu)

+

ICDHfor(Citrate2,4,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG2,4,5/KG)

26. dKG3,4,5/dt

=

ICDHfor(Citrate3,4,5/Citrate)

+

Vx_GluKG(Glu3,4,5/Glu

+

ICDHfor(Citrate3,4,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG3,4,5/KG)

27. dKG1,2,3,4/dt

=

ICDHfor(Citrate1,2,3,4/Citrate)

+

Vx_GluKG(Glu1,2,3,4/Glu)

+

ICDHfor(Citrate1,2,3,4,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,2,3,4/KG)

28. dKG1,2,3,5/dt

=

ICDHfor(Citrate1,2,3,5/Citrate)

+

Vx_GluKG(Glu1,2,3,5/Glu)

+

ICDHfor(Citrate1,2,3,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,2,3,5/KG)

29. dKG1,2,4,5/dt

=

ICDHfor(Citrate1,2,4,5/Citrate)

+

Vx_GluKG(Glu1,2,4,5/Glu)

+

ICDHfor(Citrate1,2,4,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,2,4,5/KG)

30. dKG1,3,4,5/dt = ICDHfor(Citrate1,3,4,5/Citrate) + Vx_GluKG(Glu{28}1,3,4,5/Glu{28})
+ ICDHfor(Citrate1,3,4,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,3,4,5/KG)
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31. dKG2,3,4,5/dt

=

ICDHfor(Citrate2,3,4,5/Citrate)

+

Vx_GluKG(Glu2,3,4,5/Glu)

+

ICDHfor(Citrate2,3,4,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG2,3,4,5/KG)

32. dKG1,2,3,4,5/dt = ICDHfor(Citrate1,2,3,4,5/Citrate) + Vx_GluKG(Glu1,2,3,4,5/Glu) +
ICDHfor(Citrate1,2,3,4,5,6/Citrate) - [Vx_KGGlu + ICDHrev + KGDH](KG1,2,3,4,5/KG)

Lactate
1. dLacPyr0/dt = - [PDH + PC](LacPyr0/LacPyr)

2. dLacPyr1/dt

=

PK(PEP1/PEP)

+

Vlac(IsotNA0/IsotNA)

-

[PDH

+

+

Vlac(IsotNA0/IsotNA)

-

[PDH

+

PC](LacPyr1/LacPyr)

3. dLacPyr2/dt

=

PK(PEP2/PEP)

PC](LacPyr2/LacPyr)

4. dLacPyr3/dt

=

PK(PEP3/PEP)

+

Vlac(LacBlood3/LacBlood)

-

[PDH

+

[PDH

+

PC](LacPyr3/LacPyr)

5. dLacPyr1,2/dt

=

PK(PEP1,2/PEP)

+

Vlac(IsotNA0/IsotNA)

-

PC](LacPyr1,2/LacPyr)
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6. dLacPyr1,3/dt

=

PK(PEP1,3/PEP)

+

Vlac(IsotNA0/IsotNA)

-

[PDH

+

+

Vlac(IsotNA0/IsotNA)

-

[PDH

+

[PDH

+

PC](LacPyr1,3/LacPyr)

7. dLacPyr2,3/dt

=

PK(PEP2,3/PEP)

PC](LacPyr2,3/LacPyr)

8. dLacPyr1,2,3/dt

=

PK(PEP1,2,3/PEP)

+

Vlac(IsotNA0/IsotNA)

-

PC](LacPyr1,2,3/LacPyr)

Malate

1. dOAAmMal0/dt = - [Vx_OAAAspm + PEPCK + CS](OAAmMal0/OAAmMal)

2. dOAAmMal1/dt = PC(LacPyr1/LacPyr)0/Urea) + Vx_AspOAAm(Asp1/Asp) +
ACL(OAAc1/OAAc) + 0.5SDH(Suc1/Suc) + 0.5SDH(Suc4/Suc) - [Vx_OAAAspm +
PEPCK + CS](OAAmMal1/OAAmMal)

3. dOAAmMal2/dt = PC(LacPyr2/LacPyr)0/Urea) + Vx_AspOAAm(Asp2/Asp) +
ACL(OAAc2/OAAc) + 0.5SDH(Suc3/Suc) + 0.5SDH(Suc2/Suc) - [Vx_OAAAspm +
PEPCK + CS](OAAmMal2/OAAmMal)
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4. dOAAmMal3/dt = PC(LacPyr3/LacPyr)0/IsotNA) + Vx_AspOAAm(Asp3/Asp) +
ACL(OAAc3/OAAc) + 0.5SDH(Suc3/Suc) + 0.5SDH(Suc2/Suc) - [Vx_OAAAspm +
PEPCK + CS](OAAmMal3/OAAmMal)

5. dOAAmMal4/dt = PC(LacPyr0/LacPyr)0/IsotNA) + Vx_AspOAAm(Asp4/Asp) +
ACL(OAAc4/OAAc) + 0.5SDH(Suc1/Suc) + 0.5SDH(Suc4/Suc{5}) - [Vx_OAAAspm
+ PEPCK + CS](OAAmMal4/OAAmMal)

6. dOAAmMal1,2/dt = PC(LacPyr1,2/LacPyr)0/Urea) + Vx_AspOAAm(Asp1,2/Asp) +
ACL(OAAc1,2/OAAc)

+

0.5SDH(Suc1,2/Suc)

+

0.5SDH(Suc3,4/Suc)

-

[Vx_OAAAspm + PEPCK + CS](OAAmMal1,2/OAAmMal)

7. dOAAmMal1,3/dt = PC(LacPyr1,3/LacPyr)0/Urea) + Vx_AspOAAm(Asp1,3/Asp) +
ACL(OAAc1,3/OAAc)

+

0.5SDH(Suc1,3/Suc)

+

0.5SDH(Suc2,4/Suc)

-

[Vx_OAAAspm + PEPCK + CS](OAAmMal1,3/OAAmMal)

8. dOAAmMal1,4/dt = PC(LacPyr1/LacPyr)0/IsotNA) + Vx_AspOAAm(Asp1,4/Asp) +
ACL(OAAc1,4/OAAc)

+

SDH(Suc1,4/Suc)

-

[Vx_OAAAspm

+

PEPCK

+

CS](OAAmMal1,4/OAAmMal)

9. dOAAmMal2,3/dt = PC(LacPyr2,3/LacPyr)0/Urea) + Vx_AspOAAm(Asp2,3/Asp) +
ACL(OAAc2,3/OAAc)

+

SDH(Suc2,3/Suc)

-

[Vx_OAAAspm

+

PEPCK

+

CS](OAAmMal2,3/OAAmMal)

174

10. dOAAmMal2,4/dt = PC(LacPyr2/LacPyr)1/Urea) + Vx_AspOAAm(Asp2,4/Asp) +
ACL(OAAc2,4/OAAc)

+

0.5SDH(Suc1,3/Suc)

+

0.5SDH(Suc2,4/Suc)

-

[Vx_OAAAspm + PEPCK + CS](OAAmMal2,4/OAAmMal)

11. dOAAmMal3,4/dt = PC(LacPyr3/LacPyr)0/IsotNA) + Vx_AspOAAm(Asp3,4/Asp) +
ACL(OAAc3,4/OAAc)

+

0.5SDH(Suc1,2/Suc)

+

0.5SDH(Suc3,4/Suc)

-

[Vx_OAAAspm + PEPCK + CS](OAAmMal3,4/OAAmMal)

12. dOAAmMal1,2,4/dt = PC(LacPyr1,2/LacPyr)1/Urea) + Vx_AspOAAm(Asp1,2,4/Asp) +
ACL(OAAc1,2,4/OAAc)

+

0.5SDH(Suc1,2,4/Suc)

+

0.5SDH(Suc1,3,4/Suc)

-

[Vx_OAAAspm + PEPCK + CS](OAAmMal1,2,4/OAAmMal)

13. dOAAmMal1,3,4/dt = PC(LacPyr1,3/LacPyr)1/Urea) + Vx_AspOAAm(Asp1,3,4/Asp) +
ACL(OAAc1,3,4/OAAc)

+

0.5SDH(Suc1,2,4/Suc)

+

0.5SDH(Suc1,3,4/Suc)

-

[Vx_OAAAspm + PEPCK + CS](OAAmMal1,3,4/OAAmMal)

14. dOAAmMal2,3,4/dt

=

PC(LacPyr2,3/LacPyr)0/IsotNA)

+

Vx_AspOAAm(Asp2,3,4/Asp) + ACL(OAAc2,3,4/OAAc) + 0.5SDH(Suc1,2,3/Suc) +
0.5SDH(Suc2,3,4/Suc) - [Vx_OAAAspm + PEPCK + CS](OAAmMal2,3,4/OAAmMal)

15. dOAAmMal1,2,3/dt = PC(LacPyr1,2,3/LacPyr)0/Urea) + Vx_AspOAAm(Asp1,2,3/Asp)
+ ACL(OAAc1,2,3/OAAc) + 0.5SDH(Suc1,2,3/Suc) + 0.5SDH(Suc2,3,4/Suc) [Vx_OAAAspm + PEPCK + CS](OAAmMal1,2,3/OAAmMal)
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Oxaloacetate
1. dOAAc1/dt

=

ACL(Citrate6/Citrate)

+

ACL(Citrate4,6/Citrate)

+

ACL(Citrate5,6/Citrate) + ACL(Citrate4,5,6/Citrate) - ACL(OAAc1/OAAc)

2. dOAAc2/dt

=

ACL(Citrate3/Citrate)

+

ACL(Citrate3,4/Citrate)

+

ACL(Citrate3,5/Citrate) + ACL(Citrate3,4,5/Citrate) - ACL(OAAc2/OAAc)

3. dOAAc3/dt

=

ACL(Citrate2/Citrate)

+

ACL(Citrate2,4/Citrate)

+

ACL(Citrate2,5/Citrate) + ACL(Citrate2,4,5/Citrate) - ACL(OAAc3/OAAc)

4. dOAAc4/dt

=

ACL(Citrate1/Citrate)

+

ACL(Citrate1,4/Citrate)

+

ACL(Citrate1,5/Citrate) + ACL(Citrate1,4,5/Citrate) - ACL(OAAc4/OAAc)

5. dOAAc1,2/dt

=

ACL(Citrate3,6/Citrate)

+

ACL(Citrate3,4,6/Citrate)

+

ACL(Citrate3,5,6/Citrate) + ACL(Citrate3,4,5,6/Citrate) - ACL(OAAc1,2/OAAc)

6. dOAAc1,3/dt

=

ACL(Citrate2,6/Citrate{11})

+

ACL(Citrate2,4,6/Citrate)

+

ACL(Citrate2,5,6/Citrate) + ACL(Citrate2,4,5,6/Citrate) - ACL(OAAc1,3/OAAc)

7. dOAAc1,4/dt

=

ACL(Citrate1,6/Citrate)

+

ACL(Citrate1,4,6/Citrate)

+

ACL(Citrate1,5,6/Citratec) + ACL(Citrate1,4,5,6/Citrate) - ACL(OAAc1,4/OAAc)
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8. dOAAc2,3/dt

=

ACL(Citrate2,3/Citrate)

+

ACL(Citrate2,3,4/Citrate)

+

ACL(Citrate2,3,5/Citrate) + ACL(Citrate2,3,4,5/Citrate) - ACL(OAAc2,3/OAAc)

9. dOAAc2,4/dt

=

ACL(Citrate1,3/Citrate)

+

ACL(Citrate1,3,4/Citrate)

+

ACL(Citrate1,3,5/Citrate) + ACL(Citrate1,3,4,5/Citrate) - ACL(OAAc2,4/OAAc)

10. dOAAc3,4/dt

=

ACL(Citrate1,2/Citrate)

+

ACL(Citrate1,2,4/Citrate)

+

ACL(Citrate1,2,5/Citrate) + ACL(Citrate1,2,4,5/Citrate) - ACL(OAAc3,4/OAAc)

11. dOAAc1,3,4/dt

=

ACL(Citrate1,2,6/Citrate)

+

ACL(Citrate1,2,4,6/Citrate)

+

ACL(Citrate1,2,5,6/Citrate) + ACL(Citrate1,2,4,5,6/Citrate) - ACL(OAAc1,3,4/OAAc)

12. dOAAc1,2,4/dt

=

ACL(Citrate1,3,6/Citrate)

+

ACL(Citrate1,3,4,6/Citrate)

+

ACL(Citrate1,3,5,6/Citrate) + ACL(Citrate1,3,4,5,6/Citrate) - ACL(OAAc1,2,4/OAAc)

13. dOAAc1,2,3/dt

=

ACL(Citrate2,3,6/Citrate)

+

ACL(Citrate2,3,4,6/Citrate)

+

ACL(Citrate2,3,5,6/Citrate) + ACL(Citrate2,3,4,5,6/Citrate) - ACL(OAAc1,2,3/OAAc)

14. dOAAc2,3,4/dt

=

ACL(Citrate1,2,3/Citrate)

+

ACL(Citrate1,2,3,4/Citrate)

+

ACL(Citrate1,2,3,5/Citrate) + ACL(Citrate1,2,3,4,5/Citrate) - ACL(OAAc2,3,4/OAAc)
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15. dOAAc1,2,3,4/dt

=

ACL(Citrate1,2,3,6/Citrate)

+

ACL(Citrate1,2,3,4,6/Citrate)

+

ACL(Citrate1,2,3,5,6/Citrate) + ACL(Citrate1,2,3,4,5,6/Citrate) - ACL(OAAc1,2,3,4/OAAc)

16. dOAAmMal1,2,3,4/dt

=

PC(LacPyr1,2,3/LacPyr)0/IsotNA)

+

Vx_AspOAAm(Asp1,2,3,4/Asp) + ACL(OAAc1,2,3,4/OAAc) + SDH(Suc1,2,3,4/Suc) [Vx_OAAAspm + PEPCK + CS](OAAmMal1,2,3,4/OAAmMal)

PEP

1. dPEP1/dt

=

PEPCK(OAAmMal1/OAAmMal)

+

GlyTri(Glyc3p1/Glyc3p)

+

PEPCK(OAAmMal1,4/OAAmMal) - [PK + GlcTriNeo](PEP1/PEP)

2. dPEP2/dt

=

PEPCK(OAAmMal2/OAAmMal)

+

GlyTri(Glyc3p2/Glyc3p)

+

PEPCK(OAAmMal2,4/OAAmMal) - [PK + GlcTriNeo](PEP2/PEP)

3. dPEP3/dt

=

PEPCK(OAAmMal3,4/OAAmMal)

+

GlyTri(Glyc3p3/Glyc3p)

+

PEPCK(OAAmMal3/OAAmMal) - [PK + GlcTriNeo](PEP3/PEP)

4. dPEP1,2/dt = PEPCK(OAAmMal1,2/OAAmMal) + GlyTri(Glyc3p1,2/Glyc3p) +
PEPCK(OAAmMal1,2,4/OAAmMal) - [PK + GlcTriNeo](PEP1,2/PEP)
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5. dPEP1,3/dt = PEPCK(OAAmMal1,3,4/OAAmMal) + GlyTri(Glyc3p1,3/Glyc3p) +
PEPCK(OAAmMal1,3/OAAmMal) - [PK + GlcTriNeo](PEP1,3/PEP)

6. dPEP2,3/dt = PEPCK(OAAmMal2,3/OAAmMal) + GlyTri(Glyc3p2,3/Glyc3p) +
PEPCK(OAAmMal2,3,4/OAAmMal) - [PK + GlcTriNeo](PEP2,3/PEP)

7. dPEP1,2,3/dt = PEPCK(OAAmMal1,2,3/OAAmMal) + GlyTri(Glyc3p1,2,3/Glyc3p) +
PEPCK(OAAmMal1,2,3,4/OAAmMal) - [PK + GlcTriNeo](PEP1,2,3/PEP)

Succinate
1. dSuc1/dt = KGDH(KG1,2/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG2/KG) SDH(Suc1/Suc)

2. dSuc2/dt = KGDH(KG3/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG1,3/KG) SDH(Suc2/Suc)

3. dSuc3/dt = KGDH(KG1,4/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG4/KG) SDH(Suc3/Suc)
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4. dSuc4/dt = KGDH(KG5/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG1,5/KG) SDH(Suc4/Suc)

5. dSuc1,2/dt = KGDH(KG2,3/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG1,2,3/KG) SDH(Suc1,2/Suc)

6. dSuc1,3/dt = KGDH(KG1,2,4/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG2,4/KG) SDH(Suc1,3/Suc)

7. dSuc1,4/dt = KGDH(KG1,2,5/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG2,5/KG) SDH(Suc1,4/Suc)

8. dSuc2,3/dt = KGDH(KG3,4/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG1,3,4/KG) SDH(Suc2,3/Suc)

9. dSuc2,4/dt = KGDH(KG3,5/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG1,3,5/KG{17})
- SDH(Suc2,4/Suc)

10. dSuc3,4/dt = KGDH(KG4,5/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG1,4,5/KG) SDH(Suc3,4/Suc)

11. dSuc1,2,3/dt = KGDH(KG2,3,4/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG1,2,3,4/KG)
- SDH(Suc1,2,3/Suc)
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12. dSuc1,2,4/dt = KGDH(KG2,3,5/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG1,2,3,5/KG)
- SDH(Suc1,2,4/Suc)

13. dSuc1,3,4/dt = KGDH(KG1,2,4,5/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG2,4,5/KG)
- SDH(Suc1,3,4/Suc)

14. dSuc2,3,4/dt = KGDH(KG3,4,5/KG) + Vprop(IsotNA0/IsotNA) + KGDH(KG1,3,4,5/KG)
- SDH(Suc2,3,4/Suc)

15. dSuc1,2,3,4/dt

=

KGDH(KG2,3,4,5/KG)

+

Vprop(IsotNA0/IsotNA)

+

KGDH(KG1,2,3,4,5/KG) - SDH(Suc1,2,3,4/Suc

S2. MIMOSA equations with derivations

Below we describe the stepwise derivation and solution for all metabolic fluxes, beginning
with establishing key phi ratios to establish relative flux contributions that aid in the
calculation of metabolic flux analysis
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Establishing Preliminary Relationships:
Mass Balance of anaplerosis and cataplerosis:

𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑

At steady state:

= VSDH+ VPC + VACLy– (VCS + VPEPCK)

VSDH+ VPC + VACLy= VCS + VPEPCK

Thus:
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆 +𝑉𝑉𝑃𝑃𝑃𝑃 +𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶 +𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

=1

We make the following definitions of fractional fluxes:
FSDH:
FACLy:
FPC:

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝐶𝐶𝐶𝐶 +𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴

𝑉𝑉𝐶𝐶𝐶𝐶 +𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝑃𝑃𝑃𝑃

𝑉𝑉𝐶𝐶𝐶𝐶 +𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

The sum of the fractional fluxes then equals 1.

Rearranging to solve for 𝑓𝑓𝑝𝑝

= 𝑓𝑓𝑠𝑠

= 𝑓𝑓𝑐𝑐

= 𝑓𝑓𝑝𝑝

𝑓𝑓𝑠𝑠 + 𝑓𝑓𝑝𝑝 + 𝑓𝑓𝑐𝑐 = 1
𝑓𝑓𝑝𝑝 = 1 - 𝑓𝑓𝑠𝑠 - 𝑓𝑓𝑐𝑐

Solving for 𝒇𝒇𝒄𝒄

Since malate and OAA are in isotopic equilibrium across all carbons, we can substitute
malate for OAA.
Then isotope balance for malate M+2 is:
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𝑑𝑑(𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀+2)
𝑑𝑑𝑑𝑑

= 𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆 (Succ M + 2) + 𝑉𝑉𝑃𝑃𝑃𝑃 (Pyr M + 2) + 𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 (Cit M + 2) −
(Mal M + 2)(𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )

At steady state:
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆 (SuccM + 2) + 𝑉𝑉𝑃𝑃𝑃𝑃 (Pyr M + 2) + 𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 (Cit M + 2) = (Mal M + 2)(𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )

Since there was no detectable M+2 succinate or pyruvate, this simplifies to:
𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 (Cit M + 2) = (𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )(Mal M + 2)

Rearranging:
𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴

𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀

=

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀+2
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2]

Substituting previously defined variables and relationships
𝒇𝒇𝒄𝒄 =

𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴+𝟐𝟐
𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪[𝟏𝟏,𝟐𝟐]

𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴

= 𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝒄𝒄

𝒂𝒂

Solving for 𝒇𝒇𝒔𝒔

Isotope balance for malate M+1:
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𝑑𝑑(Mal𝑀𝑀+1 )
= 𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆 (Succ𝑀𝑀+1 ) + 𝑉𝑉𝑃𝑃𝑃𝑃 (Pyr𝑀𝑀+1 ) + 𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 ��(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶�
𝑑𝑑𝑡𝑡
− (Mal𝑀𝑀+1 )(𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )
At steady state:
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆 (Succ𝑀𝑀+1 ) + 𝑉𝑉𝑃𝑃𝑃𝑃 (Pyr𝑀𝑀+1 ) + 𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 ��(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶� = (Mal𝑀𝑀+1 )(𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )
Divide by 𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀
(Succ𝑀𝑀+1 )𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆
(Pyr𝑀𝑀+1 )𝑉𝑉𝑃𝑃𝑃𝑃
��(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶�𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
+
+
= (Mal𝑀𝑀+1 )
(𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 ) (𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )
(𝑉𝑉𝐶𝐶𝐶𝐶 + 𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀 )
Substitute fraction relations

Expand

fs(SuccM+1) + (1 -fc – fs)(PyrM+1) + fc(�(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶 1) = MalM+1
fs(SuccM+1) + PyrM+1 – fc(PyrM+1)- fs(PyrM+1) +

Combine terms

Solve for fs

fc(�(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶) = MalM+1
fs(SuccM+1 - PyrM+1) + fc(�(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶 - PyrM+1) = MalM+1 - PyrM+1
fs = ((MalM+1 - PyrM+1) + fc(PyrM+1 - �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))/(SuccM+1 - yrM+1)

[Note: New isotopomer definition assuming C5 enrichment is negligible]
(1− �(4) 13C �𝐺𝐺𝐺𝐺𝐺𝐺)

�(1)(2)(3) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶 = �(1)(2)(3)(4)(5)113C

1 �𝐺𝐺𝐺𝐺𝐺𝐺

* �(1)(2)(3)(4)(5) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶

1
�(1)(2)(3) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶 + 𝐶𝐶𝐶𝐶𝐶𝐶𝑐𝑐 = �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶
2
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�(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶
=

(1 − (147/42 + 148/42))
∗ (192/112 − 192/111) + 2 ∗ 192/111
𝐺𝐺𝐺𝐺𝐺𝐺𝑀𝑀+1

Metabolic Flux Analysis

Establishing fluxes relative to OGDH
Solving for VIDH relative to VOGDH

𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

Mass Balance

𝑑𝑑𝑑𝑑

= VIDH + VGDH - VGDH + VOGDH

Isotope Balance
d(αKG M+2)
dt

= VIDH �(Cit[M + 2])� + VX (Glu M + 2) + VGDH (Gln M + 2) − αKG M + 2 ∗ (VOGDH + VGDH + VX )

Because Vx is fast::

aKGM+2 = GluM+2
then GDH: GlnM+2GluM+2

Rearrange:

𝑑𝑑(𝛼𝛼𝛼𝛼𝛼𝛼 𝑀𝑀+2)
𝑑𝑑𝑑𝑑

= 𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼 �(𝐶𝐶𝐶𝐶𝐶𝐶 𝑀𝑀 + 2)� + 𝑉𝑉𝑋𝑋 (𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀 + 2) + 𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺 (𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀 + 2)
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= 𝛼𝛼𝛼𝛼𝛼𝛼 𝑀𝑀 + 2 ∗ (𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 + 𝑉𝑉𝑋𝑋 + 𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺 )

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼

Solve:

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂

=

(Glu M+2 − Gln M+2)
(Cit M+2 − Gln M+2)

=

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

Solving for GDH relative to OGDH

𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

Mass Balance:

𝑑𝑑𝑑𝑑

= VIDH+ VGDH- VOGDH

Isotope Balance:

d(αKG M + 1)
= VIDH �(Cit[M + 1])� + VX (Glu M + 1) + VGDH (Gln M + 1) − αKG M + 1 ∗ (VOGDH + VGDH
dt
+ VX )

Rearrange:

Solve:

VIDH+ VGDH = VOGDH

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺
𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂

𝑉𝑉

+ 𝑉𝑉 𝐺𝐺𝐺𝐺𝐺𝐺 = 1

=1-

𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂

= 1-

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

186

Solving fluxes relative to SDH

Isotope Balance:

Rearrange:

Solve:

𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑

= VOGDH (GluM+2OAA+GluM1) – VSDH(Succ (1)(4))

VOGDH (GluM+2OAA+GluM1) = VSDH(Succ (1)(4))

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Succ (1)(4)

=

𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺+2𝑂𝑂𝑂𝑂𝑂𝑂 +𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺+1

=

Succ 𝑎𝑎

𝐺𝐺𝐺𝐺𝐺𝐺𝑎𝑎 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑏𝑏 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑐𝑐+𝑑𝑑

VGDH relative to VSDH can be established from the above relationships of VOGDH/VSDH and
VGDH/VOGDH
𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Substitute:

=

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺
𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂

=(

*

= 1-

𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺
𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)

Succ 𝑎𝑎
)
𝐺𝐺𝐺𝐺𝐺𝐺𝑎𝑎 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑏𝑏 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑐𝑐+𝑑𝑑

187

Solve

𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

= (1-

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)* ( 𝐺𝐺𝐺𝐺𝐺𝐺

Succ 𝑎𝑎

𝑎𝑎 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑏𝑏 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑐𝑐+𝑑𝑑

)

Establishing VPROP relative to VSDH

Mass Balance:

𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑

= VProp + VOGDH - VSDH

Rearrange:

VProp + VOGDH = VSDH

Solve:

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

+

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

=1-

=1

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Succ (1)(4)

= 1- 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺+2

𝑂𝑂𝑂𝑂𝑂𝑂 +𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺+1

188

Solving for anaplerotic and cataplerotic fluxes relative to SDH
At steady state anaplerosis equals cataplerosis

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Balance Equation:

=

𝑉𝑉𝑃𝑃𝑃𝑃
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

+

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

+

Substitute:
𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝑃𝑃𝑃𝑃

=

𝑓𝑓𝑐𝑐

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

= ( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷

𝑓𝑓𝑠𝑠

𝑓𝑓𝑝𝑝

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

=

𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺

= (1-

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

= (1-

𝑓𝑓𝑠𝑠

(

[1,2]

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝑀𝑀𝑀𝑀+1 − 𝑓𝑓𝑐𝑐 ∗ 𝐶𝐶𝐶𝐶𝐶𝐶[(2)(3)(4)(6)] +𝑃𝑃𝑀𝑀+1 )− 𝑃𝑃𝑀𝑀+1 )
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

-

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀+2
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2]

((MalM + 1 − PyrM + 1) + fc(PyrM + 1 − �(1)(2)(3)(6)13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
)
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Rearrange:

=

𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

)* ( 𝐺𝐺𝐺𝐺𝐺𝐺

Succ 𝑎𝑎

𝑎𝑎 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑏𝑏 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑐𝑐+𝑑𝑑

𝑓𝑓

+ 𝑓𝑓𝑐𝑐 +
𝑠𝑠

)

)÷

)

𝑓𝑓𝑝𝑝
𝑓𝑓𝑠𝑠

Solve:
(1 −

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)* ( 𝐺𝐺𝐺𝐺𝐺𝐺

Succ 𝑎𝑎

𝑎𝑎 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑏𝑏 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑐𝑐+𝑑𝑑

) )+
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(𝑀𝑀𝑀𝑀+1 − 𝑓𝑓𝑐𝑐 ∗ 𝐶𝐶𝐶𝐶𝐶𝐶[(2)(3)(4)(6)] +𝑃𝑃𝑀𝑀+1 )− 𝑃𝑃𝑀𝑀+1 )

((1-

(

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

Rearrange:

Substitute:

Rearrang:

Substitute:

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀+2
)
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2]

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))

(( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷ (

Mass Balance:

-

[1,2]

𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

÷

)) +

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

))

= VCS + VIDHr - VACLy - VIDHf

𝑉𝑉𝐶𝐶𝐶𝐶

=

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼

=

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑓𝑓𝑐𝑐
𝑓𝑓𝑠𝑠

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼

* 𝑉𝑉

𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂

+

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

= ( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷ (

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

=

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼

+

= 1-

[1,2]

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼

* 𝑉𝑉

𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

)

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)

190

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂

=

(Glu M+2 − Gln M+2)
(Cit M+2 − Gln M+2)

=

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

Solve:
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

= ( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷ (
(1-

[1,2]

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)) *

)+

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

In terms of CS:

Establishing PDH relative to CS
𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝐶𝐶𝐶𝐶

=

𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+1𝑃𝑃𝑃𝑃𝑃𝑃
𝜑𝜑𝐶𝐶𝐶𝐶𝐶𝐶→𝐺𝐺𝐺𝐺𝐺𝐺

÷ PyrM+1

Establishing IDHf relative to CS
Mass Balance:
Rearrange:

𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑

= VCS + VIDHr - VACLy - VIDHf

VCS + VIDHr = VACLy + VIDHf
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𝑉𝑉𝐶𝐶𝐶𝐶

Solve:

+

𝑉𝑉𝐶𝐶𝐶𝐶

1+

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

=

=1-

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

=

=

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶

+

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶

+

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

+

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

= 1-

(Mal M+2 − Cit M+2)

(Cit M+2 − Glu M+2)

(Mal M+2 − Cit M+2)

(Cit M+2 − Glu M+2)

Mass Balance:

VIDHnet = VIDHf - VIDHr

Isotope Balance:

dCitM+2/dt = aKGM+2*VIDHr – CitM+2*VIDHf

Because Vx is fast::

aKGM+2 = GluM+2

Substitute:

GluM+2*VIDHr = CitM+2*VIDHf

Rearrange:

VIDHf = VIDHr(GluM+2/CitM+2)

Substitute for VIDHr:

VIDHf = (VIDHf- VIDHnet) (GluM+2/CitM+2)

Solve:

VIDHf/VIDHnet = GluM+2/CitM+2/(GluM+2/CitM+2 - 1)
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Net IDH flux is the difference between forward and reverse IDH flux:

Mass Balance

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼

=

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

-

𝑉𝑉𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑉𝑉𝐶𝐶𝐶𝐶

From the above established relationships the following relative fluxes can be
established

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝐶𝐶𝐶𝐶

=

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

-

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Establishing SDH relative CS
From the above fluxes relative to VSDH fluxes relative to CS can be established as

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝑃𝑃𝑃𝑃

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

=

=

𝑓𝑓𝑐𝑐
𝑓𝑓𝑠𝑠

𝑓𝑓𝑝𝑝
𝑓𝑓𝑠𝑠

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

= ( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷

= (1-

[1,2]

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))

)

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝑀𝑀𝑀𝑀+1 − 𝑓𝑓𝑐𝑐 ∗ 𝐶𝐶𝐶𝐶𝐶𝐶[(2)(3)(4)(6)] +𝑃𝑃𝑀𝑀+1 )− 𝑃𝑃𝑀𝑀+1 )
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

– 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷
[1,2]
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(
𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

= (1-

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2]

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

)* ( 𝐺𝐺𝐺𝐺𝐺𝐺
− 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

= ( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷ (

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

[1,2]

𝑎𝑎 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑏𝑏 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑐𝑐+𝑑𝑑

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

= 1-

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

𝑉𝑉𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

)

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶)))

(1-

=1-

Succ 𝑎𝑎

)

)) *

)+

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)

Succ (1)(4)

= 1- 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺+2

𝑂𝑂𝑂𝑂𝑂𝑂 +𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺+1
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Establishing SDH relative to CS
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Equation:

𝑉𝑉𝐶𝐶𝐶𝐶

=

1

𝑉𝑉𝐶𝐶𝐶𝐶
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Solve:
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆
𝑉𝑉𝐶𝐶𝐶𝐶

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

= 1 ÷ (( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷ (
(1-

[1,2]

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)) *

)+

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

))

Establishing PC relative to CS

𝑉𝑉𝑃𝑃𝑃𝑃

Equation:

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉

= 𝑉𝑉 𝑃𝑃𝑃𝑃 ÷
𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Solve:
𝑉𝑉𝑃𝑃𝑃𝑃
𝑉𝑉𝐶𝐶𝐶𝐶

= ( (1-

�(MalM+1 – PyrM+1)+ fc�PyrM+1 – �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶��
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

– 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷
[1,2]
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((
(

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))

(1-

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)) *

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

))÷ ( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷
[1,2]

)+

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

))

Establishing Prop relative to CS

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

Equation:

𝑉𝑉𝐶𝐶𝐶𝐶

=

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

÷

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

Solve:
𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃
𝑉𝑉𝐶𝐶𝐶𝐶

Succ (1)(4)

= (1- 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺+2

𝑂𝑂𝑂𝑂𝑂𝑂 +𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺+1

(

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

÷ ( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 )) ÷
[1,2]

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(1-

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2]

)) *
− 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)+

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)
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Establishing GDH relative to CS
𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺

Equation:

Solve:

𝑉𝑉

𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺
𝑉𝑉𝐶𝐶𝐶𝐶

(

= ((1-

𝑉𝑉𝐶𝐶𝐶𝐶

= 𝑉𝑉𝐺𝐺𝐺𝐺𝐺𝐺 ÷

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑆𝑆𝑆𝑆𝑆𝑆

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)* ( 𝐺𝐺𝐺𝐺𝐺𝐺

Succ 𝑎𝑎

𝑎𝑎 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑏𝑏 + 𝐺𝐺𝐺𝐺𝐺𝐺𝑐𝑐+𝑑𝑑

)) ÷

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))

(1-

)+

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2]

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)) *
− 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)

Since at steady state anaplerosis is equal to cataplerosis

𝑉𝑉𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃+𝑀𝑀𝑀𝑀
𝑉𝑉𝐶𝐶𝐶𝐶

=

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶

=

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

𝑉𝑉

÷ 𝑉𝑉 𝐶𝐶𝐶𝐶

𝑆𝑆𝑆𝑆𝑆𝑆

Establishing ACLy relative to CS
Equation:

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶

=

𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆

÷

𝑉𝑉𝐶𝐶𝐶𝐶

𝑉𝑉𝑆𝑆𝑆𝑆𝑆𝑆
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Solve:
𝑉𝑉𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴
𝑉𝑉𝐶𝐶𝐶𝐶

𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

= (( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 ) ÷ �
𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀

[1,2]

�(MalM+1 – PyrM+1)+ fc�PyrM+1 – �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶��

( 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑀𝑀+2 )) ÷ ((
(1-

[1,2]

(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

�÷

((MalM+1 − PyrM+1) + fc(PyrM+1 − �(1)(2)(3)(6) 13C1 �𝐶𝐶𝐶𝐶𝐶𝐶))
(𝑆𝑆𝑀𝑀+1 − 𝑃𝑃𝑀𝑀+1 )

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)) *

)+

(𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2𝑂𝑂𝑂𝑂𝑂𝑂 − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[1,2] − 𝐺𝐺𝐺𝐺𝐺𝐺 𝑀𝑀+2)

)

S3. Mass Spectrometry (MS) (additional description)
Since Mass spectrometry is primarily an ex vivo and in vitro technique MS based assays
oftentimes incorporate additional technical steps to obtain higher resolution, including
chromatographic separation, ionization of molecules, separation of molecular ions mass
analyzer, counting of the ions by a detector and lastly processing of the spectral data.

S3.1 Chromatography
Tissue and plasma samples from tracer experiments usually consist of a highly complex
mixture of various analytes along with additional matrix molecules, such as proteins and
salts. If not purified and separated properly, co-eluting analytes can cause overlapping
signals on the mass spectrum, while interfering matrix molecules can lead to ion
suppression, adduct formation and poor signal to noise ratios. This will result in poor
spectral resolution, difficulties discerning molecules of interest and spurious flux analysis.
Therefore, chromatography is commonly set up as an initial step of separation before the
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analysis by Mass Spectrometry. Chromatography was first described by Russian Botanist
Mikhail S. Tswett in 1900 as a technique to separate plant pigments. He took ground-up
plant extract, poured it into a glass column and saw different colored “bands” develop as
the plant pigments separated. He named the procedure chromatography based on the
Greek words ‘chroma’ for “color” and ‘graphein’ for “to write” [147]. Since its discovery the
basic principles of chromatography have remined the same: A mobile phase containing
the compounds of interest moves through a chromatography column in which the sample
interacts with the immobilized “stationary” phase. The time it takes for an analyte in the
mobile phase to elute from a chromatographic column is called retention time (RT). The
velocity of the RT is governed by the dynamic equilibrium of adsorption to and desorption
from the stationary phase. Some molecules will interact more strongly with the stationary
phase than molecules with only weakly interaction. The latter compounds move faster
through the column, meaning that they elude at a shorter retention time than molecules
that have a high affinity to the stationary phase. Retention time is characteristic for a
specific molecule in a given chromatographic set up. However, molecules with similar
chemical properties, such as the same atomic weight but different chemical structures
(isobars), can be difficult to separate chromatographically and thus can show significant
overlap in RT. The two types of chromatography coupled with Mass Spectrometry are
Gas Chromatography (GC) and Liquid Chromatography (LC).
GC is a well-established method for analyzing and quantifying small molecules (<1kDa)
and their isotopic composition. Before analysis, GC requires 1) extraction of metabolites
from the sample matrix, 2) addition of an internal standard to the sample and 3)
derivatization of the molecules of interest [55, 69, 70]. The derivatization step is crucial
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for chromatographic separation in GC because it renders the compounds of interest
volatile and allows them to be taken up by an inert carrier gas, i.e. He, N, H, that functions
as the mobile phase. Derivatization reagent can add a large number of additional atoms,
i.e., carbons, to the compound of interest and can thereby artificially dilute its isotopic
enrichment. This as well as the fragmentation pattern of the derivatized molecule need to
be taken into consideration in the analysis of GC data [69]. Different derivatization
protocols are used depending of the type of stable isotope investigated. After the initial
preparation steps, the derivatized sample is injected into the GC column and evaporated
in the heated injector. The volatile compounds are taken up by the mobile phase and
moved through a very long high-resolution column. Based on their partitioning coefficient
K, different compounds interact longer with the stationary phase of the column than others
and thereby have different retention times [55].
In LC, the mobile phase is a liquid solvent and the stationary phase a surface of solid
particles. The polarity of the mobile phase, stationary phase, and sample impact the
adsorption and desorption equilibrium, that is, how long different compounds are retained
on the column. In Normal Phase Chromatography the stationary phase is polar, and the
mobile phase is a nonpolar or less polar solvent. Therefore, polar compounds have a
higher affinity for the stationary phase, causing them to be retained longer on the column
(i.e., have a longer retention time), whereas non-polar molecules are attracted to the
mobile phase of equal polarity and therefore elute faster from the column (shorter
retention time). In Reverse Phase Chromatography the polarity is opposite to Normal
Phase Chromatography. Hence, the stationary phase is nonpolar, whereas the mobile
phase is polar. Nonpolar compounds are retained longer on the column (longer retention
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time) than polar compounds which elute faster (shorter retention time). Of note, by mixing
two solvents of different polarity, i.e., a polar and a non-polar one, at different ratios, the
overall polarity of the mobile phase can be adjusted during or between runs. The process
of gradually increasing concentrations of organic solvent and decreasing the
concentration of the polar solvent in the mobile phase to mobilize analytes of decreasing
polarity off the stationary phase is called a ‘gradient – solvent run”. During an isocratic
solvent run on the other hand the solvent composition of the mobile phase is not change.
The stationary phase of chromatography columns can consist of tightly packed silica
beads whose surface is coated with an organic layer, such as siloxanes with various alkyl
or aryl end groups. The end groups determine the interaction of the surface with the
analyte. Long alkyl chains (C18) bind stronger to organic molecule of low polarity and let
high polar/ionic analytes pass through whereas shorter alkyl chains (C8) are less
retentiveness for low polarity analytes. Non-polar analytes typically require a higher
fraction of organic solvent to move along the stationary phase.

S3.2 Ionization
Since mass analyzers take advantage of the movement of charged molecules through an
electromagnetic field, neutral molecules cannot be studied by mass spectrometry (see
Mass Analyzer below). Therefore, an ion source as part of a mass spectrometer ensures
the generation of charged molecules (ions) before entering the mass analyzer. Once a
molecule is charged it can then be accelerated in the electromagnetic field of the mass
analyzer and directed towards a detector. Many different types of ionization have been
developed, but the ones discussed here are electron ionization, chemical ionization, and
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electrospray ionization. In electron Ionization EI gas molecules enter a high-energy beam
of electrons (70eV) that is generated by a heated filament and then directed towards a
positively charged plate. The bombarded and subsequent collision of electrons with the
neutral sample molecules results in the formation of cations (M+) and anions (M-). Due
to the high energy impact of EI this type of ionization leads to multiple highly reproducible
and unique fragmentation patterns of each/individual molecule(s). In the process of
chemical Ionization (CI) a reagent gas, such as methane or ammonia, reacts with
molecules under high pressure leading to their ionization. The ionized bulk of reagent
gas is usually present in excess to the sample molecule (1000:1). Both negative and
positive ions are produced by CI. Since CI employs very little energy in the process of
ionization it leads to little fragmentation. Therefore, EI is often used to identify positional
labeling information whereas CI is more for suitable for non-positional, total mass
enrichment information. However, especially when ammonia is used as a reagent gas
adduct formation can lead to higher masses of the sample molecules than seen with EI
[55, 69, 70].
Electrospray Ionization (ESI) is a soft ionization technique which results in little to no
fragmentation of labile analytes. ESI begins at atmospheric pressure and then proceeds
into a high vacuum in the mass analyzer. The overall principal underlying ESI is the
transfer of ions from a volatile solution to a gas phase, while only very low concentrations
of the ionic analyte are required. The process of ESI starts with the production of a
charged droplet, followed by droplet size reduction and fission, and finally gas phase ion
formation. ESI is highly efficient in ion production and both positively and negatively
charged ions can be formed. The type of ion produced depends on the functional group
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of the sample molecule, that is, whether it readily accepts or donates a proton. Anions
are usually observed in the process of protonization of amine groups, while cations are
seen with the deprotonization of carboxylic groups. ESI serves a wide analytical range,
especially of small polar molecules; large, non-volatile, chargeable molecules, ionic metal
complexes, soluble inorganic analytes and thermally labile molecules. The ionization
processed predominantly used in conjunction with LC in studies of polar molecules is
electrospray ionization, while EI and CI are traditionally interfaced with GC-MS [55, 69,
70]
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Glossary
βOx/FAO = Fatty acid beta oxidation
ACC = Acetyl-CoA carboxylase
ACS= Acetyl COA Synthetase
ACLy = ATP citrate Lyase
APE: Atom Percent Excess (%)
ATP= adenosine triphosphate
C= carbon atom
CAC= Citric Acid Cycle (Krebs Cycle)
CS =Citrate synthase
D= aminotransferase
DD= di-deuterated
DMS= Differential Mobility Spectrometry
GC= Gas Chromatography
GDH= Glutamate dehydrogenase
IDHf,r,net= Isocitrate dehydrogenase, (f) forward, (r) reverse, (net)
Isotopologue: position non specific label information
Isotopomer: position specific label information
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LC= Liquid Chromatography
LDH= Lactate dehydrogenase
ME= Malic enzyme
MFA= Metabolic Flux Analysis
MS= Mass Spectrometry
MS/MS= Tandem Mass Spectrometry
NA= Natural Abundance
NAFLD= non alcoholic fatty liver disease
NMR= Nuclear Magnetic Resonance Spectroscopy
OGDH= α Ketoglutarate dehydrogenase
PC= Pyruvate carboxylase
PCC= Propionate CoA carboxylase
PDH= Pyruvate dehydrogenase
PEPCK = phosphoenolpyruvate carboxykinase
SDH= Succinate dehydrogenase
T2DM= Type 2 diabetes mellitus
TCA= Tricarboxylic Acid Cycle (Krebs Cycle)
V=Flux (metabolic flow)
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X= aminotransferase
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